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Abstract
Astrocytes are the most abundant cell within the central nervous system (CNS) and yet
despite this, the true extent of their role in health and disease has not been fully elucidated.
In the undamaged CNS, they are termed quiescent, where they maintain homeostasis.
However, after injury or disease astrocytes become reactive where they are described as a
physical and molecular barrier to regeneration. Emerging literature has suggested the
existence of an additional phenotype of astrocyte, termed the activated astrocyte. These
astrocytes are thought to enhance regeneration by creating a more growth-permissive
environment for repair. In addition, it has also been reported that astrocytes may play a role
in regulating myelination; however, it is unclear how the phenotype of the astrocytes may
affect this process. Therefore, this thesis will focus on the variable phenotypic state of
astrocytes and subsequently how this relates to their ability to support myelination.
Using an in vitro myelinating culture, where dissociated spinal cord cells were plated on a
monolayer of astrocytes, myelination can be followed over time. Since it is hypothesised
that astrocytes can affect myelination we used two protocols known to affect the reactive
status of the astrocyte, i) activate the astrocytes by treating with ciliary neurotrophic factor
(CNTF) or ii) induce a quiescent astrocyte state by plating them on Tenascin C (TnC).
It is hypothesised that CNTF changes the activation state of the astrocyte therefore making
it more supportive to myelination. The addition of the astrocyte derived factor ciliary
neurotrophic factor (CNTF) was shown to enhance myelination. My results demonstrate
that CNTF addition does not lead to an increase in oligodendrocyte or microglia cell
numbers or an increase in the diameter of the neurites, thus suggesting that this CNTF-
induced increase in myelination is mediated via the astrocyte.
Conversely, culturing astrocytes on the extracellular matrix molecule Tenascin-C (TnC), a
method to make the astrocytes quiescent (Holley et al., 2005), resulted in a reduction in
myelination. Astrocytes cultured on TnC were shown have decreased expression of nestin,
which is typically a marker for reactivity. A microarray gene study comparing gene
expression of the various astrocyte phenotypes identified CXCL10 to be upregulated in
astrocytes on TnC. Furthermore, the addition of CXCL10 into the myelination cultures
resulted in a decrease in myelination. Conversely, the addition of anti-CXCL10 to
myelinating cultures on quiescent astrocytes increased myelination.
xvii
Taken together, these data indicate that the astrocyte phenotype has considerable influence
on myelination; where activated astrocytes support myelination whilst quiescent astrocytes
do not.  The identification of factors which may modify astrocyte phenotypes could lead to
potential therapeutic strategies for CNS pathologies.
xviii
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1Chapter 1
Introduction
Introduction
1.1 Glial Cells in the Central Nervous System
The central nervous system (CNS) comprises the brain and spinal cord and its primary
function is to conduct sensory information from the peripheral nervous system (PNS) to
the brain as well as conducting motor information from the brain to various effectors, such
as muscles. The two major types of cells in the CNS are neurons and glia, which can be
further divided into two groups: microglia and macroglia. In the CNS, macroglia consist of
oligodendrocytes, the myelin forming cells, and astrocytes which are the major ‘house-
keeping’ cells of the CNS. Resident macrophages in the CNS are the microglia which
react quickly following an immune response to restore homeostasis. In order for these
primary functions to take place, the microenvironment has to be highly controlled. Each of
these cells types will be explored in turn, with special emphasis on astrocytes and their
functions in myelination.
1.1.1.1 Oligodendrocytes
Oligodendrocytes are the myelin forming glial cells of the CNS. Myelin is the fatty
proteolipid membrane that ensheaths axons by a process known as myelination. In order to
myelinate axons, an oligodendrocyte extends its processes and wraps myelin in segments,
known as internodes, around axons. The organisation of the myelin sheaths consists of
functional domains which include the Node of Ranvier and paranode and juxtaparanode
areas (Salzer, 2003). Each of these areas consists of a unique compilation of cell adhesion
molecules and voltage regulated ion channels (Fig 1.1). One of these molecules is Caspr
(Peles et al., 1997), a transmembrane protein located at the paranode. Neurofascin 155
(Nf155), a member of the L1 family of cell adhesion molecules, is expressed solely by
oligodendrocytes and is found at the myelin paranodal loops (Tait et al., 2000). Together,
these molecules form a complex with the main aim of anchoring the myelin to the axon.
In the exposed region of the node, clusters of the voltage dependent sodium channels (Nav)
can be found.  These are responsible for the propagation of action potentials down an axon
(Rasband and Trimmer, 2001). Neurofascin 186 (Nf186), another isoform of neurofascin,
is also located at the node (Fig 1.1). Recently, the role of Neurofascin autoimmune
antibodies has been described in Multiple Sclerosis (MS, Mathey et al., 2007; Defruss et
2
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Figure 1.1 Nodes of Ranvier Location and Structure. The
illustration represents a myelinated axon, where myelin sheaths from
the oligodendrocytes are wrapped around the axon exposing the
Nodes of Ranvier (A). The subdomains of the Nodes of Ranvier are
the paranodes and juxtaparanodes (not shown), which are on either
side of the node (box). Some of the cell adhesion molecules and
voltage regulated ion channels are shown in B. Myelin associated
Neurofascin155 (Nfasc155) is located at the myelin paranodal loops
and Caspr the paranode. At the node, sodium channel and axonal
neurofascin (Nfasc 186) are present. Figure adapted from Sherman
and Brophy (2005) and Suzuki and Rasband (2008).
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4al., 2010). MS is an auto-immune attack on myelin sheaths leading to demyelination, glial
scar formation and related axonal pathology. These researchers use an animal model of
MS, known as experimental autoimmune encephalomyelitis (EAE), where they show that
the transfer of anti-neurofascin antibodies (pan, recognising both Nf155 and Nf186) into
these animals results in the exacerbation of disease severity. The authors show that
neurofascin antibodies selectively bind to Nf186 where they mediate axonal damage,
which is interesting as it is now thought that neuronal loss is a chief contributor to
disability in MS (Ferguson et al., 1997).
The assembly of the Nodes of Ranvier and internodes of myelin is required for the fast
propagation of action potentials. This method of rapid conduction allows communication
between neurons over relatively long distances. The presence of the myelin sheath and the
assembly of the nodes of Ranvier allow action potentials to ‘jump’ from node to node by a
process known as saltatory conduction. The importance of myelin and saltatory conduction
is highlighted when considering MS. The loss of myelin and axonal damage disables
salutatory conduction. The features of MS will be discussed in further detail in Section
1.3.1. Briefly, the loss of myelin sheaths and axonal damage leads to interruption in signal
propagation and leads to disability.
1.1.1.2 Oligodendrocyte Development
Oligodendrocyte precursor cells (OPCs) are the precursors to the myelin forming cells in
the CNS. They arise from a progenitor population in the ventral region of the ventricular
zone (Sun et al., 1998; Rowitch, 2004). A subpopulation of OPCs also originates from
developing brain homeobox 1 (Dbx-) expressing domain of the dorsal spinal cord (Fogarty
et al., 2005). From the location of origin, OPCs then migrate down the spinal cord
populating their final areas of maturation. The process of migration is tightly controlled
and not yet fully understood but it is thought to be highly dependent on environmental
cues, including secreted and extracellular matrix molecules (Bradll and Lassmann, 2010).
One of these is the carbohydrate polymer, α 2-8 linked polysialic acid on neural cell
adhesion molecule (PSA-NCAM). The cleavage of PSA from NCAM, which is located on
the surface of OPCs, lead to a blockade of cells spreading from an explant model for cell
motility, where the explant was the source of OPCs (Wang et al., 1994). This suggests that
the expression of this molecule during development may contribute to guiding progenitor
cells to where they are required and presumably its downregulation may confine cells to
those specific areas.
5OPCs are the progenitor cells that give rise to mature oligodendrocytes. It has also been
suggested that OPCs have stem cell-like properties as they have the ability to give rise to
astrocytes and neurons (Kondo and Raff, 2000). The authors showed that in the presence of
platelet derived growth factor (PDGF) purified OPCs remained immature and the majority
of them expressed A2B5+, a marker for early OPCs. In the presence of PDGF and Fetal
Calf Serum (FCS), many OPCs also expressed glial fibrillary acidic protein (GFAP), an
intermediate filament of astrocytes. In the presence of basic fibroblast growth factor
(bFGF), FCS and bone morphogenetic proteins (BMPs) OPCs expressed microtubule-
associated protein 2 (MAP2) and low and high molecular weight neurofilament (NF-L and
NF-H, respectively), which are markers used to identify neurons in vitro. Furthermore,
culturing OPCs with PDGF, FCS and FGF2 in non-coated culture dishes resulted in
floating neurospheres, similar to stem cells in the CNS. Therefore, the study described the
ability of OPCs to revert back to neurosphere stem cells as well as showing their ability to
differentiate into astrocytes and neurons.
OPCs also exist in the adult CNS, where they remain undifferentiated (Wolswijk and
Noble, 1989; Reynolds and Hardy, 1997; Dawson et al., 2003). These have been found to
express the chondroitin sulfate proteoglycan, NG2 and were found in all areas of the CNS,
including the cerebral cortex, hippocampus and corpus striatum (Dawson et al., 2003). It is
hypothesised that the main function of these OPCs is to proliferate and repopulate areas
devoid of oligodendrocytes (Dawson et al. 2003). For instance, in a model of antibody-
induced demyelination, where antibodies are directed to myelin proteins leading to a loss
of myelin sheaths from myelinated axons, the number of NG2+ cells increased by 72%
over 3 days (Keirstead et al., 1998). Whether or not this increase was due to the
inflammatory environment surrounding these cells was addressed by Cenci di Bello et al.
(1999). The authors showed an increase in the NG2+ OPC population as a result of EAE
demyelination. When the authors used non-specific mouse immunoglobulins to induce an
inflammatory response without demyelination, no increase in NG2+ OPCs was observed.
These data clearly indicate that the NG2+ OPC population in the adult CNS is highly
active in demyelinating conditions.
1.1.1.3 Oligodendrocyte Differentiation and Myelination
In order for oligodendrocytes to accomplish their primary role as myelinating cells, correct
differentiation of OPCs must take place. OPCs are bipolar cells and can be identified by
their expression of A2B5 and PDGFRα and as they differentiate they progressively
6become more branched and begin to express markers such as O4 and NG2 (Zhang, 2001;
Figure 1.2). Their processes extend and retract until they find suitable axons to myelinate
(Pfeiffer et al., 1993; Kirby et al., 2006). It has been reported that oligodendrocytes have a
short time frame (12-72 hours) in which the selection of axons and the initial ensheathment
begins (Barres et al., 1992; Barres, 2010), thus forming a stable cell-to-cell contact
between the two cells. Axonal selection, contact, initiation of ensheathment, control of
myelin thickness and the extension of myelin sheaths along with neural growth are finely
tuned processes that are in need of further understanding (Sherman and Brophy, 2005).
Myelin is composed of 70% lipid and 30% protein and can be identified using a panel of
markers including, proteolipid protein (PLP), myelin basic protein (MBP) and myelin-
associated glycoprotein (MAG) (Dubois-Dalcq, et al., 1986, Fig 1.2).
Oligodendrocytes which fail to make contact with axons have been shown to undergo
apoptosis (Trapp et al., 1997). It has been suggested that the overproduction of
oligodendrocytes during development ensures that all axons which require myelination are
myelinated (Trapp et al., 1997). In fact, around half of oligodendrocytes fail to reach
maturity and subsequently die, partly due to competition for axonally-derived survival
factors and contact (Barres et al., 1992; Trapp et al., 1997). The role of axons in mediating
oligodendroglial differentiation has been described previously, where it was suggested that
axons have recognition signals which attract oligodendrocyte processes, thus initiating
myelination (Lubetzki et al., 1997). However, Rosenberg et al. (2008) demonstrated that
seeding OPCs on top of fixed dorsal root ganglion neurons (DRG) resulted in the
differentiation of OPCs to mature oligodendrocytes and they were able to myelinate fixed
neurons.  Interestingly, the authors also showed that OPCs did not myelinate axons when
plated at low densities, but do when artificial beads with a similar diameter to OPCs were
bound to the axonal surface. Therefore, the study suggests that OPCs differentiate and
myelinate due to space constraints. However, it must be noted that DRG neurons are of
peripheral origin and whether OPCs will behave in the same manner in the presence of
CNS neurons has not been established.
The environment surrounding OPCs, including growth factors and extracellular matrix
molecules, have been reported to affect their differentiation. Without any exogenous
addition of growth factors in vitro, oligodendrocytes differentiate after dropping out of
several division cycles (Raff et al., 1988). A group of proteins which has been implicated
in oligodendrocyte differentiation are the neuregulins which exist as soluble and
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Figure 1.2 Summary of Oligodendrocyte Differentiation. The illustration represents the
differentiation of oligodendrocytes and the markers used to identify them at each stage.
Bipolar early oligodendrocyte precursor cells (OPCs) give rise to late OPCs which are
more branched. These give rise to pre-myelinating oligodendrocytes. Upon axonal
contact, they become myelinating oligodendrocytes expressing mature myelin markers.
Otherwise, they undergo programmed cell death. Adult OPCs can also be found in the
adult.  Figure adapted from Trapp et al. (1997) and Siegel et al. (1999)
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8transmembrane proteins of the epidermal growth factor family. Neuregulins activate the
ErbB family of tyrosine kinase receptors, which include ErbB1, ErbB2, ErbB3 and ErbB4.
The activation of the ErbB4 receptor by neuregulin is associated with a signaling cascade
that leads to the maturation of oligodendrocytes, possibly via the activation of γ secretase
and the translocation of ErbB4 intracellular domain to the nucleus (Lai and Fang, 2004).
Neuregulins are necessary for the formation of oligodendrocytes, as in vitro spinal cord
explants from neureglulin null mice (Nrg-/-) fail to differentiate (Vartanian et al., 1999).
They are also potent mitogens for OPCs, but inhibit their differentiation into MBP+
myelinating oligodendrocytes (Canoll et al., 1996). Conversely, Park et al. (2001) showed
that spinal cord explants from ErbB2-/- mice had significantly reduced numbers of mature
oligodendrocytes, whilst those that did mature failed to ensheath axons. Myelinated axons
have been reported to have a higher expression of neuregulin than unmyelinated fibres,
suggesting an instructive signal from axons to initiate myelination (Taveggia et al. 2005).
Although neuregulin is not essential for myelination in the CNS, it has a significant effect
in myelin sheath formation in vivo (Taveggia et al., 2008).  The study showed that
myelinated segments in neuregulin null mice (Nrg-/-) were reduced significantly (70%)
compared to wildtype controls. However, this study also showed that oligodendrocyte
differentiation was similar in both types of mice, thus suggesting that neuregulin’s
importance in the process of myelination is exerted via the formation of myelin, rather than
the integrity of the oligodendrocytes. Addition of neuregulin to DRG neurons and OPCs
led to a dose dependent increase in myelination, whilst a blocking antibody showed a
significant reduction in myelination in the absence of any exogenous neuregulin (Wang et
al., 2007).  The effect of neuregulins on oligodendrocyte differentiation and myelination
differ depending on the age of the oligodendrocyte. These data provide evidence to show
that oligodendrocytes are highly influenced by surrounding soluble factors.
The precise mechanism by which an oligodendrocyte wraps its processes around axons is
still unknown. It has been suggested that whilst an oligodendrocyte wraps its processes
around several axons, its cell body remaining stationary (Bauer et al., 2009). Two models
have been proposed to describe the wrapping mechanism (Pedraza et al., 2001; Bauer et
al., 2009). One model involves the oligodendrocyte processes wrapping the axons in non-
overlapping spirals which then extend out laterally forming overlapping sheets of myelin.
The second model involves wrapping axons in a sheet-like manner and then extending by
longitudinal movements.
91.1.2.1 Microglia
Microglia are the brain’s resident macrophages and are the most common immune cells in
the CNS. The origin of microglia is a highly contested issue in neuroscience with three
main possible origins: mesodermal, nectodermal or possibly monocytic, although this has
been widely disputed (Kaur et al., 2001; Guillemin and Brew, 2004). In the normal,
healthy brain, microglia are described as resting, where their function is mainly to monitor
the environment for potential pathogens, however, other functions remain to be fully
elucidated (Gehrmann et al., 1995). As microglia are extremely sensitive to their
surrounding environment, they are the first cells to respond following disease or injury to
the CNS (Liberto et al., 2004). Thus, the majority of literature describes microglia post
activation and how this in turn changes the milieu for other cells.
1.1.2.2 Activated Microglia
Microglia become activated after injury or infection of the CNS, as well as in
demyelinating diseases such as MS (Skaper, 2007). This activation may lead to direct or
indirect production of cytokines which then contribute to the inflammatory environment.
IL-1β, a member of the interleukin-1 cytokine family, is produced by microglia and has
been described as the dominant signal after injury (Liberto et al., 2004; Auro, 1998).
Indeed, Herx et al. (2000) have demonstrated that mice lacking IL-1β signal have a delayed
astroglial reaction following acute CNS trauma in mice. Thus, the quick response shown
by microglia is required for the initiation of a more widespread reaction from other cell
types, such as astrocytes.
As MS is an immune-mediated disease, there is no doubt that a microglial reaction is
involved. However, the extent of its involvement, and whether there is a direct or indirect
cause for demyelination, still remains under investigation. Defaux et al. (2010) used three
models of in vitro demyelination; lysophosphatidylcholine (LPC), interferon-γ combined
with lipopolysaccharide (IFN-γ+LPS) and anti-MOG antibodies plus complement, using
embryonic rat brain aggregates which grew within a 26 day period. Demyelination (the
loss of myelin from myelinated axons) was assessed by the loss of MBP and MOG
expression as measured by qRT-PCR. The authors used this model to not only demonstrate
the extent of myelination, but also to demonstrate an increase in microglial numbers as a
result of demyelination. Interestingly, they found that specific genes were upregulated by
specific treatments, for instance, CXCL2, a chemokine of the CXC family, was
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upregulated only by LPC treatment whereas IL-1β and IL-14 only by IFN-γ+LPS. This
study is of great interest as not only does it strengthen the link between microglial
activation and demyelination but it also suggests that there different patterns of
demyelination depending on the cause of inflammation. This observation may shed light
on the different subtypes of MS to provide more specific treatments.
1.1.3.1 Astrocytes
Astrocytes are a type of macroglial cell representing 50% of the total cellular volume of
the CNS (Roessmann and Gambetti, 1986). They are defined by their stellate morphology
and expression of glial fibrillary acidic protein (GFAP, Eng et al., 1971). They have been
termed ‘support cells’ and in the normal adult brain are thought to have a relatively passive
role in the CNS. However, astrocytes are emerging as key players in many aspects of CNS
diseases and injury. Their diverse roles extend from energy metabolism, neurotransmitter
homeostasis, myelination, axonal outgrowth, maintenance of the blood brain barrier (BBB)
and synaptogenesis (Liberto et al., 2004; Silver and Miller, 2004; Ullian et al., 2004;
Pellerin, 2005; Nair et al., 2008, Sørensen et al., 2008; Watkins et al., 2008). The following
sections will expand on these properties.
1.1.3.2 Astrocyte Development
Astrocytes are categorised as fibrous, mainly found in the white matter; or protoplasmic,
found in the grey matter (Peters et al., 1976; Wilkin et al., 1990). Morphologically they
differ as fibrous astrocytes have numerous long processes, whilst protoplasmic astrocytes
have fewer and shorter processes (Peters et al., 1976). The heterogeneity of astrocytes
allows them to respond appropriately in each specific environment. Two subsets of
astrocytes have been described in vitro, Type-1 and Type-2, corresponding to in vivo
location, proliferative ability and morphology (Raff et al., 1983 a+b; Wilkin et al., 1990).
Type-1 astrocytes are flat and have a fibroblast-like morphology and divide in response to
FCS and epidermal growth factor (EGF, Raff et al., 1983a). Type-2 astrocytes, on the other
hand, have more processes (Raff et al., 1983a) and divide less frequently. Furthermore,
type-2 astrocytes are only found in developing white matter, whereas Type-1 astrocytes are
found in both white and gray matter (Raff et al., 1983a). It is thought that Type-2 astrocytes
and oligodendrocytes arise from a common progenitor (Raff et al., 1983b). The marker
A2B5 is also used to discriminate between these two types of astrocytes; Type 1 astrocytes do
not express A2B5, whereas Type-2 astrocytes do (Raff et al., 1983a). On the basis of
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immunohistochemistry with the A2B5 antibody and frozen sections of developing and
adult rat brain, Miller and Raff (1984) have suggested that Type-1 astrocytes represent
protoplasmic astrocytes whereas Type-2 astrocytes represent fibrous astrocytes.
Interestingly, the presence of these two subtypes has also been demonstrated in vivo
(Miller et al., 1985). The authors show that in the rat Type-1 astrocytes first appear at E16
whilst Type-2 astrocytes appear much later between P7 and P10.  However, others have
opposed this view by suggesting only one type of astrocyte exists in vivo, raising the
possibility that Type-1 astrocytes are an in vitro artifact (Skoff, 1990). The study suggests
that only one wave of astrocytes is generated in the first 2 post natal weeks, which then
proliferate to give rise to more astrocytes postnatally. Furthermore, others have suggested
that as the A2B5 marker recognises an external ganglioside epitope, and the staining of
frozen sections show A2B5 to be internal, the reliability of these studies has been
questioned (Williams and Price, 1992). In terms of other classifications of astrocyte
heterogeneity, 9 variants have been described in the normal CNS (Matyash and
Kettenmann, 2010). These variants are characterised based on their morphology, with
significant overlap in their localization.
Precursors of astrocytes originate in the subventricular zone (SVZ) where they migrate
along the medial ventrodorsal pathway and give rise to astrocytes (Marshall and Goldman,
2002). Astrocytes originate from the common neural stem cells (NSC) which are non-
committed progenitors and are able to give rise to glial restricted precursors (GRP),
astrocyte restricted precursors (ARP) and neuron restricted precursors (NRP, Liu and Rao,
2004; Dietrich et al., 2007). ARPs, although not yet identified, give rise to astrocytes
whilst GRPs give rise to both oligodendrocytes and astrocytes (Liu and Rao, 2004;
Dietrich et al., 2007). Neurospheres generated from neonatal rat striatum have the ability to
differentiate into astrocytes in the presence of FCS (Thomson et al., 2006; Thomson et al.,
2008; Sørenson et al., 2008). Similar neurosphere preparations have been shown to
differentiate into other cells types, including neurons, oligodendrocytes and astrocytes
(Maciaczyk et al., 2009; Darsalia et al., 2010), suggesting their possible use for
regeneration in neurodegenerative disorders.
Interestingly, astrocytes have emerged to have stem-cell like properties and their potential
in regeneration has been considered. For instance, Pillai et al., (2006) cultured human fetal
astrocytes for 4 weeks in a cocktail of proteases and FGF-1, after which they changed
morphology and began expressing neuronal makers. However, these newly differentiated
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neuron-like cells had no electrophysiological properties, suggesting incomplete
differentiation. Nonetheless, this study demonstrates that astrocytes have stem-cell like
properties and under the yet undefined appropriate conditions they may have the ability to
change cell type. Furthermore, Buffo et al. (2008) demonstrated the potential of astrocytes
using a stab injury model. They showed that astrocytes isolated from the lesioned cortex,
unlike the unlesioned cortex, formed neurospheres which could be further differentiated
into neurons and oligodendrocytes. In an earlier study, Doetsch et al. (1999) used an in
vitro scratch-wound model to test the multipotenital ability of astrocytes. They showed that
astrocytes generated neurospheres, proliferated and differentiated into neurons and
oligodendrocytes under specific conditions. The data above demonstrated that astrocytes in
the adult CNS have stem cell like properties under the correct guidance cues, usually
observed in injury conditions. The pronounced response from astrocytes in most CNS
injuries has been generally described as an obstacle to repair (Silver and Miller, 2004; to be
discussed in detail in Section 1.4.4). The fact that astrocytes have such potential is
extremely appealing as this can be further developed and manipulated in CNS injuries in
order to create a favourable environment for regeneration and repair.
The age of the astrocyte has been implicated in the effectiveness of the support which
astrocytes provide other cells. It has been suggested that the severity of CNS damage in
neonatal animals is much less severe than that of adult animals (Barrett et al., 1984;
Fujimoto et al., 2006; Filous et al., 2010). Barrett et al. (1984) performed spinal transaction
at T5 on neonatal and adult rats and examined GFAP immunohistochemistry of sections of
cervical, thoracic and lumbar spinal cord to determine the extent of the glial reaction.
Increase in GFAP reactivity is associated with a more pronounced glial reaction. They
found that in neonatal rats, a mild GFAP reaction was present, which was mainly restricted
to the lesion site. However, in the adult rats, not only was GFAP intensity greater, but it
also spread further anatomically. Similarly, Fujimoto et al. (2006) demonstrated a
comparable observation using fetal spinal cord. They transected fetal rats at T8-10 and then
returned them to the uterus for delivery, and compared this group to adult rat spinal cord
which had been transected. The authors report increased tissue scar formation and
persistent glial reaction 5 weeks after surgery in the adult group. In the fetal group, scar
formation was limited and the glial reaction was restored during the same time period. The
authors discuss that the degree of astrocytic involvement in injury may be different for
mature and immature tissues and the roles of astrocytes may change at different stages of
maturity.
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1.2 Functions of Astrocytes in Health and Disease
1.2.1 The Blood Brain Barrier
The blood brain barrier (BBB) is a physical barrier to restrict the entrance of harmful
chemicals from the blood into the brain parenchyma and also to control the cellular
transport of lipid soluble molecules using tight junctions. Water soluble molecules, such as
potassium and sodium ions, require the use of carrier mediated transport, such as the
sodium/potassium exchanger. The BBB is composed of specialised endothelial cells, which
usually line the interior surface of blood vessels, as well as pericytes and their basal
lamina. The main aim of the BBB is to supply the CNS with the required nutrients by
controlling the permeability of blood vessels, thus regulating homeostasis of the CNS
(Abbot et al., 2006; Fig 1.3). Astrocytes form ‘end-feet’ processes which surround blood
capillaries and are thought to play a role in maintaining the integrity of the BBB. Janzer
and Raff show direct in vivo evidence that astrocytes induce endothelial cells of non-CNS
origin to form capillary endothelial cells which form the BBB. Furthermore, co-culture of
astrocytes and endothelial cells increased the number and length of tight junctions (Tao-
Cheng et al., 1987). Thus, astrocytes play a major role in controlling and maintaining the
BBB via their direct actions on endothelial cells. In pathological conditions such as MS,
AD and PD, the integrity of the BBB is compromised and how astrocytes contribute to this
is not well understood. In MS, where there is an auto-immune attack on myelin sheaths
leading to demyelination, loss of axons, and glial scar formation, the exposure of pro-
inflammatory cytokines, which may be produced by astrocytes, enhances the migration of
monocytes  and promotes shedding of endothelial microparticles, thus contributing to the
BBB disruption (Minagar et al., 2001; Minagar and Alexander, 2003). Voskuhl et al.
(2009) used Experimental Autoimmune Encephalomyelitis (EAE), a rodent model of MS,
where mice were exposed to the myelin protein MOG resulting in an auto-immune attack
on the host’s myelin sheaths, resembling the occurrence in MS. Conversely, they showed
that activated astrocytes around the BBB formed barriers to stop the infiltration of
leukocytes and protect CNS function (Voskuhl et al., 2009). Furthermore, patients with
neuromyelitis optica, an acquired demyelinating autoimmune disease similar to MS, have
antibodies to aquaporin-4; a molecule which is highly expressed at contact junctions
between astrocytes and the BBB (Lennon et al., 2005; Satoh et al., 2007). It is clear that the
contact between astrocyte ‘end-feet’ and the BBB serve a regulatory mechanism in the
normal brain and its role in CNS pathologies is yet to be further clarified.
14
1.2.2 Neurotransmitter Control and Synaptogensis
Astrocytes are emerging as key players in the regulation of synaptic activity throughout the
brain. It has been demonstrated that astrocytes become activated by an increase in
intracellular calcium from presynaptic neurons and in turn release glutamate and ATP,
which have been shown to directly stimulate postsynaptic neurons (Parpura et al., 1994;
Hassinger et al., 1995; Newman, 2003). This increase in intracellular calcium has been
termed calcium-waves and can be mediated to neighbouring astrocytes via the diffusion of
inositol triphosphate (IP3, Finkbeiner, 1992). Experiments using cultures as well as intact
tissue have demonstrated many other examples of communication between neurons and
astrocytes in order to regulate synaptic activity and function (reviewed in Newman, 2003).
Synaptogenesis is the formation of new synapses between neurons and is an essential
process during development as well as throughout life (Eckenhoff and Rakic, 1991).
Although it is a matter involving neurons, recent evidence suggests that the correct
formation of these synapses is highly dependent on the presence of astrocytes (Slezak
and Pfrieger, 2003). Neurons cultured without astrocytes showed that although synapses
formed between neurons in the absence of astrocytes, they had little spontaneous synaptic
activity (Pfrieger and Barres, 1997; Nagler et al., 2001). However, culturing neurons with
astrocytes not only increased the number of synapses but also increased spontaneous
synaptic activity. Interestingly, Nagler et al. (2001) have also found that conditioned media
from glial cells resulted in an increase in spontaneous neuronal activity, suggesting glial
derived factor(s) may induce this neuronal activity. Although no specific astrocyte-derived
factor for synaptogenesis has been identified, the literature above suggests that astrocytes
play a dynamic role in controlling such a significant process in the CNS.
Communication of pre- and post-synaptic neurons with astrocytes is a new concept known
as the tripartite synapse, where the location of the astrocyte allows it to be in close
association with to both terminals. Amongst other neurotransmitter receptors, astrocytes
also possess G protein coupled receptors where upon activation, they lead to the formation
of IP3, which in turn leads to an increase in intracellular calcium concentration through the
release from IP3-sensitive calcium internal stores (Araque et al., 2002). This in turn, causes
the release of gliotransmitters from astrocytes, which has modulatory effects on neurons
(Halassa et al., 2007). Furthermore, astrocytes remove extracellular glutamate via
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glutamate transporters in order to clear excess glutamate from the synaptic cleft, therefore
modulating synaptic transmission (Bergles et al., 1999).
The concept of glial activation and intracellular calcium stores impact in pathological
conditions such as epilepsy. Epilepsy is a neurological disorder in which brain function is
disrupted as a consequence of intensive bursts of activity from groups of neurons.  A
biological model was presented by Halassa et al. (2007) where hyperactive astrocytes (as
well as hypoactive astrocytes) may contribute to pathological states by increasing or
decreasing calcium oscillation frequency and gliotramission. In support of this, many
epileptic drugs block calcium signalling in astrocytes (Tian et al., 2005), suggesting a key
pathological role played by astrocytes in epilepsy.
1.2.3 Water, Ion and pH Balance
Astrocytes respond to external stimulation as they express a wide range of receptors and
specialised transporters and because of this they are able to control fluid, ion and pH
balance in the CNS (Simard and Nedergaard, 2004; Fig 1.3).  For instance, astrocytes
express the water-channel receptor aquaporin-4 (AQP4; Nielsen et al., 1997), a member of
the aquaporin family of integral membrane proteins. In an interesting study using RNA
interference (RNAi) to inhibit AQP4, Badaut et al. (2010) demonstrated a significant loss
in water mobility in the rat brain as shown by the reduction in apparent diffusion
coefficient (as measured by diffusion weighted imaging). Furthermore, astrocytes have
numerous carriers of ions and other metabolites, including sodium/hydrogen exchanger,
sodium/potassium/chloride co-transporter and biocarbonate transporters (Obara et al.,
2008; Jayakumar and Norenberg, 2010; Sofroniew and Vinters, 2010) which all contribute
to regulating the internal milieu.
1.2.4 Gap Junctions
Gap junctions between astrocytes serve as a great means of communication, allowing for
direct chemical or electrical communication between cells and preventing leakage into
extracellular space. Astrocytes communicate to each other as well as with oligodendrocytes
via gap junctions forming what is known as a ‘glial syncytium’ (Nagy and Rash, 2003; Fig
1.3). The cellular components of gap junctions are connexons (group of connexins) and
these differ depending on the cell type and location. In the cuprizone model of
experimental demyelination, where mice are fed with the copper chelator cuprizone,
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leading to oligodendrocyte death and a subsequent reversible demyelination, astrocytes
were shown to infiltrate the area and begin the de novo expression of connexin Cx-47,
normally expressed by oligodendrocytes (Parenti et al., 2010). The expression of Cx-47
then shifted back to oligodendrocytes which repopulated demyelinated areas. Although the
authors do not fully describe the primary function of Cx-47, the fact that astrocytes express
a foreign connexin in a disease condition reflects their capabilities to control and maintain
homeostasis. Further evidence for astrocytes proving support for oligodendrocytes was
shown by Lutz et al. (2009), as they have demonstrated that the global loss of Cx-30 and
astrocyte specific loss of Cx-43 in mice lead to loss of oligodendrocytes as well as a
reduction of myelin basic protein, as measured by Western blotting. Furthermore, the
double knock-out mice performed poorly in sensimotor and special memory tasks. Thus,
the communication of astrocytes to other astrocytes and oligodendrocyte serves as a crucial
function in development and the maintenance of other cells types.
1.2.5 Energy and Metabolism
Astrocytes also play an active role in energy and metabolism. For instance, astrocytes store
glycogen, which can be used as a source of energy when glucose levels plunge (Cataldo
and Broadwell, 1986). The main purpose of glycogen storage in astrocytes is to supply
surrounding neurons with energy during times of large activity utilization or during
hypoglycaemia (Brown and Ransom, 2007). Recently, the role of astrocytes and their
coping mechanism with Amyloid β (Aβ) was investigated (Allaman et al., 2010). Aβ is the
main constituent of fibrous protein aggregates associated with Alzheimer’s Disease, a
neurodegenerative disease causing dementia due to loss of neurons. As astrocytes are the
major homeostatic cells in the CNS, the authors’ aim was to investigate how Aβ affected
glucose metabolism in cultured astrocytes. Astrocytes exposed to Aβ increased their uptake
of glucose as well as glycolysis. Furthermore, the authors used a co-culture model with
astrocytes to demonstrate that Aβ treatment of astrocytes reduced neuronal viability. These
observations strongly suggest that astrocytes are key players in energy and metabolism.
1.2.6 Neuronal Support
The presence of astrocytes was originally thought to be for the sole purpose of neuronal
support. Although much more is now known about key roles that astrocytes perform, their
support for neurons remains important, physically by providing structural support and
chemically by modulating the environment via the secretion of growth factors and
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cytokines (Svendsen, 2002). In vitro, astrocytes have been shown to induce neural stem
cells (NSC), which can differentiate into glial or neuronal progenitors, to a neuronal fate by
promoting their proliferation (Song et al., 2002). The authors demonstrated this
observation by culturing NSC with astrocytes, fibroblasts or neurons. Whereas the NSC
cultured with neurons or fibroblasts did not change fate, those cultured with astrocytes
increased the rate of neurogenesis by 8-fold. However, the role of astrocytes in the
damaged CNS is disputed. Original work by Aguayo and colleagues suggests that the adult
CNS environment is inhibitory to neuronal growth (Bray et al., 1991), possibly due to the
environment created by astrocytes.  Indeed, a study by Kinouchi et al. (2003) used
transgenic mice that lack GFAP and vimentin expression to demonstrate this point. The
authors transplanted donor cells engineered to express green fluorescent protein (GFP) and
tracked these cells in wild type and transgenic mice. Transplanted cells in wild type
animals failed to survive and integrate whereas those in the transgenic mice integrated
successfully and had a significant increase in neurite length and extension. Both GFAP and
vimentin are intermediate filaments which have been reported to be upregulated in glial
scar formation, where astrocytes clump together forming an inhibitory physical barrier to
repair (Fawcett and Asher, 1999). However, exactly how GFAP and vimentin contribute
the ability of neurites to integrate is not understood.  Emsley et al. (2004) argued that i)
astrocytes from GFAP and vimentin null mice may be different developmentally and less
able to form scars, ii) astrocytes from transgenic mice may have an altered secretory
profile which creates a more favourable environment for transplanted cells, or iii)
transgenic mice have altered expression of other molecules which may contribute to the
effects observed and that GFAP and vimentin may not be the sole effectors. The
contribution of the glial scar to regeneration post injury is further discussed in Section
1.4.1.
1.2.7 Other Astrocytic Functions
Some of the functions that astrocytes perform in the normal CNS are summarised in Figure
1.3. The functions of astrocytes are diverse and complex and are beyond the scope of this
thesis. Other astrocytic functions include angiogenesis, synaptic network formation,
clearance of excess neurotrasmitters, detoxification of free radicals and many more (Stein
et al., 1995; Krum and Rosenstein, 1998; Ransom et al., 2003; Sofroniew and Vinters,
2010). It is clear that with the diversity of functions astrocytes carry out throughout the
CNS, that they must play a vital role in injury and disease.
18
1.3 Astrocytes and Their Role in Multiple Sclerosis
1.3.1 Multiple Sclerosis
Multiple sclerosis (MS) is an acquired autoimmune disease with usual onset of the disease
occurring in early adulthood, making MS the most common CNS disorder to cause
disability in young people (Noseworthy et al., 2000). Scotland has the highest incidence of
MS cases in the world, with a higher incidence in females than males (Swingler and
Compston, 1986; Ramagopalan et al., 2010) Although disease etiology is not yet fully
understood, it is generally accepted that MS is acquired as a result of a combination of
genetic susceptibility and environmental factors (Compston and Coles, 2008; Ramagopalan
et al., 2010). MS was originally described by Charcot (1868) where the main observation
was the presence of demyelinated plaques. MS has 4 subtypes, namely: primary
progressive, secondary progressive, progressive relapsing and relapsing-remitting (Fig
1.4). Primary progressive tends to show the most disability, where there are no periods of
remission. Secondary progressive initially begins with episodes of disability followed by
continuous decline without periods of remission. Progressive relapsing MS is characterised
by individuals having a steady decline in disability but with defined attacks throughout.
Finally, relapsing-remitting MS is a subtype where spontaneous episodes take place
followed by long periods of remission. The disability that MS causes depends on where the
demyelinating plaques are located, for instance, reduced visual acuity if demyelination is at
the optic nerve (Compston and Coles, 2008). Generally, however, most MS patients suffer
from fatigue, muscle weakness and change in sensation amongst others (Compston and
Coles, 2008).
1.3.2 The Pathophysiology of MS
It is generally accepted that MS is an autoimmune disease, where there is a penetration of
the BBB allowing the access of auto-lymphocytes, namely T cells, into the CNS
(Steinman, 1996).  This leads to destruction of the myelin sheaths that surround myelinated
axons (demyelination). There is also an associated axonal pathology, where the progressive
element of MS is mainly due to the degeneration of axons (Anderson et al., 2008;
Compston and Coles, 2008). A characteristic feature of MS are the plaques, where
astrocytes are the main constituent. They become hypertrophic and show increased GFAP
expression and stellation (Fedoroff et al., 1984; Wu and Raine, 1992; Daginakatte et al.,
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2008). The role of astrocytes in MS is a highly debatable issue in neuroscience, where
some believe that they have a pro-regenerative role via the secretion of growth factors and
maintaining homeostasis for the benefit of the host whilst others believe that they are
completely debilitating by contributing to demyelination and the failure of OPCs to
differentiate (Rudge and Silver, 1990; Eddleston and Mucke, 1993; Silver and Miller 2004;
Williams et al., 2007; Sofroniew and Vinters, 2010). The role of the glial scar in terms of
remyelination will be further discussed in Section 1.4.4.
1.3.3 Astrocytes and Myelination
In order to understand the role of astrocytes in MS, the importance of astrocytes in
myelination in general needs to be discussed. A key indication of their role comes from a
study of mutations in astrocyte specific genes. GFAP, which is upregulated when the
astrocyte becomes activated, was mutated in a series of experiments by Liedtke et al.
(1996). The authors showed that a defective GFAP gene resulted in a loss of integrity of
CNS white matter architecture and long-term maintenance of myelination. Furthermore,
there is a strong association of GFAP mutations with Alexander disease (Brenner et al.,
2001; Li et al., 2002), a neurodegenerative disease classified as a leukodystrophy with loss
of myelin, oligodendrocytes and neuronal degeneration (Alexander, 1949). Mutations in
eukaryotic translation initiation factor 2B5, EIF2B5, causes childhood ataxia with CNS
hypomyelination (CACH) also known as vanishing white matter disease (VWM). This
mutation was found in neural progenitor cells, preventing their differentiation into
astrocytes, suggesting that a lack of astrocytic development in the brain may contribute to
VWM (Dietich et al., 2005). Additional evidence that astrocytes are important for CNS
repair came from elegant transgenic mice experiments in which dividing, and therefore
reactive, astrocytes were selectively ablated after induction of spinal cord injury. Resulting
injury was far worse in groups where astrocytes were removed with a failure of blood-
brain barrier repair, leukocyte infiltration, local tissue disruption, severe demyelination,
neuronal and oligodendrocyte death, and pronounced motor function loss (Faulkner et al.,
2004). These data clearly indicate that the presence of astrocytes is crucial for myelination.
It has been known for many years that astrocytes secrete promyelinating factors that
directly affect the oligodendrocyte lineage. Astrocyte conditioned medium (ACM) is the
media collected, usually overnight, from confluent astrocyte cultures and contains soluble
factors produced by them. ACM has been shown to increase the survival of neurons after
insults and that ACM from different regions of the brain demonstrate varying extents of
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Figure 1.4 MS Course and Subtypes. A sagittal view of
Magnetic Resonance Imaging (MRI) scans of a healthy brain
(A) and one with MS (B). Plaques (as indicated in B) reveal
areas where there is absence of myelin. MS subtypes with
their clinical course and disability scale. Section A and B
taken from health.com and adapted. Section C taken from
Wikipedia.com and adapted.
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neuroprotection (Yoshida et al., 1995; Yamamuro et al., 2003; Zhu et al., 2006). ACM has
also been used as mitogen for OPCs (Noble and Murray, 1984). Recently it has been
shown that the presence of astrocytes allowed faster and more thorough ensheathment of
axons by oligodendrocytes in an in vitro co-culture system (Watkins et al., 2008). The
addition of astrocytes on top a monolayer of reaggregated neurons and OPCs enhanced the
rate and degree of wrapping compared to cultures without astrocytes. Although the above
studies do not specify the mechanisms by which astrocytes affect myelination, it is clear
that they do have a major influence on oligodendrocyte function. Recently, a study by Arai
and Lo (2010) demonstrated that ACM molecules are able to protect oligodendrocytes
against H2O2-induced oxidative stress, starvation, and oxygen-glucose deprivation. They
show that ACM protection is partly via the upregulation of phospho-ERK levels and
phospho-Akt in OPCs, pro-survival signaling pathways in oligodendrocytes (Stariha and
Kim, 2001; Cui and Almazan, 2007). The data above indicate that ACM is rich in factors
which induce pro-differentiation and pro-survival pathways in oligodendrocytes. Although
some molecules have been identified (discussed in Section 1.4.2), many still need to be
recognised. The recognition of these molecules may contribute potential therapies in
demyelinating diseases, where there is a failure in OPC differentiation.
In terms of myelination and astrocytes in development, immunohistochemical studies of
the developing rat spinal cord show that a temporary increase in GFAP positive cells
correlated with an increase in immunoreactivity with the late myelin marker, myelin basic
protein (MBP) suggesting that this increase of GFAP positive cells accompanying
myelination is necessary for normal myelin development (Dziewulska et al., 1999).
A link has been demonstrated between astrocytes, myelination and electrical activity in
axons (Ishibashi et al., 2006). In this study it was shown that astrocytes secrete leukaemia
inhibitory factor (LIF) in response to ATP being liberated from axons firing, which in turn
increased the number of myelinated fibres. Thus, LIF-secretion by electrically stimulated
astrocytes results in enhanced oligodendrocyte differentiation. Therefore, secreted factors
by astrocytes help create an accommodating and permissive environment for
oligodendrocytes to mature into successful myelin-producing cells.
1.3.4 Astrocytes and Models of Demyelination
Experimental models of demyelination have also been used to demonstrate an important
role for astrocytes in subsequent remyelination. These use the glial toxin ethidium bromide
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(ED) to create a focal area of demyelination in the CNS (Graça and Blakemore, 1986). It
has been shown that oligodendrocytes favour the remyelination of axons in areas where
astrocytes were localised (Talbot et al., 2005). The authors show that proliferating NG2+
cells (OPCs) infiltrate demyelinated areas, and that astrocytes are localised within the
perimeter of the lesion and not within it. Interestingly, they find mature oligodendrocytes
and remyelination taking place in the region where astrocytes were localised. Likewise,
transplantation of astrocytes into these experimentally-created demyelinated lesions
enhanced remyelination by host oligodendrocytes (Franklin et al., 1991). These
observations strongly suggest that the presence of astrocytes is essential for the
remyelination process. The failure of OPCs to differentiate into mature myelinating
oligodendrocytes in astrocyte-free areas can be either due to the absence of astrocyte-
derived signaling enhancing terminal differentiation or that astrocyte-free areas have a
negative dominant signal on OPC differentiation (Talbot et al., 2005). Another suggestion
could be that both types of signals compete for the promotion of myelination.
The evidence above suggests that the presence of astrocytes has an influential effect on the
cells within the surrounding environment, including a direct functional effect on
oligodendrocytes. Astrocytes seem to have a dual role in myelination, where their presence
is crucial but they are also the main component of the glial scar, impeding regeneration and
remyelination. Further elucidating the panel of factors secreted by astrocytes in different
conditions will expand our understanding of astrocyte biology and in turn their role in
disease. It is therefore crucial that phenotypes of astrocytes are classified, where their
morphological, antigenic and physiological properties are characterised. Astrocyte
phenotypes can then be related to their biological relevance in health and disease.
1.4 Astrocytes and their Phenotype
In the normal CNS, astrocytes are often described as resting or quiescent (Eddleston and
Mucke, 1993; Holley et al., 2005) but it is more likely that they are actively regulating
normal brain function as described in Section 1.2. In response to damage, astrocytes within
the CNS tissue acquire a change in phenotype known as astrocytosis, where their
morphology, size and secretory profile changes from that of a resting/quiescent astrocyte to
one that is reactive, also known as anisomorphic astrocytosis. It has also been suggested
that there is an intermediate phenotype in which the astrocytes are activated, known as
isomorphic astrocytosis (Liberto et al., 2004). These categories are not completely
exclusive but instead show a graded progression from one to the other, with possible
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phenotypes in between (Sofroniew and Vinters 2010, Fig 1.5). The remyelinating capacity
of oligodendrocytes in the vicinity of astrocytes in injury appears to depend on the severity
of this astrocytic response, whether activated (mild gliosis) or reactive (severe gliosis). In
this section, the aim is to further elucidate the various astrocyte phenotypes and their
characteristics and secretory profiles with emphasis on those that appear to play a role in
influencing myelination.
1.4.1 Mild Gliosis (Activated Astrocytes)
Mild astrogliosis is also often described as isomorphic astrogliosis or astrocyte activation.
This phenotype usually refers to astrocytes which have slightly upregulated levels of
GFAP expression, show some degree of proliferation, and secrete anti-inflammatory
cytokines (John et al., 2003; Liberto et al., 2004). There is currently a general view that
mild astrogliosis is beneficial to axonal regeneration and remyelination in injured CNS
tissue (White and Jakeman, 2008; Sofroniew and Vinters 2010). Cytokine-treated
astrocytes are thought to be activated and have previously been shown to promote
angiogenesis, restore the BBB, neuronal survival and synaptogenesis (Krum and
Rosenstein, 1998; Gozes et al., 1999; Marz et al., 1999; Blondel et al., 2000; Herx and
Yong, 2001; Mason et al., 2001). A great deal of research has been undertaken to identify
the secretory profile of cytokine-treated astrocytes with emphasis on their effect on OPCs
differentiation (Meeuwsen et al., 2003; John et al., 2003, 2005).
1.4.2 Factors Secreted by Activated Astrocytes
Many factors have been reported to be secreted by astrocytes. For example, the treatment
of mouse spinal cord astrocytes with CNTF resulted in an increase in FGF-2 mRNA
(Albrecht et al., 2003). FGF-2 is a growth factor known to be secreted by astrocytes but
thought to act on oligodendrocytes as they express the FGF receptor (Woodward et al.,
1992; Redwine et al., 1998). In a viral-induced model of spinal cord demyelination, FGF-2
mRNA peaked 30 days post infection, the early remyelination stage of disease progression
showing a correlation of FGF-2 expression and myelination (Messersmith et al., 2000).
This study suggests that CNTF induces astrocytes to secrete FGF-2 which then acts on
oligodendrocytes. Since OPCs are present within a demyelinated lesion but are unable to
differentiate, it is suggested that astrocyte-derived FGF-2 acts directly on OPCs to induce
their differentiation and subsequently promote myelination to take place.
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Figure 1.5 Summary of Astrocyte Phenotypes and Key Molecules
used to identify them. The astrocyte can be termed quiescent in
normal adult resting CNS tissue. They can become activated by
various mechanisms that result in mild/isomorphic astrogliosis, with
a mild increase in cytoskeleton markers. Activated astrocytes are also
more distal to the injury site. The most severe phenotype is the
reactive/anisomorphic astrocyte that forms at the gliotic scar. This
phenotype is characterised by a high increase in cytoskelatal
molecules. Based on reviews from Liberto et al., 2004; Ridet et al.,
1997; and Sofroniew and Vinters, 2010. Asterisks represent predicted
information. Arrows indicate direction of expression and intensity.
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Another example of astrocytes affecting the repair process in models of MS is seen by their
interactions with vasoactive intestinal peptide (VIP). VIP is a polypeptide produced in part
by cholinergic and sensory nerves (Goetzl et al., 2001). Astrocytes are responsive to VIP
as functional receptors have been shown to be present on astrocytes in vitro (Magistretti et
al., 1983). The treatment of MOG-induced EAE mice with VIP resulted in inhibition of the
Th1 response and the down regulation of inflammatory cytokines such as RANTES (Li et
al., 2006). It is considered that EAE disease suppression and thus the beneficial clinical
outcome is consequential to VIP acting on astrocytes to release neuroprotective factors.
Indeed, Brenneman et al. (1987) show evidence that conditioned medium from VIP-treated
astrocyte cultures prevented neuronal death in neuronal cultures treated with tetrodotoxin.
VIP was shown to elevate cAMP (a regulator of oligodendrocyte development) levels
within oligodendrocytes in vitro (Wiemelt et al., 2001). The data above demonstrates that
VIP treatment of astrocytes leads to the secondary secretion of neuroprotective agents
which protect neurons, accelerate the rate of oligodendrocyte maturation as well as overall
disease amelioration in EAE.
Astrocytes have been reported to secrete leukemia inhibitory factor (LIF), a member of the
IL-6 family of cytokines (Aloisi et al., 1994; Ishibashi et al., 2006). LIF has also been
shown to promote differentiation of oligodendrocytes and its absence in transgenic mice
(null) reveals a reduction of the mature myelin protein, MBP (Mayer et al., 1994; Bugga et
al., 1998). Furthermore, Khan and De Vellis (1994) show that the addition of LIF to
immature (O4+) and mature (MBP+) oligodendrocytes resulted in a significant increase in
cell survival compared to untreated cultures. Thus, astrocyte-derived LIF has the ability to
potentiate the survival and differentiation of oligodendrocytes. These observations suggest
that LIF may be implicated in inflammatory conditions. To investigate this, Aloisi et al.
(1994) stimulated astrocytes with Interleukin-1β (IL-1β), tumour necrosis factor-α (TNF-
α), and transforming growth factor-β1 (TGF-β1), cytokines known to be increased in MS
and other inflammatory conditions (Selmaj et al., 1988; Barazini et al., 2000; Mirshafiey
and Mohsenzadegan, 2009; Uzawa et al., 2010;). They show that inflammatory cytokines
lead to the increased production of LIF from cultured astrocytes, strongly suggesting that
LIF may play a regenerative role in disease. Indeed, the administration LIF to an EAE
mouse model of MS resulted in decrease of EAE severity (Butzkueven et al., 2002). The
authors show an increase in STAT-3 signaling, which can induce transcription of the anti-
apoptotic proteins Bcl-2 and Bcl-xl (Bowman et al., 2000). Oligodendrocytes also
upregulate LIFRβ, part of the receptor for LIF, and this therefore allows an increased
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response to LIF. These data suggest that LIF secreted from astrocytes generally has a
positive effect on oligodendrocytes during inflammatory conditions.
Mild astrogliosis usually occurs in areas where there is a much less disrupted environment
usually distal from the injury site. The establishment of such astrocytes in these remote
areas may be due to i) the release and widespread diffusion of cytokines from the injury
site, ii) migration of reactive astrocytes from the injured area to distant sites, iii) neuronal
degeneration at the site of injury leading to anterograde and retrograde fibre degeneration
which affects the astrocyte at the projection territory or iv) direct astrocyte injury leading
to reduced gap junction activity which then propagated via the astrocyte syncytial network
to distant astrocytes (Malhotra and Shnitka, 2002). Thus, cytokine-activated distal
astrocytes play a role in the re-establishment of the injured CNS. The presence of these
astrocytes contributes to the regeneration capacity of the tissue, partly via the secretion of
promyelinating factors.
1.4.3 Severe Gliosis (Reactive Astrocytes)
The most extreme form of the astrocyte response, severe astrogliosis, also known as
anisomorphic astrogliosis or astrocyte reactivity, results in a much higher increase in
GFAP expression, elevated proliferation rates, and secretion of pro-inflammatory
cytokines (Fedoroff et al., 1984; Eddleston and Mucke 1993; Daginakatte et al. 2008;
Sofroniew and Vinters, 2010). This astrocytic phenotype is frequently associated with the
glial scar and can occur after any major damage to CNS tissue, for example after spinal
cord injury and in MS. The environment is generally inhibitory to regeneration due to the
presence of inflammatory cytokines, residual tissue damage products and immune cells,
which is why the glial scar is often described as an impediment for axonal regeneration
(Fawcett and Asher 1999; Fitch and Silver, 2008). Reactive astrocytes are mainly
associated with the secretion of pro-inflammatory cytokines. In the next sections, the glial
scar will be described in more detail and pro-inflammatory cytokines are identified and
discussed in terms of their effects on myelination.
1.4.4 The Glial Scar
The glial reaction is a hallmark of many CNS pathologies including multiple sclerosis
(MS), spinal cord injury and Alzheimer’s disease (Eng, 1985; Ridet et al., 1997; Nair et al.,
2008; Vekhratsky and Parpura, 2010).  A severe glial reaction usually forms the glial scar,
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typical of CNS injury. The glial scar is a characteristic feature in MS, where it forms
around areas of demyelination and in spinal cord injury where it forms around the
penetrated cavity and injured axons (Fig 1.6). CNS injuries trigger a widespread response
which is initiated with the infiltration of microglia (resident macrophages in the CNS) as
well as ones from the BBB (Fawcett and Asher, 1999). Indeed, the greater the BBB
disruption the higher the number of macrophages found within the glial scar (Silver and
Miller, 2004). Macrophages in CNS injuries become activated and their main role is to
clear away debris via phagocytosis (Brück et al., 1995). Recently, however, the roles of
macrophages are emerging to be much more complex. For instance, Neumann et al. (2009)
discuss the dual role the microglia can play in inflammatory diseases, where a blockade of
the macrophage receptor TREM2 during the EAE resulted in disease exacerbation whereas
its overproduction by transplanted cells improved disease severity (Piccio et al., 2007;
Takahashi et al., 2007).  Proliferating OPCs then move into the glial scar area, but fail to
differentiate into myelin forming cells (Levine and Reynolds, 1991; Redwine et al., 1998;
Fawcett and Asher, 1999; Talbot et al., 2005). Astrocytes are the main constituent of the
glial scar. The intermediate filaments GFAP, nestin and vimentin are upregulated, there is
cell hypertrophy and upregulation of extracellular molecules (Eddleston and Mucke, 1993;
Fawcett and Asher, 1999; Daginakatte et al., 2008; Sofroniew and Vinters, 2010). The glial
scar forms a physical barrier for regenerating axons. However, the main aim of the glial
scar is to form a barrier that secludes necrotic tissue and prevent widespread tissue damage
(Faulkner et al., 2004; Silver and Miller, 2004). Furthermore, the evolutionary
conservation of the glial scar (Larner et al., 1995) suggests that it must serve some kind of
functional role and its absence may be more detrimental than its presence (Faulkner et al.,
2004).
1.4.5 Factors Secreted by Reactive Astrocytes
As the glial scar is composed mainly of reactive astrocytes, it is necessary to examine their
molecular and secretory changes. Chondroitin sulphate proteoglycans (CSPGs) are a group
of extracellular molecules which have been associated and are thought to play a part in the
regeneration failure in demyelinated regions (Canning et al., 1996; Filious et al., 2010).
The CSPGs include neurocan, brevican, phosphacan and versican. It has recently been
shown that astrocytes treated with chondroitinase ABC (enzyme digesting chondroitin
sulphate chains) and then transplanted into a minimal brain lesion, lead to axonal
regeneration when compared to untreated astrocytes (Filous et al., 2010). Further,
Hunanyan and colleagues (2010) found that the administration of chondroitinase ABC
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prevented the reduction in conduction which is usually observed after chronic unilateral
hemisection in the rat. It is speculated that the presence of CSPG-presenting reactive
astrocytes after injury hinder axonal regeneration and subsequently re-myelination.
The deleterious effects of secreted factors of reactive astrocytes have been well
documented. The most striking is a cytokine from the tumour necrosis factor (TNF) family,
TNFα, which is secreted at low levels by astrocytes in culture but strongly amplified when
induced by pro-inflammatory agents, such as Interferon-γ (IFN-γ) and Interleukin-1β (IL-
1β) (Chung and Benveniste, 1990). TNFα levels increase in EAE (Villarroya et al., 1996)
as well as in the cerebrospinal fluid of MS patients (Tsukada et al., 1991). TNFα has been
reported to induce myelin and oligodendrocyte damage in vitro (Selmaj and Raine, 1991)
and its expression in MS plaques from patients is positively correlated with the extent of
demyelination (Bitsch et al., 2000). Furthermore, it has been shown that the major target
for TNFα is the maturation of oligodendrocytes (Cammer and Zhang, 1999) and thus
supports evidence that OPCs are locally present in lesion sites but are unable to
differentiate. These data demonstrate that the secretion of TNFα from astrocytes
contributes to the damaging and inflammatory environment in MS. However, macrophage
colony stimulating factor (M-CSF) derived from amoeboid microglial cells promoted
TNFα from astrocytes which resulted in axonal degeneration and myelin sheath
disturbance in hypoxic rats (Deng et al., 2010). This suggests that although the astrocyte
may be producing the inflammatory cytokines, it is the presence of the activated
macrophages that initiates anti-regenerative environment.
A range of molecules which are upregulated in MS are known to produce severe gliosis in
experimental models of MS and in cultures in vitro. One of these molecules interferon-γ
(INF-γ) and it is known be expressed by astrocytes and be present in MS plaques (Traugott
and Lebon, 1988; Meeuwsen et al., 2003). High levels of this cytokine are found in
preterm infants with the leukodystrophy White Matter Disease (WMD; Hansen-Pupp et al.,
2005). Yong et al. (1991) aimed to find the effect of INF-γ on the glial reaction after
corticectomy, where a region of the cortex was removed. They then packed an absorbable
Gelfoam soaked with either INF-γ or saline (control). After 7 days, they investigated the
spread and intensity of GFAP using paraffin-embedded sections. They found that IFN-γ
significantly enhanced the extent of reactive gliosis and increased its spread when compare
to controls. Furthermore, Lin et al. (2006) use two models of experimental MS, cuprizone-
induced demyelination and EAE, and transgenic mice in which IFN-γ transgene expression
Figure 1.6 The Glial Scar. Schematic representation of a glial scar.
Fibroblasts and macrophages infiltrate the area. Astrocyte proliferate and
undergo hypertrophy, forming a dense network of interwoven cells.
Astrocytes within the injury site are termed reactive. The extracellular matrix
of astrocytes is altered, where there is an increase in chondoitin sulphate
proteoglycans, amongst other molecules The glial scar forms a physical
barrier to regenerating axons. Astrocytes outside the injury site are ‘activated’
and respond by secreting anti-inflammatory molecules. Taken from Silver
and Miller (2004).
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was selectively targeted to astrocytes. Their results show that IFN-γ was an impediment to
remyelination in the cuprizone model and it also increase disease severity in EAE. They
attribute these effects to endoplasmic reticulum stress in oligodendrocytes. In addition, a
study by LaFerla et al. (2000) used similar mice strains and showed regional
hypomyelination as well as death before maturity. Therefore, not only is IFN-γ an activator
of astrocytes, it is also secreted by astrocytes. These results strongly indicate that
proinflammatory cytokines produced by astrocytes can have a direct functional effect on
oligodendrocytes.
The data presented here highlights the dual role played by astrocytes in disease
(summarised in Fig 1.7); where astrocytes become activated and aid regeneration, or
become reactive and impede it. The factors that lead to the creation of reactive astrocytes
as opposed to activated astrocytes require further investigation. Understanding these
factors may provide avenues for the possible reversal of reactive astrogliosis and may
therefore be of vast therapeutic potential for CNS diseases and injuries. Generally,
however, a reactive astrocyte is regarded as a barrier for regeneration, partly via the
secretion of factors that halt the survival and maturation of OPCs.
1.4.6 Astrocyte Phenotype and Environment
The ability of astrocytes to present a graded response to the intensity of injury highlights
the versatility and adaptability of these cells. Although severe astrogliosis is correlated
with well documented studies regarding them as an obstacle to regeneration, it must be
noted that other cell types, such as microglia (Liberto et al., 2004) are much more
responsive and can override any beneficial effects of the astrocytes. Apart from the vast
array of growth factors and cytokines secreted by astrocytes, the physical barrier they form
may be more protective than inhibitory. The evolutionary conservation of the glial scar
(Larner et al., 1995) suggests that it must serve some kind of functional role and its
absence may be more detrimental than its presence (Faulkner et al, 2004). The cytokine
activation of astrocytes is clearly favourable for OPC proliferation, maturation and
myelination. Dissecting out how cytokine activated astrocytes influence oligodendrocyte
differentiation may provide clues into devising a therapy for demyelinating diseases
The phenotypic state of astrocytes and their ability to support myelination depends on
many factors including the age of the astrocytes, the proximity to injury site and the state
of activation (Fig 1.8). As previously described in Section 1.1.3.2, the age of the astrocyte
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determines its ability to support other cells in injury conditions. This observation is likely
to relate to the activation state of the astrocyte. For instance, astrocytes in neonatal animals
may be more activated compared to the quiescent astrocytes in the adult. If astrocyte
phenotype is considered as a spectrum of reactivity intensity, it can be argued that the
closer the astrocyte is to being in an ‘activated’ state, the better it responds to injury and
subsequently its ability to support (re)myelination. Thus, the neonatal astrocyte is more
equipped to deal with insults than that of an adult. This observation highlights why many
researchers generate neural cultures from neonatal rather than adult tissue. Astrocytes in
vitro are usually grown as a monolayer, which is very different to their 3D environment in
tissue. In fact, the process of dissection and enzymatic dissociation of tissue for generation
of cells in culture may induce an activated state. Indeed, the expression of reactivity
markers, GFAP, vimentin and AQP4, were reduced in astrocytes grown on a 3D collegen
gel system compared to astrocytes grown in a monolayer (East et al., 2009). Furthermore,
astrocytes in vitro are usually exposed to foetal bovine serum whereas those in the normal
brain are not. Serum contains many factors including Bone Morphogenetic Protein-like
factors which can induce astrocyte differentiation (Obayashi et al., 2009). Therefore, the
artificial culture conditions to grow and maintain astrocytes may lead to a higher state of
activation than at their tissue source. As astrocytes in culture have been shown to be
supportive for myelination (Ishibashi et al., 2006; Sørenson et al., 2008; Watkins et al.,
2008) it can be argued that the greater the level of activation, the more supportive an
astrocyte is for myelination (Fig 1.8).
1.5 Conclusions
It is generally accepted that astrocytes within the glial scar inhibit regeneration and can
have negative effects on remyelination (Rudge and Silver, 1990; Silver and Miller, 2004).
Conversely, the emerging view is that astrocytes can also be essential for repair and
subsequently myelination (Williams et al., 2007; White and Jakeman 2008; Sonfroniew
and Vinters, 2010). However, it is thought that these astrocytes are generally at more distal
sites and probably respond to molecules emerging from the damaged area (Ridet et al.,
1997). In fact, astrocytes more distal to injury contribute a great extent to regeneration via
the secretion of growth factors and cytokines (Ridet et al., 1997; Williams et al., 2007;
Nair et al., 2007; Sofroniew and Vinters, 2010). Consistency in the terminology and
classification of astrocytes will be highly valuable for understanding their specific roles in
CNS pathology.
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Figure 1.7 Schematic Representation of Astrocytes in Activated and
Reactive States. A) An astrocyte can be activated by a number of cytokines
which lead to a mild increase in cytoskeletal molecules and the secretion of
factors which aid oligodendrocyte remyelination and development. B) An
astrocyte in reactive state upregulates chondroitin sulphate proteoglycans and
secretes molecules which reduce the ability of oligodendrocytes to remyelinate.
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Research into astrocyte phenotypes looks at a ‘snapshot’ of a very active and constantly
changing environment that is highly dependent on environmental cues. It is important for
future strategies in CNS repair to identify the molecular and cellular changes in these
polarised astrocyte phenotypes. Furthermore, it should be acknowledged that the
environment around CNS damage and demyelinated areas contain very heterogeneous cell
populations and relatively small changes in this responsive milieu may have an impact on
other areas within the CNS. Therefore, results observed are very likely to be due to an
indirect activation of complex cell-cell interactions. It is probable that the dynamic nature
of astrocytes allows them to effectively respond to minute changes in the
microenvironment mainly for the benefit of the host.
1.6 Aims
Data from animal models and in vitro studies suggest that astrocytes in injury and disease
can be protective as well as destructive to regeneration. The phenotype of astrocytes,
which is likely to be modulated by surrounding cytokines, is likely to play a big role as to
whether or not an astrocyte is considered supportive.
In our laboratory, we have developed a myelinating culture system where embryonic
mixed spinal cord cells are plated on top of a monolayer of confluent astrocytes (Thomson
et al., 2008, Sørensen et al., 2008). The cultures develop over 26-28 days and allow the
study of neuronal survival and neurite outgrowth, followed by oligodendrocyte precursor
proliferation and extension of their processes to axons, and eventually progressing to
ensheathment of axons and formation of myelin internodes. Using these myelinating
cultures, we have shown that astrocytes have a direct role in promoting myelination
(Sørensen et al., 2008). In fact myelination was poor on monolayers of other supporting
glia such as olfactory ensheathing cells or Schwann cells, suggesting that astrocytes
promote myelination either by releasing a soluble factor or via cell-cell contact.
The main aim of this thesis is to establish if there is a dual role for astrocytes in
myelination. This will be carried out as follows:
i) Establish culture conditions for astrocytes which could promote or inhibit myelination.
ii) Define and characterise these astrocyte phenotypes and the cells within the myelinating
cultures under conditions identified in i)
iii) Identify the astrocyte-derived molecules that affect myelination using a microarray
approach.
Quiescent Reactive
Activated
Activated
+ Cytokine
activation
Support For Myelination
Proximity to Injury
Distal Proximal
Maximal
Minimal
Ag
e o
f A
str
ocy
te
Ne
on
ata
l
Ad
ult
Injury
Figure 1.8 Summary of How Astrocyte Phenotype can Influence
Myelination. Astrocyte phenotype can be affected by age and location.
Astrocytes in close proximity to the site of injury are typically described as
reactive and their support for myelination is poor. Astrocytes more distal to the
site of injury receive ‘injury’ signals in the form of cytokines and increase their
state of activation, ultimately increasing their support for oligodendrocytes via
the secretion of trophic factors. Astrocyte in the neonatal animals respond
better to injury possibly due to the reactivation state of the astrocytes and are
therefore more equipped to support myelination than in the adult. Green
represents a more positive effect on myelination.
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Materials and Methods
2.1 Tissue Culture
Primary cell culture of astrocytes, olfactory ensheathing cells (OECs) and dissociated
spinal cord cultures were cultured as described below. Neurospheres were cultured in an
uncoated T75cm2 flask whilst astrocytes and OECs were grown on glass coverslips (13 mm
diameter, VWR International, Leicestershire, UK) placed in a 24-well culture plate.
Coverslips were coated with poly-L-Lysine solution (PLL, 13.3 µg/ml in distilled water,
Sigma), for 30 minutes (min) at 37˚C, washed in distilled water (dH2O) and left air dry in
tissue culture hood before use. Other coverslips were coated with Tenascin-C substrate
(TnC, 5 µg/ml, Millipore) for 30 min at 37˚C. TnC was then removed and coverslips left to
air dry. Myelinating cultures on coverslips were grown in 35 mm culture dishes.
All cultures were maintained in a humified incubator maintained at 37˚C with 7% carbon
dioxide. Cultures were fed every other day by removing half the media and replacing it
with fresh media. All media and reagents were filtered through a 0.22 µm filter.
2.1.1 Astrocyte Culture
Neurospheres were generated from both striata of Sprague Dawley (SD) rats aged less than
36 hours (based on methods from Reynolds and Weiss, 1996; Zhang et al., 1998). The
tissue was placed in 1 ml of L-15 (Invitrogen, Paisley, UK) and mechanically dissociated
using a 21G needle. The suspension was centrifuged at 800 rpm (136 RCF) for 5 min and
the pellet resuspended in 20 ml neurosphere media consisting of DMEM/F12 (1:1, DMEM
containing 4,500 mg/L glucose), supplemented with 0.105% NaHCO3, 2 mM glutamine,
5,000 IU/ml penicillin, 5 µg/ml streptomycin, 5.0 mM HEPES, 0.0001% bovine serum
albumin, (all from Invitrogen), 25 µg/ml insulin, 100 µg/ml apotransferrin, 60 µM
putrescine, 20 nM progesterone, and 30 nM sodium selenite (all from Sigma). The
suspension was then placed into a 75 cm3 tissue culture flask (Greiner, Gloucestershire,
UK) and supplemented with 20 ng/ml mouse submaxillary gland epidermal growth factor
(EGF, R&D systems). Every 2-3 days, 5 ml NSM and 4 µl EGF (20ng/ml) was added into
the flask. When the spheres are large enough, they were spun them down (800 rpm for 5
min) and triturated with 1 ml of fresh media to produce smaller spheres/cell clusters. The
cell suspension was then plated into a flask with 10 ml of original media and 10 ml fresh
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media and supplemented with 4 µl EGF for a further 24 hours. The spheres were then
differentiated into astrocytes as described in Thomson et al., (2006). Briefly, the spheres
were plated onto coverslips (13 mm diameter, VWR International, Leicestershire, UK) in
low glucose DMEM supplement with 10% foetal bovine serum (DMEM-FBS10%) and
2mM L-glutamine (both from Sigma) for 7-10 days until a confluent monolayer is formed.
Astrocytes were either plated on  PLL- coated coverslips (13 µg/ml, Sigma)  for making
the standard monolayer support for myelination or TnC coated coverslips (5 µg/ml,
Millipore) for generating a quiescent astrocyte phenotype.
2.1.2 Olfactory Ensheathing Cells (OECs)
Olfactory ensheathing cells (OECs) were isolated from the olfactory bulb of 7 day old SD
pups and purified using magnetic beads (Higginson and Barnett, 2010; STEMCELL
technologies, UK) and the p75NTR antibody (Abcam, Cambridge, UK). The cells were grown
in low glucose DMEM (1000 mg/ml glucose) with 5% FBS and further supplemented with
fibroblast growth factor 2 (FGF2, 500 ng/ml, Peprotech, London UK), heregulin -1 (50
ng/ml, R&D Systems, Oxon, UK), forskolin (5x10-7 M Sigma) and astrocyte conditioned
media (ACM, 1:5, fresh serum free-media taken after incubation with a confluent astrocyte
monolayer for 48 hours,  see Noble and Murray, 1984; Alexander et al., 2002). The cells were
grown on PLL-coated coverslips and either used as supporting monolayers or to condition
spinal cord myelination cultures.
2.1.3 Myelinating Cultures
The method of generating myelinating spinal cord cultures is based on that developed for
mice (Thomson et al., 2008) and rats (Sørensen et al., 2008), with some modifications. SD
rats were time mated and embryos used on E15.5 (day of plugging is embryonic day 0.5).
The pregnant female was killed by carbon dioxide overdose followed by cervical
dislocation. The abdomen was sterilised using 70% ethanol. Using sterile scissors, a cut
was made to expose the muscle tissue, which was also cut. This exposed the female’s
uterus and the embryos were removed, released of the embryonic sack and decapitated
about 3 mm rostra to the cervical flexure and the umbilical cord cut. The bodies of the
embryos were placed in a dish containing L-15 and the skin and tissue were gently
removed, until the spinal cord was uncovered. The meninges were then stripped and the
bare cords were placed in a bijou containing L-15 on ice.
39
The spinal cords (5-6) were then minced with a scalpel blade and enzymatically
dissociated with trypsin (100 µl of 2.5%, Invitrogen, Paisley, Scotland) and collagenase
(100 µl of 1.33%, ICN Pharmaceuticals, UK). Enzymatic activity was stopped by adding 1
ml of a solution containing 0.52 mg/ml soybean trypsin inhibitor, 3.0 mg/ml bovine serum
albumin and 0.04 mg/ml DNase (Sigma, Poole, Dorset, UK) to prevent cell clumping. The
cells were triturated through a 21G needle and spun at 800 rpm (136 RCF) for 5 min. The
cell pellet was resuspended in plating medium (PM, 50% DMEM, 25% Horse Serum, 25%
HBSS). The cells were then plated on to a confluent monolayers of astrocytes or olfactory
ensheathing cells (OECs) at a density of 150,000 cells per 100 µl. Astrocytes were either
directly plated on coverslips coated with either Poly-L-Lysine (13 µg/ml, Sigma, Dorset
UK) or tenascin-C (Tnc 5 µg/ml, Millipore, Durham, UK) to generate quiescent astrocytes
(TnC-astrocytes, Holley et al., 2005). The coverslips are placed in a 35-mm Petri dish and
left in the incubator to attach for 2 hours. A combination of 300 µL of PM and 500 µl of
differentiation medium (DM) (Thomson et al., 2006) which contained DMEM 4,500
mg/ml glucose, 10 ng/ml biotin, 0.5% hormone mixture (1 mg/ml apotransferrin, 20 mM
putrescine, 4 µM progesterone, and 6 µM selenium (formulation based on N2 mix of
Bottenstein and Sato, 1979), 50 nM hydrocortisone, and 0.5 mg/ml insulin (all reagents
from Sigma) was added. After 12 days in culture, the insulin was removed from the DM.
Cultures were fed every 2 days by removing 500 µl of media and replacing it with fresh
DM media.
In some cases on day 12 cultures received designated treatments; CNTF (Peprotech, London,
UK) at varying concentrations of 0.02 pg/ml – 20 ng/ml, CNTF ligand neutralising antibody at
0.5 µg/ml – 32 µg/ml (anti-CNTF) and CNTF alpha subunit neutralising antibody at 0.2 µg/ml
(both R&D Systems, Abingdon, UK), LIF at 2 ng/ml (Millipore, Watford, UK), LIF
neutralising antibody at 0.2 µg/ml, CXCL10 neutralising antibody at 0.2 µg/ml – 2.0 µg/ml,
Neuregulin at 10 ng/ml (all from R&D Systems, Abington, UK), CXCL10 at 10 ng, BDNF at
1 ng/ml (both from Peprotech, UK), IgG1 myeloma protein (0.2 µg/ml, Sigma) and IgG2a
myeloma protein (4 µg/ml, Sigma). The cultures were then cultured for a total of 26-28. For
some experiments, the addition of CNTF or its neutralising antibody was started at day 12, 18
or 24 and every 2 days thereafter until fixation.
2.1.4 Conditioning of E15.5 Spinal Cord Cultures
To determine the effects of OEC conditioned media on the myelination of the mixed spinal
cord cells grown on astrocytes, two coverslips containing confluent monolayers of OECs
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were placed in the same 35-mm Petri dish as the spinal cord cells. This meant that the OEC
were continuously secreting soluble factors for these cultures and alleviates problems of
adding the correct concentration of factors. As controls, 2 confluent astrocyte monolayers
were also placed in the same dish as a coverslip containing spinal cord cells plated on
OECs (results shown in Sørensen et al., 2008). Some dishes were further supplemented
with CNTF (2 ng/ml) on day 12 onwards.
To determine the effects of quiescent astrocytes (TnC-astrocytes) on myelination,
astrocytes grown on a TnC substrate, were placed in the same dish as myelinating cultures
plated on astrocytes on PLL (PLL-astrocytes) to continually condition them. In addition,
confluent PLL-astrocytes were placed in the same dish as myelinating cultures plated on
quiescent astrocytes (TnC-astrocytes). Some PLL-astrocytes were also pre-conditioned
with CNTF. In these experiments, the PLL-astrocytes were treated with 2 ng/ml of CNTF
for 24-48 hours, washed three times in PBS and placed in the same dish as myelinating
cultures plated on PLL-astrocytes or TnC-astrocytes. PLL-astrocytes pre-treated with
CNTF were continually made so that they could be changed in the Petri dish with every
feed.
2.2 Western Blotting
Astrocyte monolayers were washed 3x with PBS and lysed using CelLytic M Cell Lysis
Reagent (Sigma, Dorset, UK) for 15 min at room temperature (RT). The cells were then
scraped off the coverslip and spun down to remove debris. Protein concentrations were
measured using the Nanodrop  (under Protein setting) and equal concentrations of 5-10 µg
total protein for each condition was loaded into a NuPage 4-12% Bis-Tris Gel (Invitrogen,
Paisley, UK) with rainbow molecular-weight markers (Amersham International, Little
Chalfont, UK). The gel was run for 45 min in Running Buffer (Invitrogen), with a constant
voltage of 200V. The gel was transferred using the iBlot (Invitrogen, Paisley UK) and the
membrane blocked with 5% dried milk (Marvel) in PBS and 0.1% Tween (PBST).
Membranes were incubated with either polyclonal rabbit tenascin antibody (1:1000, kind
gift from Andreas Faissner), mouse monoclonal nestin antibody (1:1000; Chemicon
Europe Ltd, UK), polyclonal rabbit GFAP (1:100000, Dako, Glostrup, Denmark) or mouse
monoclonal GAPDH (1:1000, Abcam. UK) in 5% milk in PBST for 1 hour at RT.  The
membrane was then washed with PBST three times for 15 min each and then incubated
with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody for 1
hour at RT in 5% powdered milk in PBST (anti rabbit, 1:10000, Santa Cruz; anti mouse
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IgG1, 1:10000, Amersham). Following a further 3 washes, the membrane was developed
using enhanced chemiluminescence (Amersham) and visualised using Konica Minolta
SRX101A imaging system (Tokyo, Japan). Densitometry was carried out on the bands
using Image J. For statistical analysis, a paired 2 sample t-test was used on the
densitometry arbitrary values, comparing band intensity of treatment group to control
group for both test protein and GAPDH.
2.3 Enzyme-Linked Immunoabsorbent Assay (ELISA)
RayBio® Rat CNTF DuoSet ELISA Kit (Catalog No:  DY557) was purchased from
RayBiotech, Inc. (Insight Biotechnology, Middlesex, UK). CNTF levels were measured
using enzyme-linked immunosorbent assay (ELISA). Media assayed was collected from
astrocytes and myelinating cultures at different time points throughout the culture period
before and after treatment with CNTF and frozen until use. All antibodies and reagents
were diluted according to the manufacturer’s protocol. A 96-well well plate (flat bottom)
was coated with capture antibody overnight at room temperature. The plate was then
washed three times with PSB-Tween 0.05% (PBST 0.05%) using a squirt bottle. After the
last wash, the plate was inverted and blotted against clean paper towels. This ensures that
the complete removal of liquid which is essential for good performance. The plate was
then blocked using 1% BSA in PBS (pH 7.2 - 7.4) for a minimum of 1 hour at room
temperature. The plate was then washed three times with PBST 0.05%. Protein standards
were diluted in media which corresponds to the media in which the samples are in. For
instance, astrocytes media samples are in DMEM-FBS 10% whereas DM was used for
cultures. The same media was also used to dilute the standards. The concentration of
standards ranged from a low concentration of 32.5 pg/ml to a high concentration of 2000
pg/ml, and blank wells containing media only were also included. The standards and
samples were added to the wells in duplicate and left at room temperature for 2 hours. The
plate was washed again and detection antibody added for 2 hours. Following another wash,
Streptavidin-HRP was added to each well and left for 20 min. The plate was placed away
from direct light as Streptavidin-HRP is a light sensitive solution. The plate was washed
once again and substrate solution (1:1 mixture of Colour Reagent A (H2O2) and Colour
Reagent B Tetramethylbenzidine) was added and left for 20 min (R&D Systems Catalog #
DY999) away from direct light. Stop solution (2N H2SO4) was added and the plate was
gently tapped to ensure thorough mixing. The plate was then directly read to determine the
optical density of each well. The reader was set to 450 nm, with wavelength correction set
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to 570 nm. Readings from the standards were used to create a standard curve, off which
sample readings were read.
2.4 Bromodeoxyuridine Assay
Bromodeoxyuridine (5-bromo-2-deoxyuridine, BrdU) is an analogue of thymidine. It is
used as a marker of cell proliferation as it becomes incorporated into the DNA as the cell
divides (S-phase of the cell cycle).
Astrocytes were cultured onto glass coverslips which were previously coated with either
PLL (13.3 µg/ml) or TnC (5 µg/ml) and grown in DMEM-FBS 10% until confluency,
usually 7-10 days. BrdU (10 µM) was added into the medium and left for 18-24 hours. The
cells were then fixed and immunolabelled for anti-BrdU, as described in Section 2.5.2.
To assess whether the treatment with CNTF or its neutralising antibody (anti-CNTF)
results in an increase in oligodendrocyte proliferation, E15.5 mixed spinal cord cells were
plated on a confluent monolayer of astrocytes (PLL-astrocytes) and on day 12, treated with
CNTF (2 ng/ml) or anti CNTF (4 µg/ml) and BrdU (10 µM) and left for 24 hours. The
cells were then fixed and immunolabelled for anti-BrdU and O4 (oligodendrocyte marker,
Sections 2.5.2 and 2.5.3)
2.5 Immunohistochemistry
2.5.1 General Immunohistochemistry
Cells plated on coverslips were taken out of 24-well plate or 35 mm dish and excess media
was blotted against clean tissue paper. Primary and secondary antibodies are listed in
Tables 2.1 and 2.2 respectively. For external markers, antibodies were diluted in cells own
media. For internal marker, antibodies were diluted in blocking buffer (0.1% Triton-X-100
and 0.2% gelatine in PBS).  Between all steps, the cells were washed three times in PBS
and remaining media blotted onto tissue paper. Primary and secondary antibodies were
added at 50 µl volume per coverslip. External markers were stained live (before fixation
and permeablisation). Internal markers were fixed, permeablised and blocked before
addition of antibodies. After the final wash, the coverslips were mounted in Vecatashield
containing DAPI. However, if a blue secondary antibody was used Vectashield without
DAPI was used.
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2.5.2 BrdU Immunohistochemistry
Ice-cold methanol was used to fix and permeabilise the cells. The cells were left at -20˚C
for 10 min, washed in PBST 0.05%, and further fixed using 0.2% paraformaldehyde for 1
min at room temperature. They were washed in PBST 0.5% and 0.07 M sodium hydroxide
was used added for 10 min at room temperature. The cells were washed again and anti-
Brdu (1:20) was added for 45 min at room temperature. After another washing step, anti-
mouse IgG1-TRITC (1:100) was added for 30 min at room temperature. The coverslips
were then mounted in Vectashield with DAPI.
2.5.3 External Markers
Coverslips of cells were blotted gently against a clean tissue paper. Primary antibody was
diluted cell’s own media and added to the coverslip and left for 20 min at room
temperature. The appropriate secondary antibody was also diluted in the cells own media
and left for 20 min. The cells were then fixed in 4% paraformaldehyde for 15 min. If
markers of interest were external only, the cells were then mounted in Vectashield with
DAPI. If markers of interest included internal markers, the protocol described below is
then followed (Section 2.5.4).
2.5.4 Internal Markers
Coverslips of cells are fixed with 4% paraformaldehyde for 15 min and permeablised using
0.5% Triton-X 100. For GFAP, fixation and permeablisation was achieved by addition ice
cold methanol for 15 min at -20˚C. Cells were blocked using blocking buffer (0.1% Triton-
X-100 and 0.2% gelatine in PBS) for 15 min at room temperature. Primary antibody was
diluted in blocking buffer and added for 1 hour at room temperature. Secondary antibody,
diluted in blocking buffer, was added for 45 min at room temperature. Cells were then
mounted in Vectashied with DAPI, unless a blue secondary antibody is used.
2.6 RNA Extraction
RNA extraction was prepared using Qiagen Kit. Astrocytes, which were grown in a
monolayer, were washed three times in PBS. Buffer RLT Plus is the kit’s lysis buffer and it
was added in 380 µl volume to each coverslip and the cells scrapped off gently using a
pipette tip and placed in a sterile eppendorf. The cell lysate was triturated using a sterile
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0.9 mm needle (20 gauge). Cell lysates can be frozen at this point and used at a later time
point. However, RNA can degrade in as little as 24 hours, so it is recommended to extract
RNA immediately. The lysates were then transferred into a gDNA column and spun for 30
sec at 10,000 rpm. All spinning steps in this section are at this speed. The gDNA column
eliminates genomic DNA which will be trapped in the membrane and total RNA will be in
the flow through. A volume of 350 µl of 80% ethanol was then added to the flow-through,
mixed well and transferred into an RNAeasy MinElute column in a 2 ml collection tube
and spun for 15 seconds (sec). The flow through was discarded and total RNA was bound
to the membrane. A volume of 700 µl of RW1 Buffer was added to the membrane and
spun for 15 sec and the flow-through discarded. Another buffer, Buffer RPE, was added
and the membrane spun for a further 15 sec and flow through discarded. The buffer steps
are to wash the membrane which contains total RNA. The column was then placed in a
new 2 ml collection tube and the lid was left open and spun for 5 min to dry the membrane.
The column was then placed in 1.5 ml collection tube and 14 µl of RNA-free water was
added directly onto the membrane and spun for 1 min. The elute contained the total RNA.
The sample concentrations were then measured using Nanodrop under the Nucleic Acids
RNA-40 setting. RNA was extracted for qRT-PCR and Microarray (Sections 2.9 and 2.10,
respectively).
2.7 cDNA Synthesis
cDNA synthesis was carried out for polymerise chain reaction (PCR). RNA was extracted
as described in Section 2.6. Invitrogen Superscript First-Strand Synthesis System was used
for cDNA synthesis and manufacture’s guidelines were followed. All ingredients of the kit
and RNA samples were thawed on ice before use. The kit recommends using up to 5 µg
total RNA.  The RNA was made up in 10 µl volume consisting of 1 µl of Random
Hexamers and dNTP mix (10 mM). The maximum volume of RNA (8 µl) was added, as
long as it did not exceed 5 µg limit. Otherwise, 10 µl was made up using RNA-free water.
The master mix was made up as follows for a 1x reaction:
1x (µl)
10 RT Buffer 2
25mM MgCl2 4
0.1M DTT 2
RNase OUT 1
Superscript III 1
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Table 1.1 Primary Antibody List
Table 2.2 Secondary Antibody List
Antibody Conjugate Dilution Source
Goat anti-mouse IgG1 FITC, TRITC 1:100 Southern Biotech
Goat anti-mouse IgG1 Alexa Fluor: 350, 488,
555
1:600 Molecular Probes
Goat anti-mouse IgM FITC, TRITC 1:100 Southern Biotech
Goat anti-rat IgG FITC, TRITC 1:100 Southern Biotech
Goat anti-rabbit IgG FITC, TRITC 1:100 Southern Biotech
Antigen Raised
in
Isotype Dilution Fixation
method
Internal/
External
Source
A2B5
(oligodendrocyte
progenitor)
Mouse IgM 1:1 n/a External Hybridoma
AA3 (PLP, mature
myelin)
Rat IgG 1:100 4% Para Internal Hybridoma
BrdU Mouse IgG1 1:20 Ice cold
methanol
Internal DAKO
ED1 Mouse IgG1 1:100 n/a External Abcam
GFAP Rabbit IgG 1:500 Ice cold
methanol
Internal DAKO
Nestin Mouse IgG1 1:200 Ice cold
methanol
Internal Abcam
NG2 Rabbit IgG 1:200 n/a External Chemicon
O4 (pre-myelinating
oligodendrocyte)
Mouse IgM 1:1 n/a External Hybridoma
SMI31
(phosphorylated
neurofilament)
Mouse IgG1 1:1500 4% Para Internal Covance
Tenascin C Rabbit IgG 1:100 n/a External Gift from
Andreas
Faissner
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Superscript III is the enzyme which reverse transcribes the RNA to cDNA. The master mix
was made up according to the number of samples there were and took into account
pipetting error. The magnesium ions and the buffer, which create a neutral pH, create a
favourable environment for reverse transcription. The DTT reduces disulfide bonds and
therefore used as a stabiliser for the reaction.
Using a heating block (Biometra T3 Thermocycler) the program below was selected:
Temp (˚C) Time (hh:mm)
1. 65 00:05
2. 4 pause pause to add master mix
3. 25 00:10
4. 50 00:50
5. 85 00:05
6. 4 pause pause to add RNase H
7. 37 00:20
8. 37 pause
The mixture with the RNA was placed into the heating block for 5 min. This allows the
random hexamers to anneal to RNA. A volume of 10 µl of the master mix is added to each
RNA sample and left for a total of 65 min at varying temperatures, optimal for SuperScript
III. The enzyme reverse transcribes RNA to make copies of cDNA. A volume of 1 µl of
RNAse H is added to the mixture and left for a further 20 min at 37˚C, the optimal working
temperature for the enzyme. This step eliminates template RNA via degradation. The
concentration of resulting cDNA samples is measured using the Nanodrop under Nucleic
Acids ssDNA 30 setting.
2.8 Polymerase Chain Reaction (PCR)
The aim of using PCR is to test whether designed primers work effectively and to
acknowledge the presence of genes of interest in samples.
2.8.1 Primer Design
The full genomic sequence the gene of interest was searched for in a genome informatics
website (http://genome.ucsc.edu/cgi-bin/hgGateway). This sequence was transferred into a
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primer design website (Primer 3, http://frodo.wi.mit.edu/primer3/) and the introns were
manually removed, leaving behind coding DNA only.
For instance:
Genomic Sequence
TCTTGAGGAAGATCCATGAGGAGgtgaggccagggagggggagggaaggg
ccttacgagaaactgcaggtgatagacagagacgctcacagagggaaacggagaaaccaaatttca
ggaagaaaacaaaaacgagagaaagagtgaagactttacttttactttttgacaggatatcactgtgtag
ccttggctggcctgtataaatggcagacagaggcgtgagtctgggagagtgcagcctaggccccccs
AGTTCGAGAACTCCAGGAGCAGCTGGCCCAGCAGCAGGTCCA
GTGGAGATGGATGTGGCCAAGCCAGACCTCACAGCGGCTCTG
AGAGAGAT
Genomic Sequence after intron removal
TCTTGAGGAAGATCCATGAGGAG
AGTTCGAGAACTCCAGGAGCAGCTGGCCCAGCAGCAGGTCCA
GTGGAGATGGATGTGGCCAAGCCAGACCTCACAGCGGCTCTG
AGAGAGAT
Between the last two nucleotides of the first coding region, a left square bracket is added.
And between the first two nucleotides of the second coding region, a right square bracket is
added. This aids the program to identify the beginning and ends of region. This is shown
below:
TCTTGAGGAAGATCCATGAGGA[G
A]GTTCGAGAACTCCAGGAGCAGCTGGCCCAGCAGCAGGTCCA
GTGGAGATGGATGTGGCCAAGCCAGACCTCACAGCGGCTCTG
AGAGAGAT
The above sequences go from 5' to 3'. The product size is selected to be between 100 and
150 bases long. Primer melting temperatures were set to an optimum of 60˚C (min 57˚C,
max 63˚C). Primer 3 designs 5 primer pairs per gene.
Coding DNA (exons)
Non Coding DNA
(introns)
Coding DNA (exons)
Non Coding DNA
(introns)
Coding DNA (exons)
None Coding DNA
(introns)
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Primer 3 selects primers for the gene of interest which fit the criteria above. These primers
were then entered into the Sigma Specialty Primers E@sy Oligo® website
(http://www.sigmaaldrich.com/configurator/servlet/DesignTool?prod_type=E@SYOLIGO
). This service will construct the primers to a concentration of 100 µM. It also predicts the
likelihood of a secondary structure, i.e. the possibility of the primer folding over itself
rendering it inactive. If the likelihood is high, another primer pair was selected. Upon
arrival, a working concentration of 10 µM was made up with RNA-free water.
2.8.2 PCR Reaction
Deoxiribonucleotides (dATP, dCTP, dGTP and dTTP) were used at a working
concentration of 10 µM. The reactions were made up in snap-cap PCR tubes in 25 µl
volume for 1x reaction. The amount required was calculated depending on sample number
and took into account pipetting error.
Reaction (25 µl reaction)
1x (µl)
Taq Buffer Green 5
Forward Primer 2.5
Reverse Primer 2.5
dNTPs 0.5
Taq (DNA Polymerase) 0.25
ddH2O 13.25
cDNA template 1
The cDNA template and enzyme (DNA Polymerase) were added last. Reaction tubes were
then placed in a thermocycler (echne Touchgene Gradients) set to the conditions below:
Program:
Time Temp (ºC)
Initial denaturation 00:02:00 95
Number of Cycles: 35
Seg Max 00:00:30 95
Seg Max 00:00:30 55
Seg Max 00:00:30 72
Final extension 00:05:00 72
Final hold 4
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2.8.3 Agarose Gel Preparation
Agarose was made up in TAE buffer which is comprised of
Tris(hydroxymethyl)aminomethane (Tris), acetate and ethylenediaminetetraacetic acid
(EDTA). The combination provides optimum pH required for DNA migration down the
gel. EDTA is used due to its scavenging metal ions property therefore suppressing damage
to DNA. A 2% agarose gel was made up and heated in a microwave for 1 min. It was then
taken out and swirled. If the powder was not dissolved completely, it was returned to the
microwave for a further 10 sec. This step was repeated until powder has completely
dissolved. It was the left to cool, but not solidify. Ethidium bromide, a fluorescent dye used
to visualise DNA in Ultra Violet light, was added (final concentration 0.5 µg/ml) and the
bottle given a gentle swirl.  The gel is then poured into a casting tray with a comb, for the
desired number of wells. The gel is set when it turns into an opaque colour.
2.8.4 Running and Visualising the Gel
When the gel set, the comb was carefully removed and along with the plastic tray
underneath, the gel was fully submerged into EDTA in the electrophoresis chamber. DNA
samples were loaded into the wells, alongside a 1kb DNA ladder. The power leads were
connected and the voltage applied 80 V and current variable for 1 hour. This procedure
separates molecules on the basis on their rate of movement through a gel under the
influence of an electrical field. As DNA is negatively charged, when placed electrical field,
it will migrate towards the positive pole. Thus, the gel is used to control the movement of
these molecules depending on their size. The gel is then visualised under a gel
documentation system (Alpha Innotech). An image of the gel is then acquired and printed.
Based on the DNA ladder and migration of the DNA, the presence of genes in sample was
checked for the tested primers. This procedure is done as it inexpensive to ensure working
order of primers before embarking on Real-Time PCR (Section 2.9).
2.9 Quantitative Real-Time PCR (qRT-PCR)
Real- time PCR offers a method of measuring the extent of gene expression compared to a
sample group, using the delta delta Threshold Cycle (CT, Section 2.9.3) as an end-point
measurement.
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The RNA of TnC-astrocytes and PLL-astrocytes with or without treatment with CNTF (2
ng/ml) was extracted at 4 hours and 24 hours, post-treatment as described in Section 2.6
and the cDNA synthesised as described in Section 2.7.
2.9.1 Plate Preparation
A semi-skirted 96-well plate was used for the reaction. Triplicates of each sample were
used. SYBR Green® contains a synthetic fluorescent dye which binds non-covalently to
DNA. As it binds to DNA, it emits light (522 nm), which can be measured. By comparing
the fluorescence emission between sample groups, the relative amount of DNA can be
quantified. SYBR Green® also contains AmpliTaq Gold® DNA polymerase, the enzyme
catalyzing the polymerisation of deoxiribonucleotides into a DNA strand. The mixture also
contains all dNTPs (dATP, dCTP, dGTP and dTTP) with dUTP, the enzyme which
removes dUTP from the enzyme pool reducing the probably of dUTP being incorporated
into the DNA. The master mix was calculated for each gene (number of samples x number
of wells per sample).  The master mix for a 1x reaction is as follows:
Reaction (20 µl)
1x (µl)
SYBR Green® 10
Forward Primer 2
Reverse Primer 2
ddH2O 4
cDNA template 2
The cDNA template was added directly into the well and not incorporated into the master
mix. This was to avoid making a master mix for each gene for each condition and also to
prevent reaction taking place whilst other master mixes were being made up.
2.9.2 Reaction Conditions
A 7900HT Fast Real-Time PCR System with SDS 2.3 software was used for the reaction.
The software was set up to the conditions of the plate, setting GAPDH as an endogenous
control gene.
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The plate was inserted into the machine and the following program was performed:
Temperature (˚C) Time (mm:ss)
Stage 1 95 10:00
Stage 2 (x40 cycles) 95 00:15
60 01:00
Stage 3 95 00:15
60 00:15
Stage 4 (dissociation) 95 00:15
In stage 1, the temperature is raised so that dissociation of the double-stranded DNA
occurs. In stage 2, the temperature is lowered to allow primers to anneal. Stage 3 follows
with a raise in temperature, which is optimal of the DNA polymerase to synthesise new
DNA. As noted above, stage 2 also consists of a raised temperature phase and is repeated
40 times. This is to denature double-stranded DNA and allow the exponential growth of
DNA product. The dissociation step is to confirm the presence of one gene in the sample
tested (i.e. one peak equals one gene).
2.9.3 Data Quantification
The data output is in cycle threshold (CT) in triplicate values for each condition and each
gene. The CT value is the number of cycles required for the fluorescence to cross the
threshold level (background level). These values are inversely proportional to the amount
of target nucleic acid in the sample. Thus, the higher the CT value, the more cycles were
required to cross this threshold and the fewer amount product initially there.
The values are assessed and any outliers removed. The mean of each CT for each gene and
each condition is calculated. Relative gene expression is the chosen quantification method,
as opposed to absolute quantification. When using the relative quantification method data
is represented relative to a housekeeping gene, such as GAPDH. The comparative CT
method, known as the 2-ΔΔCT (Livak and Schmittgen, 2001), was used as it describes data
in terms of fold change. This method was used to analyse the data output and is described
below:
2-ΔΔCT = (CT gene of interest - CT internal control) Treatment Sample
- (CT gene of interest - CT internal control) Control Sample
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By performing this calculation, the expression of the Treatment Sample is expressed in
relative terms to the Control sample. The 2-ΔΔCT of treatment condition is normalised to
that of the control, presenting data as relative quantification (RQ) for straightforwardness.
2.10 Microarray
A microarray is a method of measuring the expression value of thousands of known genes
in samples.
The RNA of astrocytes plated on PLL or TnC, some PLL-astrocytes treated with CNTF (2
ng/ml) was extracted at 4 hours and 24 hours post-treatment as described in Section 2.6.
2.10.1 RNA Integrity
In order for successful hybridisation to take place, excellent RNA integrity is crucial. To
assess this, each sample was assessed using 2100 bioanalyzer. A volume of 2 µl of each
sample was placed on an RNA 6000 Nano LabChip platform, a platform to measure RNA
concentration and quality.
RNA integrity is a measure of the proportion of RNA that is full-length and thus exhibits a
ratio of 2:1 of the 28S and 18S rRNA bands. Partial degradation of RNA may translate to
incomplete cDNA which lacks the coding region required. The software takes into account
the entire electrophoretic trace of the sample, which includes degradation products, and
gives an RNA Integrity Number (RIN). A sample read out is presented in Figure 2.1.
2.10.2 RNA Amplification and Biotinylation
The amplification and biotinylation of RNA is a required step for DNA hybridization. An
Illumina® TotalPrep RNA Amplification kit was used for this procedure and
manufacturer’s guidelines were followed.
Reverse transcription to synthesize first-strand cDNA was performed using a thermal
cycler with a heat-adjustable lid.
RNA (250 ng) was placed in a 0.5 ml RNA-free tube and made up with Nuclease-free
water if required, to make up a total volume of 11 µl.
53
Reverse-transcriptase master mix was prepared as follows:
1x Reaction (20 µl) (µl)
T7 Oligo(dT) Primer 1
10X First Strand Buffer 2
dNTP Mix 4
RNase Inhibitor 1
Array Script 1
A volume of 9µl of the master mix was added to each RNA sample (11 µl). The samples
were then placed in a thermal cycler and set to the following program:
Temperature (ºC) Time (hh:mm) Cycles
42 (50 lid) 02:00 1
4 hold
The temperature and reagents are optimal for the Oligo Primers to anneal.
Second strand cDNA master mix was prepared.
1x Reaction (100 µl) (µl)
Nuclease-free Water 63
10X Second Strand Buffer 10
dNTP Mix 4
DNA Polymerase 2
RNase H 1
Second Strand master mix (80 µl) was added to each sample (total 100µl) and placed back
into a thermal cycler at the following settings:
Temperature (ºC) Time (hh:mm) Cycles
16 (disabled lid) 02:00 1
4 hold
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The temperature and reagents are optimal for DNA polymerase to bind and reverse
transcribes the first-strand whilst RNase H removes any template RNA.
cDNA binding buffer was then added and mixed by gently pipetting. The whole mixture is
then placed in cDNA Filter cartridge and spun for 1 min at 10,000 rpm. This step ‘cleans’
the amplified cDNA and traps it in the membrane. The flow-through is discarded. Wash
buffer is added to the filter cartridge and spun for another 1 min at 10,000 rpm. The flow-
through was discarded and the filter cartridge transferred to a cDNA elution tube. Pre-
heated (50˚C) Nuclease-free water (20 µl) was added to filter cartridge, left at room
temperature of 2 min then spun for 1 min at 10,000 rpm. The elute contained the double-
stranded cDNA samples were then transferred to PCR-tubes.
In vitro transcription (IVT) is a method of producing cRNA from cDNA. The reaction
takes place in the presence of biotinylated NTPs. The master mix also contains buffers and
enzymes to create biotinylated-single stranded cRNA.
1x Master mix for IVT (25 µl)
(µl)
T7 10X Reaction Buffer 2.5
T7 Enzyme Mix 2.5
Biotin-NTP Mix 2.5
A volume of 7.5 µl of the above master mix was added to each cDNA sample and mixed
thoroughly by pipetting. The mix was then placed in a thermal cycler under the following
settings:
Temperature (ºC) Time (hh:mm) Cycles
37 (lid 100-105) 04:00 – 14:00 1
4 hold
To stop the reaction, 75 µl was added to each sample. The end product is cRNA –
complementary RNA from cDNA.
The cRNA purification step removes any enzymes, salts and unincorporated nucleotides.
To each sample, 350 µl of Binding Buffer was added followed by 250 µl of 100% ethanol
and mixed by pipetting up and down. Each sample was placed in cRNA Filter cartridge
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and centrifuged for 1 min at 10,000 rpm and the flow-through discarded. cRNA filter
cartridge was then placed in a collection tube and 650 µl of wash buffer added to each
sample and spun for 1 min and flow-through discarded. The filter cartridge was then
moved into a new collection tube and 200 µl of pre-warmed (50˚C) directly onto the filter
and placed in heat block for 10 min at 55˚C. The samples were spun for 2 min. The
purified cRNA is collected in the elute of about 200 µl.
Sample A
Sample B
Figure 2.1 RNA Integrity. Sample A shows intact rRNA, with the two ribosomal peaks
clearly observed at a 2:1 ratio. Sample B has degradation of rRNA and shows a shift
towards shorter fragment sizes.
18s 28s
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2.10.3 Direct Hybridisation Assay
Two Illumina RatRef-12 Expression BeadChip microarrays were used to assess the gene
expression of the 15 samples.  These samples came from RNA generated from astrocytes
plated in 5 different conditions: PLL-astrocytes for 4 hr and 24 hr, PLL-astrocytes with
CNTF for 4 and 24 hours and TnC-astrocytes for 4 hr (n=3 / group; astrocytes were
derived from different groups of pups, each from a different outbred female). The
Beadchip was hybridized at 58˚C overnight.
cRNA was made up to 750 ng and 5 µl of RNase-free water was added into each sample.
Setting Up the BeadChip Hybridization Chamber - Humidity Control Buffer (HCB) and
Hybridization Buffer (HYB) are buffers used for the reaction and were pre-heated in a
58ºC oven for 10 min to dissolve any precipitated salts. BeadChip Chamber, gasket, and
inserts were assembled as directed by manufacturer’s instructions. A volume of 200 µl of
HCB was loaded into each reservoir (Fig 2.2) of the chambers to be used.
Preparation of Beadchip for Hybridization - All samples were preheated to 65˚C for 10
min and allowed to cool at room temperature. Samples (15 µl of each) were loaded into the
loading points (Fig 2.3). Wells without samples had HYB. The BeadChip was then placed
into the chamber. The chamber was securely fastened and placed into 58˚C oven for 16
hours.
Washing Steps - The chamber was removed from the oven and disassembled. The
BeadChip was removed and submerged into a beaker containing 1 L of diluted Wash
E1BC buffer (provided with the kit). Whilst still submerged, the cover-seal of the
BeadChip was removed. The BeadChip was transferred into a slide rack and staining dish
also containing wash buffer and then placed into a Hybex Waterbath containing High-
Temp Wash Buffer for 10 min.
Washing Steps - After the 10 min incubation, the BeadChip was returned to the staining
dish with wash buffer and plunged in and out for several times and then shook on an
orbital shaker for 10 min. This step was followed by a 100% ethanol wash for 10 min.
BeadChip was again submerged in fresh wash buffer and washed for 2 min.
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Block - BeadChip was then placed in a wash tray with 4 ml of blocking buffer and it was
shook for 10 min at room temperature.
Signal Detection - BeadChip was placed in a new wash tray containing Streptavidin-Cy3 in
block buffer and left on a shaker for 10 min. This step was followed with another wash
step in wash buffer on the shaker for 5 min.
Drying the BeadChip- BeadChip was centrifuged for 4 min at 275 rcf at 25˚C.
Reading the BeadChip- The Illumina BeadArray Reader (Illumina, San Diego, CA) was
used to measure bead fluorescence using a 2-channel 0.8 µm resolution confocal laser
scanner.
2.10.4 Analysis of BeadChip Data
Data was quantile normalised in BeadStudio (Illumina, San Diego, CA) and Rank Products
(RP) (Breitling et al., 2005) was used to assess the statistical significance of pairwise
intergroup differences. Significance was determined using the False Discovery Rates (FDR)
multiple testing correction method (Benjamini and Hochberg, 1995), with a FDR cut-off of
5%. Venn diagrams were used to look for consistent differences between TnC-astrocytes and
PLL-astrocytes, with and without CNTF. Differences between PLL-astrocytes with or without
CNTF treatment at 4 and 24 hrs were also investigated.
2.11 Microscopy and Image Analysis
Cells were imaged using Olympus BX51 fluorescent microscope and Image-Pro software.
For myelinating cultures, the SMI31-positive axons are usually immunostained with
TRITC-red whilst the PLP-positive myelin sheaths with FITC-green. Images were taken
according to these colours by taking an image of each channel individually and then
merging them to create a composite image and saved as a TIFF file.
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Figure 2.2 BeadChip Hybridization Chamber. The image shows the hybridization
chamber, its lid, the gasket and the reservoirs were buffers are added. Image taken from
Illumina Whole Genome Gene Expression Direct Hybridization Assay Guide (page 20)
and slightly modified.
Figure 2.3 Loading Bay of the BeadChip. The images represents a BeadChip and the
arrow indicates where loading bays are. Image from Illumina Whole Genome Gene
Expression Direct Hybridization Assay Guide (page 22).
Reservoirs
Lid
Gasket
Chamber
Loading Bay
59
2.11.1 Neurite Density
For quantitative analysis of neurite density and myelination, 10 images from each coverslip
were taken at random at 10x magnification. Images were taken randomly to avoid
experimental bias. Each condition for each experiment was performed in duplicate,
therefore, 20 images were taken per condition per experiments, and experiments were
performed in triplicates. Thus, a total of 60 images for each condition were used for
quantification and analysis.
Axonal density was measured using Image J software (NIH systems, version 1.45). The
pixel value of the SMI31 reactivity (neurites) was measured as a percentage of the total
pixel value in one image (total area) and therefore the ‘neurite density’. The image was
opened in Image J and split into the 3 colour channels (red, green and blue). The empty
blue window and the green myelin sheaths window were both closed down, leaving the red
channel showing the neurites open (Fig 2.4). The number of black and white pixels was
obtained from the histogram selection and the percentage of black pixels was calculated
(black pixels ÷ total pixels [black and white pixels] X 100 = % black pixels) for each
image in Microsoft Excel.
Figure 2.4 Measurement of Neurite Density. Composite image consisting of both
SMI31 (red) neurites and PLP (green) myelin sheaths and oligodendrocytes was split into
the 3 colour channels (red, green and blue) in Image J. The red channel was converted into
black and white pixels and black pixels were measured as percentage of total.
2.11.2 Myelin Quantification
The AA3 antibody recognises both myelin sheaths and oligodendrocyte cell bodies
therefore making it difficult to look at PLP immunoreactivity alone for the calculation of
myelinated axons. It was therefore essential to manually identify and draw along the
red
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myelinated sheaths using Adobe Photoshop (Elements 7.0) and brush shape size 9 using a
pure blue colour (Blue:255, Red:0, Green:0). Whilst manually drawing on the myelin
sheaths, the PLP-positive oligodendrocyte cell bodies were avoided (Figure 2.5, white
arrows). The myelin is drawn on 20 images for one condition in one experiment and 3-4
representative images are opened in Image J. The colour channels are split, this time
keeping the green channel open. The threshold of the average of the green channel is noted
for each condition. A micro was programmed (Myelin Micro, see appendix) to calculate
the amount of green and blue overlap, the pixel number representing the amount of
myelinated axons. The micro calculated the value for all images within that condition.
These values are then exported into Microsoft Excel, where they are expressed as a
percentage of the total red pixel value (SMI31 reactivity, see Section 2.11.1) and therefore
representation of the percentage of myelinated axons. Each green/blue image pixel value
will correspond to its own red axonal density value.
Figure 2.4 Myelin Quantification. Composite image consisting of both SMI31 (red)
neurites and PLP (green) myelin sheaths and oligodendrocytes was opened in Adobe
Photoshop and myelin sheaths were marked manually using a blue colour. Using a micro
in Image J, the blue and green overlap in pixel was measured and expressed as percentage
of total SMI31 reactivity for the particular image.
2.11.3 Quantification of Cell Number
In order to assess the number and type of oligodendrocyte lineage cells present, ten images
were taken per coverslip (i.e. condition) per experiment, totalling up to 30 images per
condition for three experimental repeats. Myelinating cultures were cultured as described
in Section 2.1.4 and fixed and stained at 24 hours, 6 days and 12 days post treatment
(treatment begins on day 12). The images were taken at x40 magnification and opened in
Image J. For any of the markers, all positive cells which contained a nucleus were
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manually counted using the Image J Cell Counter function. Further, all the nuclei was
counted. Positive-cells for a particular marker are then expressed as percentage of the total
number of cells for that image or the mean number of positive cells per view.
2.11.4 Cell Proliferation
To assess whether there was an increase in oligodendrocyte differentiation following
treatment, myelinating cultures were fixed and stained 24 hours post treatment (treatment
begins on day 12). Markers used were O4 (pre-myelinating oligodendrocyte marker), BrdU
(cells in S-phase) and DAPI (nuclei). Ten images were taken per time-point, per condition,
totalling in 15 images for 3 experimental repeats. The images were opened in Image J and
the Cell Counter feature was used to manually count marker-positive cells. The number of
O4-positive cells, which were also BrdU-positive were presented as mean number of
proliferating oligodendrocytes per view. The same calculation was used to compare
proliferation rates between PLL-astrocytes and TnC-astrocytes using GFAP, BrdU and
DAPI.
2.11.5 Neurite Diameter
In order to assess whether there was an increase neurite diameter with CNTF treatment, 10
images of each condition were taken at 10x magnification of myelinating cultures at day
26. Each image was opened in Image J and a representative area was zoomed into 6 times
(6 clicks). Using the Straight Line selection, a line was drawn across the diameter of the
SMI31 positive neurite and these measurements recorded. Within the area, the axons were
chosen randomly. It was also noted whether the axon was myelinated or not. The arbitrary
measurements were converted to µm using the scale bar in the image. A total of 50 images
were taken for each condition in each experiment. Experiments were done in triplicate.
2.11.6 GFAP and Nestin Immunoreactivity
In order to calculate GFAP and nestin reactivity, images within one experiment were taken
at the same threshold for all conditions. Ten images per condition for each experiment
were taken. Using Image J software, the colour channels were split separating GFAP (red
channel) and nestin (green channel). For each split channel, a freehand selection was made
around each cell for and integrated density and size were measured. The integrated
intensity was measured as ratio of the cell size.
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2.12 Statistical Analysis
For comparison of values between groups of conditions, data was analysed using paired
Student’s T-test in Microsoft Excel. All values were expressed as means ± the standard
error of the mean (SEM). Significance was represented using p-values where values below
0.05 were considered significant and were indicated by the presence of an asterisk.
For myelinating cultures, the percentage of myelinated neurites was expressed as a ratio of
the value in the untreated group. Data was analysed using one sample Student’s T-test,
using 1 as the null hypothesis mean. When different substrates were used, i.e. astrocytes
and OECs, the data was not logged and 0 was used as the null hypothesis of the mean.
Chapter 3
Characterisation of the Myelinating
Culture System
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Characterisation of the Myelinating Culture System
3.1 Introduction
3.1.1 Background
Myelination is the process by which an axon becomes insulated by a proteolipid membrane
known as myelin. Oligodendrocytes, the myelin forming glial cells of the CNS extend their
processes and wrap myelin in segments (known as internodes) around axons. This process
is necessary for axons to propagate electrical signals via salutatory conduction. Although
research has unveiled many aspects of this dynamic process, there is still more required to
fully understand it. Furthermore, myelin-related acquired diseases, such as multiple
sclerosis (MS), as well as hereditary metabolic diseases such as the leukodystrophies, are
still not understood and are treated only on a symptomatic basis. This raises the demand for
laboratory investigations to reveal the exact causes behind myelin-disorders and in turn
expose ways which they can be treated. This demand has given rise to a number of in vitro
models for myelination which will be discussed and evaluated here.
The main culture systems used to study myelination are categorised as either organotypic
(slice cultures), dissociated or co-culture. Organotypic models require a tissue fragment
from the host’s CNS, usually a segment of the spinal cord. Dissociated cultures involve the
enzymatic digestion of a CNS region to a single-cell suspension and maintaining it until it
forms a CNS-like environment. Co-cultures involve culturing purified cells, such as
neurons and oligodendrocyte precursor cells (OPCs), then cuturing them together to
generate a more defined system.
The organotypic model uses CNS tissue grown in defined conditions and it has been
widely used to observe neurite outgrowth and myelination (Bunge and Wood, 1973;
Gähwiler et al., 1997; Thomson et al., 2006). These cultures are usually generated from
neonatal tissue and one advantage is that the cytoarchitecture, the cell composition and
their arrangement in the tissue, is well established. A disadvantage is that myelination
tends to take place in the main mass of the explant and makes visualisation at a single cell
level difficult with conventional light microscopy (Thompson et al., 2006). Furthermore,
the process is also time-consuming (period 2-4 weeks). Organotypic cultures which are
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sliced into thin sections (300-400 µm) have also been developed as they allow the ease of
biochemical manipulation, for example using antibodies (Seal, 1977; Notterpek et al.,
1993).
Another myelinating culture system is the co-culture method, where the purified neuronal
cells can first be established followed by the later addition of OPCs, which over time
ensheath the axons. Chan et al. (2004) used a system where dorsal root ganglion (DRG)
neurons are dissected and purified from the embryonic rat (E14). OPCs (from P7-8 pups)
are also purified and added on top of already established DRG neurons. Myelination can be
observed after 14-15 days; where OPCs have differentiated in mature oligodendrocytes and
ensheathed axons. It must be noted, however, that DRG neurons are part of the peripheral
nervous system (PNS) and that axonal signals that prompt ensheathment differ from the
CNS (Michailov et al., 2004; Brinkmann et al., 2008). Watkins et al. (2008) used retinal
ganglion cells as the neuronal source and OPCs from a cortical origin. They demonstrated
that the co-culture of these leads to fully myelinated fibres after 3 days in vitro. The co-
culture system provides a defined system where the addition of biochemical or other cell
types, such as astrocytes, is feasible. This system allows the identification of the effect of
particular biochemical agents to a particular cell type. However, whether it is a true
representation of the CNS environment is questionable. Furthermore, another main draw-
back is the lack of other relevant cell types in the culture such as astrocytes and microglia,
therefore reducing the validation of the system.
The dissociated spinal cord culture system has been previously described in rat (Sørensen
et al., 2008) and mouse (Thomson et al., 2008). These cultures require the use of intact
CNS tissue which is then enzymatically digested and plated on a coverslip, or in the case
of rat cultures, on a monolayer of neurosphere-derived astrocytes. The cultures develop
over a period of 4 weeks, where neuronal growth, OPC proliferation and differentiation
take place and ensheathment of surrounding neuronal processes. Although the cultures are
plated on coverslip, they grow dense enough to create a 3D environment. The cultures also
allow for easy immunolabelling, visualisation as well as protein and RNA extraction.
However, the culture’s main drawback is the presence of so many cell types makes it
difficult to pinpoint the exact cell type(s) affected by a particular treatment. However, this
can be overcome with markers to identify particular cells types and/or receptors, to some
extent.  Ironically, this is also an advantage, as the heterogeneous cell population more
closely resembles the intact CNS.
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The spheroid model is another type of a dissociated culture system. It comprises of
dissociated embryonic rodent CNS cells, and by constant rotation, sphere-like cultures
form (Vereyken et al., 2009). The authors argue that this model creates a 3D environment,
more closely resembling the CNS in situ. They were able to demonstrate that
lysophosphatidyl choline (LPC) results in a loss of myelin basic protein (MBP) expression
and thus mature myelinating oligodendrocytes, whilst neurons, astrocytes and microglia
were unaffected. Furthermore, using this model, the authors were able to identify Vitamin
E as an alleviator of LPC damage demonstrating that this model can be used for testing
potential therapeutics. However, the cause of LPC damage is unknown and thus alleviating
the damage it causes does not answer key questions about the process of demyelination.
The main drawback of the system is the difficultly encountered when visualising individual
cells. As this model has been shown to work in rat and mouse cells, the authors argue that
in combination with transgenic animals, this model offers researchers the ability to test
potential therapeutics on specific cells types and therefore answering key questions about
drug mechanisms.
Science benefits from having a diverse range of models in which myelination can be
closely investigated. Although the benefits of the models are often highlighted, the
drawbacks are often overlooked.
3.1.2 Aims
Although the myelinating culture system has previously been validated (Sørensen et al.,
2008; Thomson et al., 2008), it has not been fully characterised and its potential has not
been investigated. Therefore, the aim of this chapter is to further characterise the
myelinating culture system used in our laboratory with a more detailed identification of
other cell types within the culture. Neurite growth and oligodendrocyte differentiation over
the time frame of the culture period will also be investigated. Furthermore, because it was
shown previously that astrocytes secrete a factor that promotes myelination I aim to use a
candidate growth factor approach as a first screen to identify the astrocyte-secreted factor.
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3.2 Results
3.2.1 Establishment of the Myelinating Culture System
The myelinating cultures used throughout this thesis compromises of dissociated rat
embryonic day 15.5 (E15.5) spinal cord cells which are plated on a confluent monolayer of
neurosphere-derived astrocytes on PLL-coated coverslips (PLL-astrocytes). The cultures
are grown for a period of 26-28 days which leads to a reasonable amount of myelination
for assessment (Fig 3.1). Although the cultures can be kept longer (up to 50 days, data not
shown) and reach higher levels of myelination, it was decided to stop the culture system at
26-28 days before reaching full saturation. Although myelination of all axons is not likely
due to their size (Friede, 1972), the time point was chosen to all allow the system to
respond to changes before axons which are likely to be myelinated become myelinated. In
this system, a monolayer of astrocytes was used as Poly-L-Lysine (PLL) alone does not
support the long term development of dissociated spinal cord cultures (Sørensen et al.,
2008). Although this system is already established (Thomson et al., 2008; Sørensen et al.,
2008), a closer look was taken for the purpose of this thesis. Figure 3.1 demonstrates the
methods used to produce these myelinating cultures (also described in Methods section
2.1.3). Briefly, astrocytes derived from striatum-derived neurospheres were differentiated
and grown to confluency in media containing serum (Fig 3.1 A). The spinal cord of E15.5
embryo is dissected (top 2-3 mm rostral to the cervical flexure, and approximately 8–10
mm of spinal cord) cleared of meninges, minced and enzymatically (Trypsin and
collagenase) digested to form a single-cell suspension of  mixed CNS cells which are then
plated on a confluent monolayer of PLL-astrocytes (Fig 3.1 B). The culture is then
maintained in defined media, allowing neuronal survival and neurite outgrowth followed
by myelination by resident oligodendrocytes (Fig 3.1 C). Therefore, these myelinating
cultures provide a simple and straightforward system to study all aspects of myelination.
The main complexity of these cultures is preparing the variety of appropriate media
(Section 2.1).
GFAP DAPI
SMI31 axons PLP myelin
Neurospheres originating from rat
stria cultured in serum-free
conditions
Neurosphere derived astrocytes on PLL
(PLL-astrocytes) grown in a monolayer
immunolabelled with Glial fibrillary
acidic protein (GFAP)
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Spinal cord is removed from
an embryo at E15.5
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Figure 3.1 Methodology of Generating a Myelinating Culture System. A) Neurospheres
originating from rat striata are cultured in serum-free media. The sphere are resuspended in
media containing serum and plated on Poly-L-Lysine (PLL) coated coverslips. The spheres
differentiate into a confluent layer of neurosphere-derived astrocytes plated on PLL (PLL-
astrocytes), which can be labelled with the intermediate filament glial fibrillary acidic
protein (GFAP). B) Spinal cords taken from embryos at E15.5 are removed, minced and
enzymatically digested. The mixed spinal cord cells are dissociated into a single-cell
population and plated at a density of 150,000 cells per confluent coverslip of PLL-
astrocytes. C) At 10 days in vitro (DIV) cell body clusters with connecting neurites are
visible under light phase microscope and by day 28 DIV cultures can be immunolabelled to
show dense networks of neurites and myelinated axons.
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3.2.2 Astrocytes, Microglia, and Oligodendrocytes at Different
Maturation Stages
The main cell types which reside in the CNS include neurons, oligodendrocytes, astrocytes
and microglia. If the myelinating culture system is to resemble, as closely as possible, the
intact CNS, then these main cells types must be present. Myelinating cultures were grown
for 26-28 and immunolabelled with various cell type markers (Fig 3.2). Astrocytes were
visualised using GFAP, and not only the cells as a monolayer but also other GFAP positive
cells, were present in abundance throughout the culture, covering the entire expanse of the
coverslip (Fig 3.2 A). Activated microglia, visualised using ED1, were also present
throughout the culture (Fig 3.2 B), but at a much lower amount than astrocytes. Bipolar
A2B5+ OPCs (Fig 3.2 C) were present suggesting that not all OPCs had differentiated into
myelin-forming oligodendrocytes. O4+ pre-oligodendrocytes were visualised extending
out processes (Fig 3.2 D), presumably to myelinate axons. Indeed, oligodendrocytes with
numerous branches appearing to search for axons have been previously demonstrated by in
vitro time-lapse in a co-culture system (Watkins et al., 2008). Mature oligodendrocytes
were visualised using antibody to the mature myelin marker proteolipid protein (PLP).
Oligodendrocytes can make many internodes of myelin from a single primary process (Fig
3.2 E, one asterisk) and sometimes from a secondary process (Fig 3.2 E, two asterisks).
The culture system allows the visualisation of axo-glial interactions using antibodies to
different cell types. Also, the process of myelination can be further dissected in terms of
morphological changes of oligodendrocytes, time course of the process, axonal selection
and initiation of myelination.
3.2.3 Neurite Density Increases and OPC Numbers Fall during the
Culture Period
For the purpose of characterising the cellular events taking place over time in culture,
myelinating cultures were set up,  fixed and immunolabelled on day 9, 18 and 27 with
antibodies SMI31 for axons, NG2 for OPCs and O4 for pre-oligodendrocytes (Fig 3.3).
Neurites become thicker and denser throughout the coverslip (Fig 3.3 A-C, J). NG2+ OPCs
reduce in number throughout the culture period (Fig 3.3 D-F, K) suggesting either
differentiation into myelin-forming oligodendrocytes or cell death due to competition for
the enormous growth factor demand of mature oligodendrocytes in the culture (Barres et
al., 1992).  O4+ oligodendrocyte numbers remain relatively stable throughout the culture
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Figure 3.2 Astrocytes, Microglia, and Oligodendrocytes at Different
Maturation Stages. E15.5 mixed spinal cord cultures were plated onto a
confluent monolayer of astrocytes and cultured for 26-28 days. On Day 12, the
insulin was removed to allow oligodendrocyte to differentiate. The cultures
were immunolabelled with GFAP for astrocytes (A), ED1 for microglia (B),
A2B5 for OPCs (C), O4 for immature oligodendrocytes (D) and PLP for
mature myelin (E and F).  Astrocytes in the culture covered the entire expanse
of the coverslip (A) whilst there was a relatively small population of microglia
(B). Oligodendrocytes were present at all different maturation stages, including
bipolar OPCs (C) and branched O4+ pre-myelinating oligodendrocytes (D).
Oligodendrocytes labeled with the mature myelin marker PLP can make many
internodes of myelin from a single primary process (E, one asterisk) and
sometimes from a secondary process (E, two asterisks). Scale bar 100 µm for
A and B, 50 µm for C-F. GFAP, glial fibrillary acidic protein, PLP,
proteolipid protein.
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period, although at day 9, oligodendrocytes had simple processes and at day 18 they
contained more membrane-like processes. By day 27, oligodendrocytes with myelin
sheaths were visible (Fig 3.3 G-I, K). The myelinating culture system is a versatile and
clear-cut system which allows the tracking of neurite outgrowth and oligodendrocyte
differentiation.
3.2.4 Myelination Increases over Time in the Myelinating Culture
System
In order to assess the time frame suitable for the addition of pharmacological or
biochemical agents, which can influence myelination, myelinating cultures were set up,
fixed and immunolabelled with PLP and SMI31 at a range of time points (Fig 3.4). On day
13-15 thin myelin segment can be observed in close contact with neurites (Fig 3.4 A, B).
From day 21 to 24, oligodendrocyte take on a more typical shape, where many processes
are in contact with many neurites, and thicker myelin sheaths can be seen (Fig 3.4 C, D).
By day 27, numerous oligodendrocytes can be seen myelinating surrounding axons with
thick and relatively lengthier myelin sheaths (Fig 3.4 E). Myelination was measured (as
described in Section 2.11.2) and an exponential increase in myelination was observed from
day 15 to day 21 (Fig 3.4 F). Insulin was withdrawn at day 12 to allow oligodendrocyte
differentiation as it has been reported that its presence promotes excessive OPC numbers
(Thomson et al., 2008). It was concluded that the best time frame for the addition of
biochemical agents that may influence myelination is when insulin is removed at day 12
which coincides with the start of oligodendrocyte precursor differentiation.
3.2.5 Underlying Monolayer of Astrocytes contains O4+
Oligodendrocytes
As embryonic spinal cord cells are plated on top a monolayer of PLL-astrocytes to create
the myelinating cultures, it was essential to identify the purity of these cells. PLL-
astrocytes after differentiation were maintained in media containing serum until confluency
(7-10 days, see Methods Section 2.1.1). The monolayers were fixed and immunolabelled
with anti GFAP for astrocytes and the O4 antibody for oligodendrocytes (Fig 3.5). The O4
antibody was used as a marker as it typically allows the visualisation of simple early
progenitors as well as more mature phenotypes (Fig 3.2). The number of GFAP+
astrocytes and O4+ oligodendrocytes were counted (Fig 3.5 C). Astrocytes made up the
vast majority of cells present within the monolayer, with 78.95±2.4% of positive cells per
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Figure 3.3 Neurite density Increases and OPC Numbers Fall during the Culture
Period. E15.5 mixed spinal cord cultures were plated onto a confluent monolayer of
astrocytes and cultured for 9 days (A,D,G) 18 days (B,E,H) or 27 days (C,E,I). The
cultures were immunolabelled with SMI-31 for neurites (A-C), NG2 for OPCs (D-F)
and O4 for pre-myelinating oligodendrocytes (G-I). There is a gradual increase in
neurite density throughout the culture period (J). The number of NG2 cells decreases
in the culture over time whilst O4 cell numbers remain relatively similar (K). Scale
bar 100 µm for A-F, 25 µm for G-I.  Errors bars indicate standard errors of the mean.
Experiments were carried out in triplicate.
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Figure 3.4 Myelination Increases over Time in the Myelinating Culture System.
E15.5 mixed spinal cord cultures were plated onto a confluent monolayer of astrocytes
and cultured for 13 (A), 15 (B), 21 (C), 24 (D) and 27 (E) days in vitro (DIV). At each
time point, the cultures were fixed and immunolabelled with SMI31 for neurites and
PLP for mature myelin. There is an increase in myelination over time, which gradually
plateaus (F). Scale bar 100 µm. Errors bars indicate standard errors of the mean.
Experiments were carried out in triplicate.
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field of view. O4+ oligodendrocytes made up 7.17±2.59% of positive cells per field of
view.  DAPI+ nuclei with no marker made up the remaining 13.88±2% of cells. The cell
bodies of these cells seem to cluster together and are likely to be neuronal in origin (further
elucidated in Chapter 6, Fig 6.2). Although the purity of these astrocyte monolayers is
lower than average, it must be noted that they are of neurosphere origin. Therefore, the
likelihood of cells differentiating into other cell types is higher than astrocytes derived
from a cortical origin, where the majority of cells have already differentiated into
astrocytes. However, a direct comparison between PLL-astrocytes and astrocytes of
cortical origin was not made. Nonetheless, the astrocyte monolayer provides a particularly
exceptional substrate in which the myelinating culture can grow and myelination can be
studied, possibly because in the intact CNS, astrocytes are in close contact with neurites
and oligodendrocytes.
3.2.6 Growth Factors can Promote Myelination
The intention of this thesis is to understand the role astrocytes play in the process of
myelination. In order to assess whether the myelinating culture system can be influenced
by exogenous factors known to be secreted by astrocytes, three candidates were chosen and
added to the myelinating cultures. Brain derived neurotrophic factor (BDNF) was chosen
as it is secreted by reactive astrocytes (Dougherty et al., 2000; Yoo et al., 2003). It is also
able to induce neurogenesis and myelin formation in the injured adult spinal cord due to
direct or indirect action on the proliferation of oligodendrocytes (McTigue et al., 1998).
Ciliary neurotrophic factor (CNTF) is a cytokine of the interleukin-6 family and is known to
be released by astrocytes (Rudge et al., 1994). It is also known to act on oligodendrocytes
to induce their survival and proliferation (Albrecht et al., 2007). Neuregululin (Nrg) is a
protein of the epidermal growth factor family, which are implicated in growth and
developmental signalling and known to be secreted by astrocytes (Francis et al., 1999).
Neuregulins have been reported to induce the proliferation and survival of
oligodendrocytes precursor cells (Canoll et al., 1996). Myelinating cultures were set up and
on day 12, treated with BDNF (1 ng/ml), CNTF (2 ng/ml) or Nrg (10 ng/ml) continuously
until the end of the culture period. The concentrations chosen were based on a combination
of information provided by suppliers as well as previously published articles (Rao et al.,
1992; Stankoff et al., 2002; Ritch et al., 2005; Li et al., 2006). Cultures were fixed and
immunolabelled and neurite density and myelination measured for all conditions (Fig 3.6).
BDNF treatment resulted in a slight increase in myelination compared to untreated control
(Fig 3.6 A, B, E). CNTF and Nrg promoted myelination, where more myelinated fibres
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Figure 3.5 Underlying Monolayer of Astrocytes contains O4+
Oligodendrocytes. PLL-astrocytes were grown in media containing
serum. On day 7, the cultures were fixed and immunolabelled with
GFAP for astrocytes and O4 for immature oligodendrocytes (A, B). Both
cells types were counted expressed as a percentage of the total using
DAPI as a nuclear marker for cells (C). The majority of cells were
GFAP-positive with a small population of O4-positive immature
oligodendrocytes (A, arrow). GFAP and O4-negative cells (B, arrow) are
counted as other in C. These cells are likely to be of a neuronal
progenitor origin. Scale bar 25 µm. Errors bars indicate standard error of
the mean. Experiments were carried out in triplicate.
25µm
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were observed compared to untreated controls (Fig 3.6 C-E, p < 0.05). Neurite density was
similar in all conditions (Fig 3.6 F) indicating that the treatments did not affect neuronal
survival and allowed a sound comparison of each factor for myelination. Whether these
growth factors act directly on the oligodendrocyte or indirectly via another cell type is not
yet known and will be further investigated in this thesis.
3.3 Discussion
These myelinating cultures provide a flexible and simple method for the visualisation and
the quantification of different cell types over a time frame in which myelinated fibers form.
These cultures were found to contain all four major cell types found in the CNS, show the
correct assembly of nodal proteins in the nodes of Ranvier (Sørensen et al., 2008) and most
importantly, the system is able to respond to the addition of growth factors, with a
measurable increase the amount of fibres myelinated.
The myelinating cultures allow accurate measurement of myelinated fibres and distinguish
them from differentiated oligodendrocytes that have not wrapped a myelin sheath. The
type of myelin measurement described here is more advantageous than using other
methods, such as Western blot, as measuring levels of myelin-related proteins may be
misleading. For instance, PLP is expressed both in the cell bodies of oligodendrocytes and
the myelin sheaths enwrapping an axon. Thus, an increase in oligodendrocyte
differentiation could lead to an increase in PLP protein levels on a Western blot or even
mRNA using qRT-PCR, and may therefore be misinterpreted as an increase in
myelination. Therefore, an increase in myelin proteins and/or message does not necessary
reflect as an increase in oligodendrocyte ensheathment of axons. This is usually offset with
the use of another system for myelin measurement such as morphometric analysis or an
enzymatic assay which measures the activation of myelination genes (Stankoff et al., 2002;
Karim et al., 2007).  In our myelinating cultures, manually drawing myelin around axons
was necessary, as frequently, oligodendrocytes were present in the field of view but were
not wrapping axons with a myelin sheath (Fig 3.7 A). When measuring myelination, the
myelinating cultures therefore focus solely on myelinated fibres.
The myelinating culture system also has its flaws. Manual selection of myelinated neurites
is a subjective process. However, as long as the assessment of myelination is consistent
analysis is reproducible. Furthermore, there is no distinction between ensheathment, the
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Figure 3.6 Growth Factors can Promote Myelination. E15.5 mixed spinal cord
cultures were plated onto a confluent monolayer of astrocytes and cultured for 26-
28 days. On day 12, some cultures left untreated (A), treated with brain-derived
neurotrophic factor (BDNF, 1 ng/ml), cilliary neurotrophic factor (CNTF, 2 ng/ml)
and neuregulin (Nrg, 10 ng/ml). The cultures were fixed and immunolabelled with
SMI31 for axons and PLP for mature myelin. Myelination was increased
significantly in all conditions, except BDNF (E, p < 0.05). The neurite density was
comparable across all treatments (F). Scale bar 100 µm. Error bars indicate
standard error of the mean. Experiments were carried out in triplicate.
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initial contact and wrapping on an oligodendrocyte process around a neurite, and
myelination, the formation of thick segments of myelin separated by Nodes of Ranvier.
However, some images show what looks like ensheathment, but with the presence of the
nodes (Figure 3.7 B). Therefore, this makes the myelinating culture system a relatively
subjective method of myelin analysis. To improve this, a more specific marker for
oligodendrocytic myelin sheath, such as MOG, should have been used.
For the purpose of studying diseases such as multiple sclerosis (MS), a reliable model or
myelination with axonal wrapping is required. It can be argued that in vivo models of
demyelination are a more accurate representation of the CNS as well as producing possible
therapeutic approaches to demyelinating diseases. Models of demyelination in vivo can be
mediated by an immune reaction, the exposure of the animal to auto-antibodies, or via
cytokine/viral-induction (Bradl and Linington, 1996). All models either directly target
oligodendrocytes and/or the myelin sheath or change the microenvironment inducing an
inflammatory response. Although these models shed light on the events proceeding
demyelination, they do not contribute to the understanding of myelination as a process.
The models all lead to extensive demyelination via different methods, adding to the
complexity and efforts to dissect out the cause of demyelination and the subsequent failure
of remyelination. Although demyelination is present, it must be noted that the models
create an artificial scenario of demyelination and thus the response from all cells may also
be artificial and contribute to the outcome of any attempts to reverse it. Another major
drawback of the animal model is the requirement of a large number of animals to produce
statistically sound data. Furthermore, in the animal, it is difficult to study different
variables, due to the complexity of whole tissues and organs and may all contribute to the
end-result.
The myelinating culture system was able to respond to exogenous addition of growth
factors (Fig 3.6). This is a very powerful observation as it suggests that the myelinating
culture system can be used to test an unrestricted number of biochemical agents. As the
cultures contain most cell types present in the CNS, it provides a testing ground not only
for myelination, but for axonal-glial interactions, proliferation, apoptosis and
differentiation of numerous cell types. This greatly expands the use of this myelinating
culture system in the field of neuroscience.
Although the myelinating culture system has not been used for the study of
demyelination/remyelination, it is still a valuable tool for the study of axo-glial interactions
and how the ‘normal’ system can be manipulated to further the understanding of
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myelination. This model is currently being used a model for spinal cord injury (Boomkamp
et al., 2010, in preparation).  The model here is by no means perfect, but nonetheless, it
provides a good platform on which myelination can be studied.
The exogenous addition of factors known to be secreted by astrocytes has led to an
increase in myelination in the myelinating cultures. Although the supportive roles of
astrocytes have been described in terms of neuronal support, maintenance of homeostasis,
synaptogensis and many more (Section 1.2), their role in myelination remains widely
disputed due to the conflicting evidence the literature presents of their secretory molecules.
It is the intention of the next sections of this thesis to investigate how exogenous molecules
can modulate the state of the astrocyte in order to promote an environment which is
supportive to myelination.
100µm 50µm
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Figure 3.7 Excess Oligodendrocytes, Ensheathment and
Myelination Issues. E15.5 mixed spinal cord were plated on a
confluent monolayer of astrocytes and cultured for 26-28 days and
immunolabelled with SMI31 for axons and PLP for mature myelin.
Occasionally, there is an excess of PLP+ oligodendrocytes but no
sign of myelination (A) which may lead to misleading
interpretation of data if other methods, such as Western blot, were
used. Some axons are ensheathed by oligodendrocytes, but not
myelinated, despite having what appears to look like a Node of
Ranvier (B, white arrow). Scale bar 100 µm for A and 50 µm for
B.
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Chapter 4
The Effect of Ciliary Neurotrophic Factor
on Myelination
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The Effect of Ciliary Neurotrophic Factor on Myelination
4.1. Introduction
4.1.1 Background
It has previously been shown that a glial substrate generated from neurosphere-derived
astrocytes was supportive for neuronal survival as well as myelination (Sørensen et al.,
2008). Furthermore, it was shown that astrocytes secrete a factor that promoted
myelination. To try and identify this factor, a candidate approach was taken and CNTF was
chosen as a potential candidate (Fig 3.6). More interestingly, CNTF has been proposed as a
molecule to activate astrocytes (Liberto et al., 2004) and for this reason this protocol was
used to assess how activated astrocytes affect myelination.
Ciliary Neurotrophic Factor (CNTF) is a cytokine and member of the IL-6 family of
cytokines, including IL-6, IL-11, IL-27, leukaemia inhibitory factor (LIF), oncostatin M
(OSM), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CTC) and neuropoietin
(NPN) (Stahl and Yancopoulos, 1994). The 24kD protein was identified based on its
ability to support the survival of embryonic chick ciliary ganglion neurons in vitro (Adler
et a1., 1979; Lin et a1., 1989; Stöckli et al., 1989). Since then, its regenerative effect after
injury on different subtypes of neurons, such as dopaminergic and motor neurons, has been
reported (Sendtner et al., 1990; Hagg and Vern, 1993; Lee et al., 2008).
In development, CNTF is expressed at very low levels (Stockli et al., 1989; Sendtner et al.,
1994). CNTF knock-out mice generated by the disruption of the CNTF gene show that at 4
weeks there were no detectable differences in motor neuron survival. However, there was a
loss of neurons and associated muscle atrophy in the adult (Masu et al., 1993). This study
suggests that CNTF may not be important developmentally as other members of the IL-6
family may compensate for its actions. The roles of CNTF in the adult centre on its role
post-injury, for instance, by contributing to cell body development of sensory and motor
neurons after sciatic nerve injury (Chen et al., 2010). However, although CNTF knockout
(KO) mice develop relatively normally, mice in which CNTFRα is knocked out in all cells
do not (DiChara et al., 1995). These KO mice are unable to feed, have reduced motor
neuron numbers and usually die at birth. The authors argue that the paradoxical effect
where CNTF is not expressed developmentally yet mice lacking its α subunit die
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prematurely means that there must be a CNTF-like ligand which may also use this subunit
and may be more important developmentally. Although no CNTF-like molecule has been
discovered to date, this explanation cannot be dismissed. An exquisite study by Lee and
colleagues (2008) demonstrated the effect of CNTFRα in the adult exclusive of its effects
developmentally. They show this by using a floxed CNTFRα mouse line and administered
an adeno-associated virus vector to drive Cre recombinase expression to selectively delete
the floxed genes in motor neurons. As a result, a greater loss of motor neurons was
observed, an effect which was independent of developmental requirements (Lee et al.,
2008). This adult gene disruption study enforces the idea that CNTF is required for the
survival of neurons.
In MS, there is a relative failure for remyelination to occur although it has been shown that
proliferating OPCs migrate and populate areas of demyelination (Redwine et al., 1998;
Levine and Reynolds, 1999). CNTF’s action on glial cells has been wildly documented.
Glial progenitors have been shown to differentiate into astrocytes after CNTF treatment
(Hughes et al., 1988). Secretion of CNTF by astrocyte cultures has also been reported
(Lillien et al., 1988; Rudge et al, 1992). CNTF administration into the rat neocortex
resulted in an upregulation of genes associated with gliosis such as GFAP, vimentin and
clusterin (Levison et al., 1996). In this study, astrocytes also underwent morphological
changes where they became hypertrophic and the presence of microglia became apparent.
However in another study by Winter et al. (1995), CNTF did not illicit a microglial
response but the number of GFAP-positive cells increased. The increase in reactivity
markers has also been demonstrated in vitro (Albrecht et al., 2000). CNTF was also
detected in cerebrospinal fluid (CSF) of MS patients after a demyelination attack (Massaro
et al. 1997). The above suggests that the glial reaction may be involved in repair and CNTF
may be part of this protective mechanism.
The role of CNTF in repair and protection has raised questions as to whether genetic
defects to the CNTF gene would contribute to neurological disease (Takahashi et al.,
1994). Interestingly, CNTF-null MS patients have early disease onset and faster decline,
although the incidence of CNTF null mutation is similar to that of the control population
(Geiss et al., 2002). Hoffman and colleagues (2002) concur the findings regarding the
incidence of null mutations amongst the normal population, but the authors argue that
CNTF genotypes are not related to age of MS onset, course or severity of the disease.
These studies demonstrate that CNTF may be involved in an immunoregulatory
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mechanism; however, to what extent this could affect the disease outcome is not yet
established.
As discussed previously (Section 1.4.2), astrocytes can be activated by CNTF to release
factors which can promote oligodendrocyte survival and maturation as well as myelination
(Albrecht et al., 2003; Albretch et al., 2007; Williams et al., 2007). Astrocytes respond to
CNTF by becoming ‘activated’ upregulating cytoskelatal molecules, increase in
proliferation and the secretion of anti-inflammatory molecules (Liberto et al., 2004; John et
al., 2005). Escartin et al. (2006) developed an in vivo model for astrocyte activation
whereby they use a lentivirus-mediated CNTF overexpression in the rat striatum. They
showed that CNTF overexpression resulted in the activation of astrocytes as measured by
immunohistochemistry and Western blot of GFAP, nestin and vimentin. Interestingly, they
also showed that intrastriatal injection of quinolinic acid, a dicarboxylic acid with a
neurotoxic effect, resulted in improved handling of extracellular glutamate and increased
energy supply. This study clearly demonstrates that astrocytes respond to CNTF in
beneficial ways to regeneration.
4.1.2 Aims of the Chapter
As there is a strong background to CNTF’s role in injury and activation of astrocytes, the
main aim of this chapter is to investigate the effects of activating the astrocytes monolayer
by using CNTF and to how this activation can affect myelination.
4.2 Results
4.2.1 Expression of O4 in Myelinating Cultures after CNTF
Treatment
 CNTF was previously found to increase the level of myelinating fibres (Fig 3.6). To
determine the optimal concentrations of CNTF for myelination, myelinating cultures were
plated on a monolayer of neurosphere-derived astrocytes (PLL-astrocytes) and CNTF was
added at 20 pg/ml, 200 pg/ml and 2 ng/ml. CNTF was added on day 12 onwards, and
cultures were fixed and immunolabelled on day 26-28. The initial assessment of
myelination was made using the oligodendroglial marker O4, marker of oligodendrocytes
at most stages of development (Fig 1.2). The level of expression of the O4 antigen
represents not only the myelin sheaths, but also non-myelinating oligodendrocytes. There
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was a significant increase in O4 coverage with the addition of 200 pg/ml and 2 ng/ml of
CNTF (Fig 4.1 C, D, E, p < 0.05) compared with untreated controls (Fig 4.1 A) but not
with 20 pg/ml (Fig 4.1 B, p > 0.05). This initial observation led to a more diverse range of
concentrations and a more detailed analysis of myelination and axonal ensheathment (see
below).
4.2.2 Concentration-Dependent Effect of CNTF
Spinal cord cells were plated on top of PLL-astrocytes and CNTF was added directly into
the culture dish from day 12 onwards. CNTF was added at concentrations ranging from
0.02 pg/ml to 20 ng/ml and the cultures were immunolabelled on day 26-28 for axonal
density (%SMI31 immunoreactivity/total area) and axonal ensheathment with PLP myelin.
At low concentrations (Fig 4.2 B-D), the percentage of axons covered in a myelin sheath
was comparable to that found for untreated cultures (Fig 4.2 A). CNTF increased
myelination in a dose-dependent manner. The optimal concentration was 2 ng/ml (Fig 4.2
E, G) and found to be significantly different to untreated control cultures (p < 0.005). The
promyelinating effect of CNTF at 20 ng/ml (Fig 4.2 F) was absent. Neurite density was
comparable in all concentrations (Fig 4.2 H).
4.2.3 CNTF does not have a Promyelinating Effect when Cultures
are plated on a Monolayer of OECs
It has previously been shown that olfactory ensheathing cells (OECs) support neurite
survival and extension but not myelination (Sørensen et al., 2008). This observation was
used to investigate whether CNTF was acting directly on the oligodendrocytes; spinal cord
cells were plated on top of monolayers of PLL-astrocytes and OECs and some dishes were
treated with CNTF (2 ng/ml) from day 12 onwards. CNTF treatment of myelinating
cultures plated on OEC monolayers did not lead to an increase in the amount of
myelination (Fig 4.3 E, G) compared to untreated OECs controls (Fig 4.3 E, G). As seen
previously, there was an increase in myelination with CNTF treatment in cultures on PLL-
astrocytes (Fig 4.3 A, B, G). Furthermore, there was no difference in neurite density
between cultures plated on OECs and PLL-astrocytes with or without CNTF treatment (Fig
4.3 H).
Since myelination was less on OEC monolayers it was possible that OECs may be
secreting an inhibitory factor that prevents myelination. To address this possibility
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Figure 4.1 CNTF Addition increases Expression of the O4
Ligand. E15.5 mixed spinal cord cultures were plated onto a
confluent monolayer of neurosphere-derived astrocytes on PLL
(PLL-astrocytes) and cultured for 26-28 days. On day 12, cultures
were either left untreated (A) or treated with CNTF at varying
concentrations; 20 pg/ml (B) 200 pg/ml (C) or 2 ng/ml (D).
Cultures were immunolabelled with an antibody which recognises
the O4 ligand. There is a gradual increase in O4 expression with
increasing concentration, which is significantly higher in 200
pg/ml and 2 ng/ml (E, p < 0.05). Error bars indicate ± SEM. Scale
bar, 100µm. Experiments were carried out in triplicates.
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Figure 4.2 Titration of CNTF Produced Variable Effects on Myelination. E15.5
mixed spinal cord cultures were plated onto a confluent monolayer of neurosphere-
derived astrocytes on PLL (PLL-astrocytes) and cultured for 26-28 days. On Day 12,
cultures were either left untreated or treated with varying concentrations of CNTF
(0.02 pg – 20 ng/ml). Treatment with low concentrations (B-D) and high
concentration (F) of CNTF had no effect on myelination when compared to untreated
controls (A). Conversely, treatment with 2000 pg/ml (E) had a significant increase in
myelination when compared to control. Thus, addition of exogenous CNTF into
myelination cultures leads a concentration dependent increase in myelination (G),
where very low and very high concentration of CNTF do not have an effect dissimilar
to untreated control. Myelination data was standardised to untreated control. Neurite
density (assessed by SMI31 reactivity) was unchanged in all concentrations (E). Error
bars indicate ± SEM. Scale bar, 25 µm. Experiments were carried out in in triplicate.
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myelinating cultures were plated on PLL-astrocytes which were continuously conditioned
by two coverslips containing monolayers of OECs in the same Petri dish. OECs
conditioned media increased myelination on cultures plated on PLL-astrocytes (Fig 4.3 C,
G). Although this finding eliminates the possibility that OECs secrete inhibitory molecules,
it does not rule out the likelihood of an inhibitory molecule/contact on OEC extracellular
matrix which may be inhibiting oligodendrocyte differentiation. The presence of two
monolayers of PLL-astrocytes in the same dish as a myelinating culture on OEC
monolayer increased the level of myelination (Fig 4.3 F, G), confirming the idea that
astrocytes secrete a promyelinating factor, corroborating data observed in Sørensen et al.
(2008).
4.2.4 CNTF does not Induce Oligodendrocyte Proliferation
The addition of CNTF may be a mitogen for pre-myelinating oligodendrocytes, increasing
the total number of oligodendrocytes capable of myelinating, and hence increasing the
number of myelinated neurites observed with CNTF treatment. In order to assess this,
cultures on PLL-astrocytes were treated with CNTF and bromodeoxyuridine (BrdU) on
day 12. On day 13, the cultures were fixed and immunolabelled with the O4 antibody, anti
BrdU (to visualise cells in S phase) and DAPI. Three experimental repeats were
performed, taking 5 random images from each experiment and the number of positive cells
counted. The average number of total cells counted per experiment (DAPI+) were
1373±267 and 1528±227 for control and CNTF-treatment, respectively. The average
number of O4+ cells counted per experiment were 124±13 and 146±25, and 97±48 and
98±49 for BrdU for control and CNTF-treatment, respectively. The mean number of O4+
cells per view was similar for both control and CNTF-treated cultures at day 12 (Fig 4.4,
24±1.7 and 29±2.5, respectively, p > 0.05). The total number of proliferating cells (BrdU+)
was also similar between both conditions (19±3.7 and 19±5.1, respectively, p > 0.05),
suggesting that CNTF is not triggering the proliferation of other cell types, such as
microglia. Crucially, the number of proliferating oligodendrocytes (both O4+ and BrdU+)
was no different between control and CNTF treatment (1.6±0.4 and 1.0±0.3, p > 0.05). It
can therefore be concluded that CNTF does not act as a mitogen for oligodendrocytes.
4.2.5 CNTF and Oligodendrocyte Differentiation
To examine whether the addition of CNTF subsequently leads to oligodendrocyte
differentiation, cultures were treated on day 12, and fixed and immunolabelled after 24
A B C
Figure 4.3 CNTF does not have a Promyelinating Effect when Cultures are plated on
a Monolayer of OECs. Spinal cord cells were plated on neurosphere-derived astrocytes
plated on PLL (PLL-astrocytes) (A, B and C) or OECs (E,F,G) and left untreated (A and
D), treated with 2ng/ml CNTF (B and E). Further,  cultures on PLL-astrocytes were
placed in the same dish as two monolayers of OECs (C) and cultures on OECs were
placed on the same dish as two PLL-astrocyte monolayers (F), therefore cultures were
being continuously conditioned by monolayers. Myelination on cultures on OECs was
poor and treatment CNTF does not lead to any further increase (D and E and H). OEC
conditioned media (CM) is not inhibitory to myelination of PLL-astrocyte cultures but
rather an increase in myelination is observed (C and G) compared to untreated PLL-
astrocytes control cultures (A and G). The presence of PLL-astrocyte CM with cultures of
OECs leads to an increase in myelination (F and G) as previously reported by Sørensen et
al. (2008).  The neurite density was similar in all conditions (H). Error bars indicate ±
SEM. Scale bar, 25µm. Experiments were carried out in triplicate.
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Figure 4.4 CNTF Treatment does not lead to a increase in OPC
Proliferation. Spinal cord cells were plated on neurosphere-derived
astrocytes on PLL (PLL-astrocytes) and either left untreated (A,B) or
treated with 2ng/ml CNTF (C,D) on day 12. All cultures were also treated
with BrdU on day 12. All cultures were fixed and immunolabelled with O4
and anti-BrdU. No difference in the number of proliferating O4+ cells
between control and CNTF-treated cultures. Error bars indicate ± SEM.
Scale bar, 100µm for A and C, 25µm for B and D. Experiments were
carried out in triplicate.
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hours, 6 days and 12 days post-treatment (Fig 4.5). The panel of markers include A2B5,
which labels OPCs, NG2, an early to middle progenitor and O4, a late progenitor to early
myelinating oligodendrocytes (Fig 1.2).
At 24 hours and 6 days post treatment with CNTF (day 13 and 18 of entire culture period,
respectively), no change in the number of A2B5+ cells was observed. However, a decrease
in A2B5+ progenitors was observed 12 days post CNTF treatment (Fig 4.5 A, p < 0.05).
This may suggest that more progenitors differentiated into the myelinating phenotype after
CNTF treatment. NG2+ late progenitors showed a similar pattern, whereby at 12 days
post-treatment, there is a reduction in NG2+ progenitors in treated condition, which was
statistically significant (Fig 4.5 B, p < 0.05). However, at 6 days post-treatment, there is a
transient increase in NG2+ cells in the treated condition. O4+ cell numbers show a similar
pattern in control and the treated conditions (Fig 4.5 C) where there is a gradual increase in
numbers over the culture period. There was no difference in the number of O4+ cells
towards the end of the period in the CNTF treatment to the untreated controls. Thus, the
increase in myelination may not be due to an increase in differentiated oligodendrocytes.
However, as a more mature oligodendrocyte marker was not used, such as MOG, this can
not be confirmed. It must be noted, however, that PLP was trialled and all cells were found
to be PLP+ even at day 13. Thus, counting these cells did not truly represent the number of
mature myelinating oligodendrocytes. CNTF treatment may create a more favourable
environment for progenitor differentiation, leading to fewer progenitors present at later
stages in the culture. However, as can be seen from Fig 4.5 B, the number of O4+ cells is
unaffected 12 days post treatment.
4.2.6 CNTF and Microglial Activation
The presence of microglia in the myelinating culture system introduces another variable to
the targets of CNTF. In order to assess whether treatment with CNTF can increase the
number of activated microglia, spinal cord cells were plated on PLL-astrocytes, and on day
12 onwards, some cultures were treated with CNTF. After 26-28 days, the cultures were
fixed and immunolabelled with EDI, a marker for activated microglia (Slepko and Levi,
1996). Five images were taken from each condition, a mean total of 1288±11 and
1450±116 nuclei were counted for control and CNTF-treated conditions, respectively, for
each experiment. There was no difference between the mean number of ED1+ cells of
control and CNTF-treated cultures (Fig 4.6 A, B, C). However, when ED1+ cells were
expressed as a percentage of the total DAPI count, 0.12±0.01% of total cells per view were
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Figure 4.5 Addition of CNTF does not lead to an increase in O4+ Oligodendrocytes.
Embryonic spinal cord cells were plated on a confluent monolayer of neurosphere-derived
astrocytes (PLL-astrocytes). On day 12, cultures were either left untreated or treated with
CNTF (2ng/ml). The cultures were fixed and immunolabelled 24 hours, 6 or 12 days post
the beginning or treatment with A2B5 (A), NG2 (B) or O4 (C).  The number of positive
cells were expressed as a percentage of the total cells were view (DAPI count) and the
mean per view for each time-point is plotted. With treatment, there is a large decrease in
A2B5+ cells at 12 days post treatment (A, p < 0.05). NG2+ cell population increased at 6
days post treatment with CNTF (p < 0.05) but decreased compared to untreated cultures (p
< 0.05). Finally, the O4+ cell population remains relatively consistent for untreated and
were carried out in triplicate.
CNTF-treated cultures. Error bars indicate standard error of the mean (SEM). Experiments
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ED1+ in the untreated control conditions compared with 0.09±0.01% in the CNTF
treatment (Fig 4.6 D, p < 0.05). Thus, CNTF-treatment does not lead to an increase in
ED1+ microglia, but possibility a slight decrease. What remains to be identified is the
effect of CNTF treatment on microglial secretory profile.
4.2.7 Effect of CNTF on Neurite Diameter
Neurite diameter is related to whether an axon becomes myelinated or not (Duncan, 1935).
In order to assess neurite thickness, a total of 50 images were taken per condition, per
experiment. The measurements were made in Image J and arbitrary units were converted to
µm using the image scale bar (Fig 4.7 B, C). There was no difference between neurite
diameter in control and treated conditions (Fig 4.7A, C, D; 1.6±0.16 and 1.98±0.14 µm, p
> 0.05). Furthermore, no differences were found between myelinated and non-myelinated
neurites in either condition (Fig 4.7 D). However, there is a trend for neurites in CNTF
treatment to be slightly larger. When all values for every individual neurite were compared
(n=150), there was a significant increase in neurite diameter in cultures treated with CNTF
whether they were myelinated or not. The number of myelinated neurites was compared to
those that were non-myelinated. Of the neurites counted, 25% were myelinated compared
to 43% with treatment (Fig 4.7 E). These data may indicate that CNTF treatment may
increase the likelihood of a neurite to be myelinated due to its larger diameter, although, it
cannot be assumed that CNTF does not make the neurites more ‘responsive’ to be being
myelinated.
4.2.8 Effect of CNTF on Astrocyte Reactivity
Astrocytes make up a larger number of the dissociated spinal cord cells as well as
comprising the underlying monolayer. It can be assumed that CNTF may be acting on
these astrocytes, changing their phenotype to one which may be more supportive to
myelination. The biological properties of untreated and CNTF-treated astrocytes were
compared. Astrocytes were plated onto PLL-coated coverslips, grown to confluency and
treated with CNTF (2 ng/ml, Fig 4.8 A, B) for 24 hours or 48 hours. As reactive astrocytes
undergo hypertrophy, their cell size was measured in Image J. A contour around the cell
was drawn and the arbitrary units converted into µm2. Astrocytes treated with CNTF were
slightly smaller than controls (Fig 4.8 C, 1041±122 µm2 and 853±82 µm2, respectively)
although this was not statistically significant.  Nuclear hypotrophy is also an indication of
astrocyte reactivity (Levison et al., 1998) and was also measured. The straight line
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Figure 4.6 anti-CNTF Slightly Increases the Number of Activated
Microglia. Embryonic spinal cord cells were plated on a confluent
monolayer of neurosphere-derived astrocytes on PLL (PLL-astrocytes). On
day 12, cultures were either left untreated (A, B) or treated with CNTF (C,
D) on day 12 onwards. On day 26-28, cultures were fixed and
immunolabelled with ED1, a marker for activated microglia and DAPI. The
number of ED1+ cells per view were counted and represented as mean
number of cells per view (E) and expressed as percentage of total cell
number (F). There is no change in EDI+ or DAPI+ cells between untreated
and treated cultures. However, a significant increase (p < 0.05) is observed
when cells are expressed as percentage of total cells per view (F).
Experiments were performed in triplicate.
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Figure 4.7 Addition of CNTF does Increase Neurite Diameter. Embryonic spinal cord
cells were plated on a confluent monolayer of neurosphere-derived astrocytes (PLL-
astrocytes). On day 12, cultures were either left untreated (A) or treated with CNTF (B)
(2ng/ml). The cultures were fixed and immunolabelled on day 26-28 with SMI-31, and
PLP. Using Image J, the diameter of the random neurites was measured (C) and it was
noted whether the neurite was myelinated or not. Neurite diameter did not differ between
untreated or CNTF treated cultures (D), although there is a slight increase in diameter with
CNTF treatment. Many more unmyelinted axons were present in untreated conditions
compared with CNTF-treatment (E). Experiments were performed in triplicate.
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selection on Image J was used to draw across DAPI+ nuclei. There was no increase in
nuclear size between control and CNTF treated astrocytes (Fig 4.8 D, 13.71±0.48 and
13.97±0.38, respectively, p > 0.05). The most documented observation of astrocyte
reactivity is an increase in GFAP expression. Western blot analysis using anti-GFAP and
cell lysates of astrocytes shows a slight increase in GFAP content after treatment with
CNTF (Fig 4.8 E). Sister astrocyte monolayers were treated with CNTF for 24 hours,
washed in PBS, and fresh media was added to collect astrocyte secretory products post
CNTF treatment to assess if CNTF addition to astrocytes led to an increase in CNTF
production. There was no difference between untreated and CNTF treated astrocytes in
terms of further CNTF production (75.6±21 pg/ml in untreated vs. 61.1±9 pg/ml in treated,
Fig 2.8 F).  Thus, CNTF-treatment of astrocytes does not alter the markers of reactivity
reviewed here.
4.2.9 Effect of CNTF Treatment on Astrocytic Expression of
Nestin
Nestin has been used as a marker of reactivity in injury and development (Clarke et al.,
1994; Lin et al., 1995). Lipopolysaccharide (LPS) is frequently used in vitro experiments
to induce a reactive phenotype in astrocytes (Pang et al., 2001; Gomez-Nicola et al., 2010;
Lu et al., 2010). LPS treatment was used in these experiments to confirm a change in
phenotype status with CNTF treatment, if indeed there is one. Astrocytes were grown to
confluency and left untreated (Fig 4.9 A), treated with CNTF (2 ng/ml, Fig 4.9 B) or
treated with LPS (1 µg/ml, Fig 4.9 C) for 24 hours. Astrocytes were immunolabelled with
GFAP and nestin. Sister monolayers were lysed and the proteins were run on a gel.
Intensity of nestin (red) immunolabelling in the LPS treated condition is much stronger
than control and CNTF conditions. This observation correlates with the literature
suggesting that LPS is an activator of astrocytes. Visually, there is no striking difference
between control and CNTF treatment. Protein levels were verified using Western blot (Fig
4.9 D).  An insignificant increase in protein content was observed with CNTF and LPS
treatment. The band intensity of 3 experimental repeats for CNTF and LPS treated
astrocytes were verified and found to be no different to controls (Fig 4.9 E).
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Figure 4.8 Addition of CNTF does Increase Markers of Reactivity. Neurosphere-
derived astrocytes were plated on PLL (PLL-astrocytes) until confluency. On day 7,
cultures were either left untreated (A) or treated with CNTF (2ng/ml, B). The cultures
were fixed and immunolabelled with GFAP and DAPI. Using Image J, cell area and
nuclear diameter were measured. No difference was observed between control astrocytes
and CNTF-treated astrocytes for cell area (C) or nuclear diameter (D). Sister astrocyte
monolayers were lysed 24 hours and 28 hours after treatment and western blot was
performed to measure GFAP protein levels. No increase in GFAP content was observed at
24 hours or 48 hours post treatment (E). GAPDH was used as a loading control. In another
set of sister astrocytes, some astrocytes were treated with CNTF for 24 hours and others
left untreated. The CNTF-containing media was then removed and fresh media was added
for a further 24 hours. This media was assayed for CNTF using ELISA (F). No increase in
performed in triplicate.
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Figure 4.9 Addition of CNTF does Increase Nestin Reactivity.
Neurosphere-derived astrocytes were plated on PLL (PLL-astrocytes) until
confluency. On day 7, cultures were either left untreated (A) or treated with
and immunolabelled with GFAP, nestin  and DAPI. Using Image J, cell area
and nuclear diameter were measured. No difference was observed in
immunoreactivity of nestin in CNTF treatment (B) whereas there was a visible
increase in LPS treatment (C) compared to untreated control astrocytes (A).
Western blot was performed to measure nestin protein levels. A slight increase
in nestin protein content was observed (D). Densitometry of bands on was
performed on experimental repeats and nestin content was similar in all
conditions (E). Experiments were performed in triplicate.
CNTF (2 ng/ml, B), or LPS (1 µg/ml, C) for 24 hours. The cultures were fixed
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4.3 Discussion
The experiments detailed in this chapter report that CNTF increases the percentage of
myelinated fibres in a dose dependent manner in the myelinating cultures due to an
activation of the astrocyte phenotype to one which is more supportive to myelin formation.
CNTF addition did not increase neurite density or diameter but the responsiveness to
myelination has not been investigated. CNTF was not a mitogen nor did it affect number of
resident microglia in these cultures. When astrocytes alone were treated with CNTF, only a
slight increase in activation markers was observed. This may be due to the requirement of
the CNTFRα subunit of the signalling complex (see below).
The α subunit of the CNTF receptor is critical for signalling but its expression is confined
to neuronal cells in the rat adult brain (MacLennan et al. 1996; Kahn et al., 1997)
suggesting that for CNTF to exert its actions, the α subunit has to be ‘shed’ from neurons.
Indeed, CNTF, in combination with the soluble form of the CNTFRα subunit, increased
proliferation in a cell line (TF-1) not normally responsive to CNTF (Davis et al., 1993).
TF-1 cell lines are responsive to LIF indicating the presence of gp130 and LIFRβ. Thus,
this cell line had the ‘potential’ to be responsive to CNTF if the CNTFRα component were
present. This could therefore explain the effects of CNTF in the culture system but not on
astrocytes alone (Fig 4.2 and 4.4). In the cultures, the addition of CNTF leads an increase
in the number of myelinated neurites. As it was hypothesised that this effect was due to an
activation of astrocytes, an increase in activation markers such as GFAP and nestin were
expected when astrocytes alone were treated with CNTF as previously shown in vivo
(Kahn et al. 1997; Escartin et al., 2006). As no increase in these markers was observed, it
can be concluded that this may be due to the lack of axons and the thus the presence of the
CNTFRα subunit. Furthermore, astrocytes originating from the grey matter in the mouse
were found to contain CNTFRα whereas ones from the white matter did not (Dallner et al.,
2002). Neurosphere-derived astrocytes used here are originally harvested from the corpus
striatum, a region of the brain rich with white matter. It is likely that the origin of the
astrocytes used stems from a white matter origin and therefore may not express CNTFRα.
CNTF’s actions have become prominent in disease and injury. Astrocytes of a retinal
origin induced CNTF expression post injury to the lens in adult rats (Müller et al., 2007),
which later contributed to the regeneration of axotomised retinal ganglion cells.
Furthermore, Rudge et al. (1994) have described how the CNTFRα subunit switches
expression to astrocytes (from being predominantly neuronal) following injury and
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therefore proposing that CNTF only forms a functional complex when required, in injury
conditions. This observation suggests that CNTF-treated astrocytes in the myelinating
cultures behave as though the exogenous CNTF is a ‘damage signal’ and alter their
secretory profile and therefore release other promyelinating factors which then increase the
myelinating capability of oligodendrocytes.
CNTF knockout mice experience a more severe form of EAE as well as early onset of
disease, compared to wild type controls (Geiss et al., 2002; Linker et al., 2002) suggesting
than an absence of CNTF impairs the activation mechanism of astrocytes and hence their
pro-regenerative effects. The authors attribute the effects of lack of CNTF directly on the
oligodendroglial lineage cells effecting their survival, maturation and myelin sheath
maintenance. Although this may be the case, the fact that astrocytes are the main source of
CNTF cannot be dismissed. It has been reported that CNTF acts directly on
oligodendrocytes in vitro, to favour their final maturation (Stankoff et al., 2002). This is
unlikely to be the case in the data presented as i) CNTF addition to myelinating cultures
plated on OEC did not produce a promyelinating effect and ii) OEC conditioned media did
not inhibit myelination and therefore the lack of myelination can not be attributed to a
negative secretory factor. It has also been suggested that CNTF may be activating
astrocytes indirectly, where OPCs in vitro were shown to proliferate after exposure to
astrocyte conditioned media after exposure to CNTF (Albrecht et al., 2007). Although
myelination was not investigated in the above study, the results shown here confirm that no
increase in proliferation was observed after CNTF addition (Fig 4.4). From the literature
above, astrocytes may release CNTF in injury conditions, to support surrounding neurons
and oligodendrocytes, and to also act on their own receptors for further activation and
additional release of trophic support.
Microglia make up less than 1% of the total cells within the myelinating culture system but
they should not be overlooked as activated microglia have been shown to destroy
developing OPCs via the secretion of Tumor necrosis factor alpha (TNFα) (Miller et al.,
2007; Pang et al., 2010). Activated microglia express the CNTFRα and can therefore be
responsive to CNTF (Lin et al., 2009). However, conditioned media from CNTF-treated
microglial cells have been shown to enhance the survival to spinal cord motor neurons
(Krady et al., 2008). Interestingly, IL-6 conditioned media, despite being from the same
family of cytokines, led to a reduction in the number of neurons after treatment with IL-6
conditioned media. No difference in the number or morphology of microglia was observed
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in the cultures used here after CNTF treatment. However, as the secretory profile has not
been evaluated, it can not be assumed that the promyelinating effect is solely due to the
activation of astrocytes. For instance, CNTF can activate microglia to secrete a product
which may make neurites more responsive to being ensheathed.
The treatment of astrocytes with CNTF does not lead to a further increase in CNTF
secretion as shown by ELISA. This observation suggests that in response to CNTF
treatment, further CNTF cannot be attributed to be the promyelinating factor released by
astrocytes. Although CNTF may be released from astrocytes, work from other laboratories
suggest that CNTF lacks a signaling peptide and more likely to be a cystolic protein which
is not available for conventional release methods (Lin et al., 1989; Stöckli et al., 1991).
However, Kamiguchi et al., (1995) used an enzyme to cleave the
glycosylphosphatidylinositol (GPI) linkage of the CNTFRα subunit of cultured astrocytes
and demonstrated that astrocyte conditioned media contained up to 257.3 pg/ml of CNTF
compared to less than 100pg/ml in non-treated astrocytes. This study suggests that cultured
astrocytes do secrete CNTF but it is then trapped by surface receptors of the astrocytes and
may possibly be acting via an autocrine loop.
There is still some controversy as to how CNTF acts on astrocytes and this depends on i)
whether astrocytes possess the CNTFRα subunit or are situated in an environment where
axonal shedding can take place, ii) whether an astrocyte needs to be damaged/activated to
release the cystolic protein and iii) whether the α subunit of the astrocytic surface
sequesters CNTF in an autocrine loop rather releasing it. On the whole however, CNTF’s
actions on astrocytes are well documented and it seems to be imperative that for this
reaction to take place, the astrocyte needs to be in an environment that most resembles the
in vivo situation, i.e. 3-dimentional milieu surrounded by other cell types.
Chapter 5
Understanding the Role of CNTF and its
Receptor
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Understanding the role of CNTF and its Receptor
5.1 Introduction
5.1.1 Background
The effects of CNTF are mediated via its tripartite receptor complex, consisting one
ligand-binding subunit, the CNTF receptor alpha (CNTFRα), and two signal transducing
proteins, LIF receptor β (LIFRß) and gp130. In order for CNTF to exert its actions, it first
binds to CNTFRα. Once CNTF and CNTFRα are bound, the complex recruits gp130,
which in turn recruits LIFRß, leading to the activation of the Jak and Tyk kinases and
STATs (Boulton et al., 1994; Stahl et al., 1994; Ip and Yancopoulos, 1996; Müller et al.,
2007; Fig 5.1). The activation of gp130 alone is not sufficient for the activation of
intracellular signalling substrates.
The CNTFRα subunit is a specialised receptor component which can either be soluble or
membrane bound (Fig 5.2). This unique feature is due to a lack of a transmembrane
domain for CNTF. Instead, the receptor is anchored to the cell surface via glycosyl
phosphatidylinositol (GPI) linkage (Ip et al., 1993; Davis et al., 1991). The CNTFRα may
also exist in soluble form. However, it has been suggested that the existence of the soluble
form is only observed during injury in order to provide greater response from non-
responding cells (Davis et al., 1993; Stahl and Yancopoulos, 1994).
Other members of the IL-6 family may use a combination of gp130 and LIFRß to elicit
their effects. For instance, IL-6 requires its own specialised ligand binding subunit IL-6Rα
(like CNTF) and two signal transducing gp130 components. LIF, however, requires gp130
and LIFRß (Ip and Yancopoulos, 1996) with no ligand binding component required (Fig
5.3). Because members of the IL-6 family share many receptor components, it is likely to
find overlapping signalling pathways (Ip et al., 1993; Patterson, 1992). For instance, both
CNTF and LIF have trophic activity on neurons. In a study by Martinou et al. (1992),
motor neuron survival was measured after treatment with, amongst others, CNTF and LIF.
The authors report an almost identical increase in the number of motor neurons after
treatment when compared to the untreated controls. Therefore, due to sharing some of the
receptor components, members of the IL-6 family can have very similar roles. However,
Davis et al. (1993) demonstrate that these effects highly depend on the types of cells used.
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Figure 5.1 An illustration of CNTF Binding and Signalling. CNTF binds
to its ligand binding subunit, CNTFRα (A), which recruits the membrane
bound gp130 subunit (B) forming an inactive complex. The binding to
gp130 recruits LIFRβ (C) which leads to signal transduction via Jak-Tyk
and STATs.
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Figure 5.2 CNTFRα can be Soluble or Membrane Bound. CNTF receptor
signalling is unique as the CNTFRα ligand-binding subunit is not a
transmembrane component. Instead, CNTFRα is anchored to the cell
membrane by glycosyl-phosphatidylinositol linkage (GPI, A). This GPI
linkage allows the CNTFRα to be either be soluble or membrane bound (A).
CNTF will bind to either the soluble form and then recruit the other two
signal transducing membranes or CNTF can directly attach membrane
bound subunit (B). Signal transduction is activated once a tripartite complex
is formed (C).
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Figure 5.3 Receptor Complexes of the IL-6 Cytokines. Other
members of the IL-6 cytokines share some of their receptor
components. IL-6 does not require a LIFRß, but instead utilises two
gp130 components and its own ligand binding IL-6Rα subunit. CNTF
requires an CNTFRα as well as gp130 and LIFRβ. LIF, however,
does not require a specialised ligand binding unit and only uses gp130
and LIFRß.
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For instance, they show that the addition of IL-6 and its ligand-binding subunit IL-6Rα
resulted in the phosphorylation of Jak-1 in EW-1 cells, Jak-2 in SK-MES cells and Jak-1,
Jak-2 and Tyk-2 in U266 cells. Furthermore, addition of CNTF to EW-1 cells resulted in
the phosphorylation of both Jak-1 and Jak-2. This study using cell lines demonstrates that
not only can different cytokines of the IL-6 family elicit different kinase phosphorylation
patterns in different cell lines but that cytokines also elicit different phosphorylation
patterns depending on the cell type. Therefore, the IL-6 family of cytokines have shared
and distinct patterns of regulation depending on the cells used. This may explain the wide
range of actions that cytokines have in different tissues and cells.
5.1.2 Aims of the Chapter
The aim of this chapter is to further investigate the roles of CNTF by using i) neutralising
antibodies, ii) comparing the actions of other members of the IL-6 family and iii) study of
its time-course of action.
5.2 Results
5.2.1 Neutralising antibodies to CNTF lead to an Increase in
Myelination
In Chapter 4, the addition of CNTF to myelinating cultures resulted in an increase in
myelination. To further confirm this promyelinating effect of CNTF, myelinating cultures
were plated on neurosphere-derived astrocytes plated on PLL (PLL-astrocytes) and
neutralising antibodies against CNTF were added from day 12 onwards. Two neutralising
antibodies are commercially available, one that recognises CNTFR and one that
recognises CNTF itself. It was hypothesised that the addition of neutralising antibodies
would inhibit the promyelinating effect seen with CNTF. Unexpectedly, antibodies against
CNTF ligand (Fig 5.4 C, G) and against the CNTFR receptor (Fig 5.4 D, G) both
produced an increase in myelination, although only CNTF ligand antibody was significant
(p < 0.05) when compared to the untreated control cultures (Fig 5.4 A, G). The addition
of both neutralising antibodies together also increased myelination (Fig 5.4 E, G, p < 0.05)
but not to the same extent as the CNTF ligand antibody alone. The addition of CNTF
together with its neutralising ligand antibody did not affect myelination (Fig 5.4 F, H)
presumably because CNTF and its antibody bound forming an inactive complex prior to
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reaching the membrane bound or soluble α subunit target necessary for CNTF signal
transduction. Neurite density was similar in all conditions measured (Fig 5.4 H, p > 0.05).
These results indicate that the role of CNTF on astrocytes may be more complex than
originally anticipated, where there may be a dual role which highly depends on control
concentration.  For instance, the endogenous levels of CNTF in the culture may be
inhibitory to myelination and withdrawal of CNTF therefore leads to an increase in
myelination. Considering that the exogenous addition of CNTF also increases myelination,
likely via the activation of astrocytes, it can be hypothesised that astrocytes behave
differently to different concentrations of CNTF. For instance, high levels of CNTF lead to
an increase in myelination whereas its withdrawal also leads to an increase in myelination
via either the same (bi-phasic response) or different pathways that secrete promyelinating
factors.
5.2.2 Increase in Myelination with Neutralising Antibodies is only
observed at 4 µg/ml
In order to test whether there is a concentration dependent increase in myelination with the
addition of neutralising CNTF ligand antibodies, concentrations ranging from 0.5-32 µg/ml
were added to cultures from day 12 onwards. Very low (0.5 µg/ml, Fig 5.5 B, E) and very
high concentrations (32 µg/ml, Fig 5.5 D, E) had no affect on myelination compared to
untreated control cultures (Fig 5.5 A). There is a significant increase in myelination at 4
µg/ml (Fig 5.5 C, E, p < 0.05) whilst the neurite density remains similar in all conditions
(Fig 5.5 F). The data therefore suggests that the addition of 4 µg/ml of anti CNTF may
reduce the concentration of CNTF in the culture to a level which promotes myelination and
thus aiding the concentration dependency hypothesis. Taken together with the results from
the previous chapter (Fig 4.2), CNTF may act in a biphasic manner to increase
myelination. However, it is not known whether the addition of neutralising CNTF
antibodies actually reduce the amount of CNTF in the culture media.
5.2.3 There is a Slight Reduction in CNTF Concentration after
Antibody Treatment
To test whether CNTF levels were reduced when the neutralising ligand antibody was
added, cultures were either left untreated or treated with varying concentrations of
antibody (0.5-32 µg/ml). On day 28, media was collected from the cultures and levels of
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Figure 5.4 Neutralising CNTF Leads to an Increase in Myelination. Embryonic
spinal cord cells were plated on confluent layer of astrocytes and cultured for 26-28
days. On day 12, cultures were either left untreated (A), treated with CNTF (2 ng/ml,
B), treated with ligand neutralising CNTF antibody (4 µg/ml, C), α subunit neutralising
antibody (0.2 µg/ml, D), both neutralising antibodies at the same concentrations (E)
and the CNTF with the ligand neutralising antibody (F). An increase in the amount of
myelinated neurites was observed with the addition of CNTF, as previously
documented. An unexpected increase in myelination was also observed upon the
addition of CNTF neutralising antibodies, although only the ligand antibody was
significant to untreated controls (G, p < 0.05). Interestingly, the addition of both
antibodies together also resulted in an increase in myelination, although not to the
same extent as one antibody alone (G, p < 0.05). Finally, the addition of both CNTF
and its ligand neutralising antibody together results in no change from untreated
controls (ns, p < 0.05) possibly suggesting that an inactive complex is formed before
reaching cell surface CNTFRα subunits. Experiments were performed in triplicates.
Scale bar 25 µm. Error bars indicate standard error of the mean.
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Figure 5.5 Myelinating is only Increase at 4 µg/ml. Embryonic spinal
cord cells were plated on a confluent layer of astrocytes and cultured for
26-28 days. On day 12, cultures were either left untreated (A) or treated
with a range of CNTF ligand neutralising antibody (0.5-32 µg/ml, B-D).
An increase in myelination was only detected at 4 µg/ml (E, p < 0.05)
where all other concentrations had similar amounts of myelination to
untreated control. The neurite density was unaffected by antibody
treatment at all concentrations (F). Experiments were performed in
triplicate. Error bars indicate standard error of the mean. Scale bar 100
µm.
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CNTF assayed using an ELISA kit. There is a minor reduction (2-5 pg/ml) in the amount
of CNTF within the cultures which have been treated with neutralising antibody compared
to untreated controls (Fig 5.6). A few questions remain unanswered, including i) is the
minor reduction in CNTF biologically relevant, ii) is the neutralising antibody functional
since the reduction is so low and iii) since there is no information of CNTF values
throughout the culture period, it is not known whether the cultures ‘compensated’ for the
loss of CNTF via negative feedback mechanisms.
5.2.4 CNTF and anti-CNTF May act via Different Pathways
Although high concentrations of CNTF and treatment with the neutralising antibodies
result in an increase in myelination when compared to untreated controls (Fig 4.2 and Fig
5.4) it is not known if they act via the same mechanisms. In order to clarify their
mechanisms of action, treatments were started at either day 12 (internal control), 18 or 24.
Treatments were given every 2-3 days until the end of the culture period. Experiments in
which CNTF treatments began on day 12 and not at 18 or 24 produced the most myelinated
axons (Fig 5.7, B-D, H). In experiments when the neutralising antibody was added at the
various time points it was seen that maximal myelination was seen if treatment started on
day 12 and 18, but not 24 (Fig 5.7 E-G, H), although only addition at day 12 was
significant (p < 0.05). The neurite density of all treatments at all time-points did not differ
(Fig. 5.7 I). Although the mechanism of action for the growth factor and its neutralising
antibody are yet to be identified, this data may suggest that there may be different
mechanisms of action for CNTF and its neutralising antibody.
5.2.5 Neutralising Antibodies and Oligodendrocyte Differentiation
In order to examine whether the addition of neutralising antibodies to CNTF (anti-CNTF)
lead to oligodendrocyte differentiation, cultures were treated on day 12, and fixed and
immunolabelled at 24 hours, 6 and 12 days post-treatment (Fig 5.8). The panel of markers
used included A2B5, perinatal oligodendrocyte progenitor cell, NG2, an early to middle
progenitor marker and O4, a middle to late progenitor marker which is also expressed by
myelinating oligodendrocytes (see Fig 1.2).
The percentage of A2B5+ cells in the culture at 24 hours and 6 days post anti-CNTF
treatment were similar to the untreated condition (Fig 5.8 A). At 12 days post treatment,
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Figure 5.6 Antibody Treatment Leads to Slight Reduction in CNTF in
Media from Cultures. Embryonic spinal cord cells were plated on a
confluent layer of astrocytes and cultured for 26-28 days. On day 12,
cultures were either left untreated or treated with a range of CNTF ligand
neutralising antibody concentrations (0.5-32 µg/ml) throughout the culture
period. On day 26, the media from cultures was collected and assayed for
CNTF using a commercially available kit (R&D Systems). There is a slight
reduction in the amount of CNTF in the media after antibody treatment (2-
5pg-ml). Experiments was performed in duplicate. Error bars indicate
standard errors of the mean.
112
+ CNTF+ anti CNTF
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Control 12 18 24
My
eli
nat
ion
 (S
tan
dar
dis
ed)
Start of Treatment (DIV)
B C D
E F G
H
CNTF 12 DIV CNTF 18 DIV CNTF 24 DIV
anti CNTF 12 DIV anti CNTF 18 DIV anti CNTF  24 DIV
A
I
Untreated Control
0
20
40
60
80
100
Control 12 18 24
Ne
uri
te D
ens
ity
 (%
)
Start of Treatment (DIV)
25µm
25µm25µm
25µm25µm
25µm
25µm
ns
* *
ns
Figure 5.7 Addition of CNTF and anti CNTF at Different Time Points
Suggests that there may be Two Different Mechanisms for their Actions.
Embryonic spinal cord cells were plated on confluent monolayer of astrocytes and
left untreated (A) or treated CNTF (B-D) and anti CNTF (ligand neutralising
antibody, E-G), beginning treatment on either Day 12 (B, E), 18 (C, F) or 24 (D,
G), and continuing onwards until day 26-28. As previously observed, there was an
increase in both CNTF and anti-CNTF when added on day 12 (H, p < 0.05). For
CNTF, no increase was observed when addition was on day 18 or 24 in vitro
(DIV). However, the addition of anti-CNTF on day 18 resulted in an increase in
myelination but this was not found to be statistically different (H, ns p < 0.05). No
change in myelination was observed when anti-CNTF was added on day 24.
Neurite density was unchanged compared to untreated controls in the CNTF and
anti CNTF treatments (I). Experiments were performed in triplicate. Error bars
indicate the standard error of the mean.
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there is a large reduction in the number of A2B5+ cells in the culture system with
treatment (Fig 5.8 A, p < 0.05). This data indicates that treatment with neutralising
antibodies promoted the differentiation of A2B5+ cells into more mature cells. However, it
can not be ruled out that treatment may also lead to the premature death of excess A2B5+
cells. NG2+ cells levels remain relatively consistent with a significant increase at 6 days
post treatment (Fig 5.8 B, p < 0.05). The percentage of NG2+ cells at 12 days post
treatment is slightly higher in the untreated condition compared to that in treatment. These
cells may represent the peak increase seen in A2B5 cell population at 12 days post
treatment. Finally, the percentage of O4+ cells in the culture was consistent throughout the
culture period (Fig 5.8 C), although there is an initial increase of O4+ in the treated
condition (Fig 5.8 C, p < 0.05). Although the data initially suggests that there is a reduction
in the progenitor cell population and therefore a larger pool of differentiated cells able to
myelination, this can not be the case as the O4+ percentages per view are similar in both
treated and untreated conditions. It is hypothesised that oligodendrocytes in the treated
condition are ‘primed’ for more efficient myelination, i.e. more myelinating processes per
oligodendrocytes, explaining why there are similar numbers of O4+ labelled cells at the
end of the culture.
5.2.6 Antibodies to CNTF do not lead to an Increase in
Proliferation
The withdrawal of CNTF from the culture system may be inducing the proliferation of
oligodendrocytes and therefore increasing the number of cells capable of myelinating.
Myelinating cultures were set up and neutralising antibodies were added on day 12 along
with BrdU. Day 12 was chosen as it is the day CNTF is normally added to the cultures,
which results in an increase in myelination. The cultures were then fixed and
immunolabelled with the O4 antibody, anti BrdU and DAPI (Fig 5.9 A, B). Three
experimental repeats were performed, taking 5 random images from each experiment and
cells counted. The mean number of cells expressing the O4 antibody (O4+) cells was
similar in both treated and non-treated conditions (29±3 and 24±1.7, respectively).
Crucially, O4+ cells which were also BrdU+, the proliferating oligodendrocyte population,
were slightly higher in numbers in the treatment compared to the controls (1.6±0.45 and
2.8±0.9, respectively, Fig 5.9 C), although this was not found to be statistically different (p
> 0.05).
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Figure 5.8 Addition of anti-CNTF does not lead to an Increase in O4+
Oligodendrocytes. Embryonic spinal cord cells were plated on a confluent monolayer
of astrocytes. On day 12, cultures were either left untreated or treated with anti-
CNTF. The cultures were fixed and immunolabelled 24 hours, 6 or 12 days post the
beginning or treatment with A2B5 (A), NG2 (B) or O4 (C).  The number of positive
cells were expressed as a percentage of the total cells were view (DAPI count) and the
mean per view for each time-point is plotted. With treatment, there is a large decrease
in A2B5+ cells at 12 days post treatment (A, p < 0.05). NG2+ cell population was
relatively unchanged, but there was an increase in NG2+ cells on day 6 post
treatment. Finally, the O4+ cell population peaks with anti-CNTF treatment at 24
hours post treatment (p < 0.05) but then remains consistent between untreated and
treated cultures.  Experiments were performed in triplicate. Error bars indicate
standard error of the mean.
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Figure 5.9 Addition of anti-CNTF does not lead to the Proliferation of
O4+ cells. Embryonic spinal cord cells were plated on a confluent
monolayer of astrocytes. One day 12, cultures were either left untreated
(A) or treated with anti-CNTF (B) on day 12. BrdU was also added to
both cultures on day 12. On day 13, the cultures were fixed and
immunolabelled with O4 and anti-BrdU and counted and number were
represented as mean number of cells per view. There was no difference
between untreated control cultures and anti-CNTF treatment in the total
number of O4 cells and BrdU+ cells (C, p > 0.05). The numbers of
proliferating oligodendrocytes (O4+/BrdU+) were also similar in both
conditions (C, p > 0.05). Scale bar 20 µm. Experiments were performed in
triplicates. Error bars indicate standard error of the mean.
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4.2.7 Neutralisation of CNTF may lead to a slight increase in
Microglial Activation
It has already been observed that the addition of exogenous CNTF does not lead to a
change in numbers of activated microglia in the myelinating cultures (Fig 4.6). The next
question is to investigate what happens when neutralising antibodies are added to the
cultures. Myelinating cultures were treated with anti-CNTF from day 12 onwards. The
cultures were then fixed and immunolabelled with ED1, a marker for activated microglia
(Fig 5.10 A, B). There is an increase in both number of nuclei and in the number of ED1+
cells in the cultures with treatment (Fig 5.10 C, p < 0.05). However, when the ED1+
population was expressed as the total number of DAPI+ cells, there was no difference to
the untreated condition (Fig 5.10 D).
5.2.8 LIF and anti-LIF Increase Myelination
All IL-6 cytokine family members signal via gp130 and may therefore compensate for
each other (Drögemuller et al., 2008). Therefore, it is possible that the neutralisation of
CNTF could allow other members of the IL-6 family to act on the gp130/LIFRβ receptor
complex. Leukemia inhibitory factor (LIF) is also known to be secreted by astrocytes
(Ishibashi et al., 2006) and was thus chosen as a candidate to add to the myelinating
cultures. Its addition (2 ng/ml) resulted in a slight increase in myelination and neurite
density (Fig 5.11 B, F, G), although the increase in myelination was not significant. The
increase in neurite density was not observed with CNTF or anti-CNTF. To examine
whether its neutralising antibody (anti-LIF) leads to a similar increase in myelination as the
CNTF antibody, it was added to the cultures alone and with anti-CNTF. Both treatments
resulted in a significant increase in myelination (Fig 5.11 C, D, F) compared to untreated
control (Fig 5.11 A, p < 0.05), suggesting a similar mechanism of action to CNTF although
the levels of myelination were less. There was no increase in myelination when both CNTF
and LIF were added into the cultures (Fig 5.11, E, F). This observation is similar to the
addition of CNTF at 20 ng/ml (Fig 4.2) suggesting that an excess of IL-6 cytokines does
not promote myelination at such excessive concentrations. Other conditions did not affect
the neurite density (Fig 5.11 G). Thus, members of the IL-6 family may have a bi-phasic
mechanism of action where their addition at high (but not supra-maximal) levels as well as
very low levels induced by their neutralisation leads to an increase in myelination.
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Figure 5.10 anti-CNTF does not Increase the Number of
Activated Microglia. Embryonic spinal cord cells were plated on a
confluent monolayer of astrocytes. On day 12, cultures were either
left untreated (A) or treated with anti-CNTF (B) on day 12 onwards.
On day 26-28, cultures were fixed and immunolabelled with ED1, a
marker for activated oligodendrocytes and DAPI. The number of
ED1+ cells per view were counted and represented as mean number
of cells per view (C) and expressed as percentage of total cell
number (D). There is an increase in both DAPI and ED1+ cells with
treatment with anti-CNTF (C, p < 0.05). However, when expressed
as percentage of total cell number, there was no difference betwee
conditions. Scale bar 50 µm. Experiments were performed in
triplicate. Error bars indicate standard error of the mean.
118
C D
E
+ anti LIF
F
A B
Untreated Control +  LIF
SMI31 PLP
25µm
25µm
25µm
25µm
Co
ntr
ol0
*
10
30
50
70
90
Ne
uri
te D
ens
ity
 (%
)
ant
i L
IF 
+
ant
i C
NT
F
LIF
ant
i L
IF
CN
TF
 + L
IF
+ LIF + CNTF
G
ant
i L
IF 
+ a
nti 
CN
TF
0
1
2
3
4
Co
ntr
ol LIF
ant
i L
IF
CN
TF
 + L
IFM
yel
ina
tio
n (
sta
nda
rdi
sed
)
* *
D
+ anti LIF + anti CNTF 25µm
Figure 5.11 anti-LIF addition leads to an Increase in Myelination. Embryonic
spinal cord cells were plated onto a confluent monolayer of astrocytes for 26-28
days. On Day 12, cultures were left untreated (A), treated LIF (2 ng/ml, B), LIF
neutralising antibody (0.2 µg/ml, C), anti-LIF and anti-CNTF (0.2 µg/ml and 0.4
µg/ml, respectively, D) or LIF and CNTF (both 2 ng/ml, E). Cultures were fixed and
immunolabelled with SMI31 for axons and PLP for mature oligodendrocytes and
myelin. Addition of LIF resulted in an increase in myelination, although this was not
significant (D, p > 0.05). Addition of anti-LIF alone and anti-LIF with anti-CNTF
together led to an increase in myelination which was significant compared with
untreated controls (G, p < 0.05). The addition of both LIF and CNTF do not affect
myelination (F). Neurite density was similar to untreated controls in all conditions
except LIF, where there was a slight increase (G, p < 0.05). Experiments were
performed in triplicate. Error bars indicate standard error of the mean.
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5.3 Discussion
CNTF’s actions appear to operate in a biphasic fashion on astrocytes. The addition of
CNTF increases myelination in a dose dependent manner. In this chapter, the effect of
CNTF withdrawal was explored and it was found that the reduction of CNTF in the culture
does not affect myelination until a certain amount is withdrawn. This paradigm is
illustrated in Figure 5.12. It must be noted that at either end of the spectrum, myelination is
not inhibited or reduced, but it is unaffected when compared to untreated cultures. This
suggests that the actions of CNTF may only be necessary during injury or disease, where
there is a need for secretion of pro-myelination factors, or rather, the reduction of myelin-
inhibitory factors. It is not known whether this biphasic effect controls differing
descending pathways.
The biphasic affect of CNTF has been previously observed on its actions on adrenergic
cells from the neural crest (Sun and Maxwell, 1994). CNTF was added from 0.001 to 10
ng/ml where the increase in adrenergic cells was observed between 0.001-0.01 ng/ml.
Unlike the data presented here, at high concentrations of CNTF (10 ng/ml), there was a
reduction in number of adrenergic cells when compared to the untreated condition. In
another study looking at the differentiation of late retinal progenitors, Bhattacharya et al.
(2004) use RT-PCR to show that several genes increase with the addition of CNTF in a
dose-dependent manner (10-50 ng/ml). At 0.1 ng/ml and 100 ng/ml (very low and very
high), the expression of these genes remained unchanged. The concentration ranges
between experiments that elicit responses are different possibly because the cell types used
are not the same. This biphasic affect is further strengthened by the observation where the
addition of CNTF and LIF together had no affect on myelination when compared to
controls. It is therefore suggested that supra-maximal levels of one or a combination of IL-
6 cytokines can withdraw their effect on astrocytes leading to the loss of the
promyelinating effect.
As CNTF has been reported to activate astrocytes, Ishii et al. (2006) have hypothesised
whether its neutralisation could resulted in an improved regeneration using a model of
spinal cord injury. The authors demonstrated that the addition of anti-CNTF during the
initial 2 week of injury resulted in a decrease in the number of GFAP+ astrocytes and an
increase in number of oligodendrocytes. The authors argue that the neutralisation of CNTF
reduces glial astrogliosis and therefore creating a more accommodating environment for
regeneration.  This is reasonable as the astrocytes within the spinal cord lesion are known
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to be in a reactive state (Silver and Miller, 2004). However, untreated astrocytes in the
cultures used here are presumed to be ‘activated’, due to the culture setting and the
artificial environment (Section 1.4.6 and East et al., 2009). Thus, can endogenous CNTF
be activating astrocytes at a level where they are unable to support myelination? This
seems unlikely as the cultures support myelination without CNTF. However, to draw
parallels between the study above and our data, it is hypothesised that the addition of
CNTF at supra-maximal level (> 20 ng/ml) will activate pathways which lead to the
discontinued release of promyelinating factors, though this was not tested. This may make
the astrocytes ‘reactive’ and direct comparison can be made with those seen within the
glial scar.
An alternative hypothesis to explain the increase in myelination with CNTF withdrawal is
the possible activation of other unknown descending pathways which lead to the secretion
of other promyelinating factors. This is supported by a similar bifunctional, concentration-
dependent effect which was reported for Schwann cell myelination after neuregulin 1 (Nrg1)
treatment (Syed et al., 2010). In this study, the difference in myelination at high and low
concentrations of Nrg1 was due to a concentration-dependent differential activation of its
receptor. High concentrations activated Erk pathways but low concentrations activated the Akt
pathways. A similar mechanism may explain our results with the range of CNTF treatments.
CNTF and anti-CNTF possibly act on different cell types or act at different periods during
the development of the myelinating culture. This observation is supported by the varying
time-courses of CNTF and anti-CNTF (Fig 5.7). Although CNTF clearly acts on the
astrocyte monolayer (Chapter 4), anti-CNTF (withdrawal of CNTF) may be inducing
another cell type to elicit an additional response which indirectly leads to the increase in
myelination. This hypothesis was not investigated further. To further understand the
differences between CNTF and anti-CNTF a more detailed, cell specific look into their
signaling pathways is required.
The observation that LIF and its neutralising antibody show an increase in myelination in
the myelinating cultures resembles that observed with CNTF and its neutralising antibody.
As described previously, IL-6 family members share some receptor components. A theory
arose where there may be competition between endogenous IL-6 family of cytokines
within the culture for the same receptors (illustrated in Figure 5.13). The neutralising of
one cytokine may make it more likely for another to bind. Some cytokines may have
higher affinities to the receptor than the cytokines which were neutralised, leading to an
122
increase in response as a result. For instance, it is hypothesised that the neutralisation of
CNTF may allow LIF to bind. As demonstrated, LIF does have promyelinating effects.
Thus, the neutralisation of CNTF may lead to the increased activity of LIF, which shows
similar increase in myelination when added to the cultures. Furthermore, since the
inhibition of both CNTF and LIF also led to an increase in myelination, but not to the same
extent as anti-LIF alone, it could be suggested that the neutralisation of two or more
cytokines may lead to a ‘dampening effect’ where the neutralised cytokines may have been
more potent.
Although the roles of CNTF in combination with its neutralising antibody and LIF have
not been fully deciphered, it can been seen that their roles are complex, varying greatly
from concentrations and differing cell types. Preliminary experiments were started using
mice cultures to investigate whether CNTF has the same role on mouse cells. In fact,
CNTF was found to have a much greater effect on mouse cultures. To further dissect the
role of CNTF, transgenic mice which lack astrocyte specific gp130 expression (gp130-/-)
can be used (Drögemuller et al., 2008). Astrocytes from these animals would be used as a
monolayer for myelinating cultures which are then treated with CNTF. It is hypothesised
that the pro-myelinating effect CNTF would be lost, as astrocytes would lack the
expression of the CNTF receptor subunit gp130. Experiments are underway to investigate
this.
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Figure 5.12 Illustration of the Possible Biphasic Effect of CNTF. From
the data demonstrated here and in Chapter 4, CNTF exhibits a biphasic
mechanism of action. The illustration demonstrates myelination (y axis) in
relation to CNTF concentration (x axis) where the withdrawal of CNTF
before 0 represents further CNTF release due to a negative feedback
mechanism from cells in the culture. When very high concentrations of anti-
CNTF are added to the cultures, myelination is not affected. However, when
a certain amount was withdrawn (4 µg/ml of anti-CNTF) there is an increase
in myelination. On the other side of the spectrum, low concentration of
CNTF do not affect myelination, however, there is a dose-dependent
increase reaching optimal levels when 2 ng/ml of CNTF is added to the
cultures. Going beyond the optimal concentration, no increase in
myelination is observed.
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LIFRβgp130
LIF
α
CNTF OSM
LIFRβgp130
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α
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α
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Figure 5.13 Illustration of the Possible Competition between IL-6
Cytokines. IL-6 cytokines share receptor components of gp130 and LIFRß.
Assuming all members are expressed and secreted in the culture, it is
possible that there is competition between the cytokines for available
receptor subunits. Upon the neutralisation of one cytokine, others
cytokines, which may be more potent but have a lower affinity to the
receptor are able to bind. For instance, when CNTF is neutralised, OSM or
LIF can bind in its place and their actions may be more effective at
activating signal transduction mechanisms. Finally, the neutralisation of
one or more cytokines may lead to the ‘dampening’ effect where the
neutralised antibodies were more potent and therefore a reduction in the
original effect observed.
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Changing the Phenotype of the Astrocyte and its Effect
on Myelination
6.1 Introduction
6.1.1 Background
Although it has been shown that astrocytes can secrete pro-myelinating factors (previous
chapter), it is not clear if in CNS pathology the astrocyte status/phenotype can affect
myelination. In the normal CNS, astrocytes are often described as resting or quiescent
(Eddleston and Mucke, 1993). In injury or disease, astrocytes respond to the surrounding
inflammatory environment by upregulating their expression of cytoskeletal molecules,
such as GFAP and nestin, and by secreting cytokines and extracellular matrix molecules
(Silver and Miller, 2004; Williams et al., 2007; Sofroniew and Vinters, 2010). As
previously described in Section 1.4, the degree of this response determines whether an
astrocyte is supportive (activated) or non supportive (reactive) for repair/myelination.
To mimic quiescence, astrocytes were plated on a Tenascin-C substrate (TnC, TnC-
astrocytes) in serum-free conditions (Holley et al., 2005). TnC is a highly conserved
glycoprotein of the extracellular matrix and is expressed by astrocytes (Kruse et al., 1985;
Faissner et al., 1988). During development, TnC expression is high in the cerebellar cortex
and reduces over time (Bartsch et al., 1992; Czopka et al., 2009). Levels for TnC mRNA
are relatively low in the adult CNS (Zhang et al., 1995; Ferhat et al., 1996) indicating that
its role may be primarily developmental and/or pathological. Astrocytes plated on TnC
expressed several characteristics of quiescence including a lower expression of molecules
associated within the glial scar such as embryonic neural cell adhesion molecule (E-
NCAM), epidermal growth factor receptor (EGFR), basic fibroblast growth factor (bFGF)
and nestin, compared to astrocytes which are plated on PLL (Holley et al., 2005).
Furthermore, the authors showed that TnC-astrocytes had a lower proliferation rate than
those on PLL. These observations indicate that Holley et al. (2005) have successfully
produced an in vitro astrocyte phenotype which resembles astrocytes in the normal CNS.
There have been many studies describing the association of TnC expression with neurite
outgrowth and its role in regeneration post CNS injury. To investigate the expression of
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TnC on astrocytes when in contact with neurites, Ard and Faissner (1991) cultured
astrocytes from newborn rat cerebral cortex and used embryonic rat retina as a source of
axonal outgrowth. They found that astrocytes downregulated their expression of TnC when
in contact with axons, suggesting that astrocytes control the expression of TnC in order to
allow axonal extension. As the expression of TnC is associated with the CNS injury
(Niquet et al., 1995), its is interesting to investigate why astrocytes fail to downregulate
TnC in these conditions. Indeed, another study has shown that a TnC substrate is inhibitory
to axonal outgrowth (Treloar et al., 2009). The authors used a stripe assay, a method
widely used to test the extension capability of neurites on different substrates, and use a
TnC and poly-D- lysine (PDL) a control substrate. They showed that neurites extending
from olfactory epithelium explant stopped extending when they reached the TnC substrate.
This study clearly demonstrates neurite outgrowth is inhibited in the presence of TnC. In
another study, using an in vivo model of reactive gliosis, in which a piece of nictrocellulose
was implanted into the cortex of neonatal and adult animals, it was found that the
expression of TnC correlated with the astrocytes most proximal to the glial scar, but only
in adult animals (McKeon et al., 1991). Furthermore, the glial scar from the lesion of
neonatal animals supported neurite outgrowth wheras the adult tissue did not, suggesting
that the expression of TnC is highly associated with hindering axonal regeneration after
injury. In the neonate, however, astrocytes may have more control over their expression of
TnC.
TnC expression has also been implicated in oligodendrocyte survival and maturation.
Czopka et al. (2009) demonstrated that when OPCs were grown on a residual ECM
substrate taken from TnC-positive astrocytes they failed to differentiate into MBP-positive
oligodendrocytes when compared to those grown on control substrate (poly-ornithine).
Furthermore, the addition of residual matrix from TnC-negative astrocytes (astrocytes
taken from TnC-null mice) was able to ‘rescue’ OPC differentiation, although not to the
same extent as the control substrate. In another study, a TnC substrate was shown to be
anti-adhesive and anti-migratory to primary rat OPCs (Keirnan et al., 1996).
The presence of TnC evidently has a role in OPC development and migration and axonal
survival and extension. Holley et al. (2005) argue that astrocytes plated on TnC have a
phenotype  that resembles the ‘normal’ astrocyte in the adult CNS, whereas those on PLL
are ‘activated/reactive’ and show a more similar profile to those within the glial scar. As
outlined in Section 1.4.4, the glial scar is a major impediment for regeneration. The
understanding how markers within a glial scar correlate to the phenotype of the astrocyte
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and mechanisms by which this may alter processes such as axonal regeneration and
oligodendrocyte differentiation may be of key importance in the treatment of CNS disease
and injuries.
6.1.2 Aims of the Chapter
The experiments below describe whether modulating the astrocyte phenotype in vitro can
influence the myelinating capacity of endogenous oligodendrocytes and whether these
effects can be reversed using cytokines and astrocyte conditioned media. The aim of this
chapter is to assess whether astrocytes plated on TnC are truly ‘quiescent’ and how this
phenotype will ultimately affect myelination in our myelinating culture system.
6.2 Results
6.2.1 Myelination is Reduced on TnC-Astrocytes
To assess if modulating the astrocyte phenotype could affect myelination, astrocytes were
plated on either PLL (PLL-astrocytes, Fig 6.1 A) or TnC (TnC-astrocytes, Fig 6.1 B) to
create an intact confluent monolayer of cells. Dissociated embryonic spinal cord cells were
plated on top of these monolayers and myelination (axonal ensheathment) and neurite
density was assessed at day 26-28. Neurite density was comparable on both types of
astrocytes (Fig 6.1 E, p > 0.05) suggesting that neurite extension was unaffected by the
TnC substrate. Myelination on TnC-astrocytes (Fig 6.1 D, F) was reduced significantly,
compared to myeliantion found on PLL-astrocytes (Fig 6.1 C, F; p < 0.05). This data
suggests that the phenotypic state of the astrocyte plays a major role in the capacity of
oligodendrocyte to myelinate axons.
6.2.2 Astrocytes on PLL and TnC Show Similar Cellular
Characteristics
Since the astrocytes plated on TnC had such a dramatic effect on myelination, several
classical astrocytic properties were compared. The purity, proliferation and antigenic
characteristics of astrocytes on PLL and TnC substrates were assessed in order to identify
differences which may contribute to their myelinating capacity, for instance, an inherently
higher number of O4+ in the monolayer cells may contribute to the final number of
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Figure 6.1 Myelination was Reduced on Astrocytes plated on TnC.
Astrocytes were plated on top of coverslips which were either coated
with poly-L-lysine (PLL-astrocytes, A, C) or TnC (TnC-astrocytes, B,
D) in DMEM-FBS. Astrocytes were cultured for 7-10 days and some
were fixed and immunolabeled with GFAP to check for confluency.
When astrocytes were confluent, spinal cord cells (SCC) were plated on
top and cultured for 26-28 days. Coverslips were then fixed and
immunolabeled with SMI31 (axons, red) and PLP (myelin, green).
Neurite density was similar in both conditions (E, p > 0.05), whilst the
number of myelinated axons was significantly higher on astrocytes
plated on PLL compared to those plated on TnC (F, p < 0.05). Scale bar
25 µm for A and B, and 100 µm for C and D. Experiments were
performed in triplicate. Error bars indicate standard error of the mean.
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myelinating oligodendrocytes. Five images were taken from astrocytes plated on each
substrate were taken. An average of 250 ± 38 cells were counted for each substrate,
totalling up to an average of 676 ± 38 cells per condition. The mean percentage for GFAP+
cells on PLL and TnC was 78±3 and 78±2 respectively (Fig 6.2 A, C, E). The percentage
of O4+ pre-oligodendrocytes constituted 10±2.5 and 9.59±2 for PLL-astrocytes and TnC-
astrocytes respectively. The percentage of O4/GFAP positive cells, which were previously
described by Black et al. (1993) as astrocytes due to their stellate and process-bearing
morphology were also counted; 2±1.5 and 1.99±1.48 for PLL-astrocytes and TnC-
astrocytes respectively (Fig 6.2 A, C, E). Tuj1+ cells, a marker for neuron-specific class III
beta-tubulin was also counted and found to be similar in both PLL and TnC astrocytes
(5±0.7 and 8.6±1.4, respectively) (Fig 6.2 B, D, E). No differences in percentages (or
number of cells per view, data not shown) were found between PLL-astrocytes and TnC-
astrocytes for any of the markers immunolabelled (p > 0.05). Tuj1 immunolabeling was
for a sister coverslip to O4. The ‘other’ category represents DAPI nuclei without GFAP or
O4 reactivity. The relative percentages of the ‘other’ category are strikingly similar to
those of Tuj1 on the second coverslip (12.85±1.2 and 14.7±2 for PLL and TnC
respectively) suggesting that the majority of non-labelled nuclei on coverslips labelled with
the O4 antibody could be Tuj1-positive cells. The O4+ cells counted in both conditions
contained a morphologically heterogeneous population of cells including small branched
pre-oligodendrocytes (Fig 6.2 F) and oligodendrocytes with a sheath-like appearance (Fig
6.2 G). Likewise, Tuj1 cells also exhibited different morphologies; simple bipolar-like
cells (Fig 6.2 H) and highly branched cells (Fig 6.2 I).
6.2.3 Astrocytes on PLL Resemble the ‘Activated’ Phenotype
In response to damage, CNS tissue will undergo some form of astrocytosis, whereby
astrocyte morphology, size and secretory profile changes from that of a resting astrocyte to
a reactive astrocyte. The characteristics of PLL-astrocytes and TnC-astrocytes were
compared to assess essential differences in size, antigenic phenotype and proliferation. No
change in proliferation was found between PLL-astrocytes and TnC-astrocytes (Fig 6.3 D),
although PLL-astrocytes were larger than those plated on TnC (Fig 6.3 C, p < 0.05).
Furthermore, PLL-astrocytes had higher levels of nestin immunoreactivity (p < 0.05) when
compared to TnC-astrocytes. In addition, a greater number of astrocytes on PLL were
nestin-positive compared to those plated on TnC (Fig 6.3 E, p < 0.05). Nuclei diameter as
assessed using DAPI staining was larger in PLL-astrocytes than TnC-astrocytes (Fig 6.3
G, p < 0.05). An increase in size, nucleus diameter and nestin expression are
characteristics typical an ‘activated’ astrocyte phenotype whilst the reduction of nestin
Figure 6.2 Cellular Characteristics of Astrocytes on PLL or TnC are
Similar. Astrocytes were plated on top of coverslips which were either
coated with poly-L-lysine (PLL-astrocytes, A, C) or TnC (TnC-astrocytes,
B, D) in DMEM-FBS and cultured for 7-10 or until confluency. Coverslips
were then immunolabelled with GFAP (intermediate filament for
astrocytes, green), O4 (pre-myelinating oligodendrocyte, red) or TUJI
(neuron-specific class III beta-tubulin, red). Images were taken for all
markers and a positive cell for a particular marker was expressed as a
percentage of the total DAPI count. There were no differences in the
number of GFAP, O4, GFAP/O4 and TUJI cells between astrocytes plated
on PLL and on TnC (E, paired t-test, p > 0.05). Heterogeneous populations
of O4 and TUJ1 cells were observed on both substrates (F-I, all images
from PLL substrate). Scale bar 25 µm for A-D and 20 µm for F-I.
Experiments were performed in triplicate. Error bars indicate standard error
of the mean.
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observed in TnC-astrocytes is typical of ‘quiescent’ in accordance with observations by
Holley et al. (2005).
6.2.4 TnC-Astrocytes as a Substrate for Myelinating Cultures; Can
TnC Directly Influence Oligodendrocyte Differentiation?
As TnC has been shown to inhibit oligodendrocyte differentiation (Czopka et al., 2009), it
is not known whether or not the TnC substrate for astrocytes is exposed to developing
OPCs present in the myelinating culture and therefore limiting their differentiation. In
order to assess true confluency, phalloidin, a toxin which binds to F-actin, the filamentous
protein in the cytoskeleton, was used to visualise the extent of confluency in astrocytes on
PLL and TnC. It can be seen from Figure 6.4 that GFAP grossly underestimates the size of
the cell. Using phalloidin to visualise astrocytes, it can be seen that astrocytes cover more
space than when using GFAP (Fig 6.4 A-F arrows) on both PLL and TnC substrates.
However, due to the nano-scale nature of such molecules, it can not be assumed that TnC
can not still penetrate through the F-actin filaments.
6.2.5 Expression of TnC is Comparable on PLL-Astrocytes and
TnC-Astrocytes
It is possible that astrocytes ‘take-up’ the TnC substrate and re-express it on their surface,
which could result in an inhibition of oligodendrocyte differentiation leading to a lower
level of myelination. TnC surface expression was similar in both PLL and TnC astrocytes
by immunohistochemistry (Fig 6.5 A, B). Comparison of TnC levels by Western blot of
astrocytes plated on PLL and TnC show that there is no difference in TnC expression (Fig
6.5 E, F). Arbitrary units of the bands (Fig 6.5 F) were measured in Image J from 3
separate experimental blots. As TnC has been described an as inhibitory molecule to
neurite outgrowth (McKeon et al., 1991), SMI31-reactivity was confirmed to be similar on
astrocytes plated on either substrate, as a dense expanse of SMI31 positive neurites can be
seen (Fig 6.5 A, D and Fig 6.1 C, D). TnC-astrocytes are therefore not inhibitory to neurite
outgrowth. Rather, astrocytes grown on TnC compared to PLL may differ in their
expressional and/or secretory profile.
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Figure 6.3 Astrocytes plated on PLL Exhibit an ‘Activated’ Phenotype
whilst those on TnC Exhibit a ‘Quiescent’ Phenotype. Astrocytes were
plated on top of PLL (A) or TnC (B) coated coverslips. Bromodeoxyuridine
(BrdU) was added to coverslips for 18-24 hours, then fixed and
immunolabelled with anti-BrdU. Sister coverslips were directly fixed and
stained for GFAP and nestin expression. The numbers of positive cells per
marker were counted as percentage of total DAPI count. Cell size, DAPI size
and integrated density were measured. Astrocytes on PLL have a significantly
larger area and DAPI diameter to those on TnC (C, G). Astrocytes on PLL
also had a greater number of nestin positive cells and a larger nestin
integrated density than astrocytes on TnC (E, F). There was no difference in
rate of proliferation between PLL-astrocytes and TnC-astrocytes (D). Scale
bar 25 µm for A and B. Experiments were carried out in triplicate. Error bars
indicate standard error of the mean.
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Figure 6.4 Confluency is Achieved when Astrocytes are plated on PLL
or TnC. Astrocytes were plated on top of coverslips which were either
coated with poly-L-lysine (A, C, E) or TnC (B, D, F) in DMEM-FBS and
cultured for 7-10 or until reaching confluency. Cell were fixed and
immunolabelled with GFAP and phalloidin. Astrocytes visualised with
Phalloidin cover more space than GFAP (A-F arrows) on both PLL and
TnC conditions. Scale bar for A-F 20 µm.
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Figure 6.5 Plating Astrocyte on a TnC Substrate Does Not Affect Neurite
Extension or Expression of TnC on Astrocytic Surface. Astrocytes were
plated on coverslips which were either treated with PLL (A) or TnC (B) in
DMEM-FBS. The cells were fixed and immunostained with GFAP and TnC.
Spinal cord cultures were added to PLL or TnC monolayers and cultured for 26-
28 days and then fixed and stained for SMI31 (C, D respectively). Sister
astrocyte monolayers were lysed and immunoblotted for TnC and GAPDH
expression (E) and the intensity of blots was quantified from 3 experiments (F).
Astrocytes did not express higher levels of TnC when plated on a TnC substrate
(A, B). Axonal extension was unaffected by either substrate. Scale bar 50 µm
for A-D and 100 µm for E and F.
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6.2.6 Quiescent Astrocyte Phenotype can be Overcome by
Activated Astrocyte Conditioned Media or CNTF
To assess if the quiescent ‘status’ of the astrocytes could be overcome, cultures were
treated in several ways. Two groups of cultures were set up: i) classical myelinating
cultures placed on PLL-astrocytes and ii) myelinating cultures placed on TnC-astrocytes.
Each group contained control non treated cultures (Fig 6.6 A, D); addition of 2 ng/ml
CNTF (images not shown); addition of a monolayer of astrocytes plated on the opposite
monolayer than its grouping, i.e. TnC-astrocytes were used to condition a myelinating
culture on PLL-astrocytes (and vice versa); and lastly PLL-astrocytes which were pre-
treated with CNTF (2 ng/ml) for 24-28 hours and washed with PBS before being placed in
the same Petri dish as myelinating cultures (see Methods Section 2.1.4). It can be seen that
CNTF alone or after pretreating astrocytes led to an increase in myelination in both groups
(Fig 6.6 G).  TnC-astrocytes allowed to condition a typical myelinating culture (culture on
PLL-astrocytes) did not affect the resulting levels of myelination (Fig 6.6 B, G) but PLL-
astrocytes allowed to condition a myelinating culture plated on TnC-astrocytes increased
the level of myelination (Fig 6.6 E, G) possibly by secreting CNTF (Chang et al., 2003).
Thus, astrocytes plated on TnC appear to inhibit myelination which could then be
overcome by CNTF treatment. The effect appears to be via the expression of a molecule
rather than a secretory factor, as conditioning a culture on PLL with TnC conditioned
media does not lead to a reduction in myelination. The axonal density of all groups and
conditions was similar (Fig 6.6 H). It is therefore suggested that if astrocytes on TnC can
be termed ‘quiescent’ then myelination is affected by this astrocyte phenotype.
6.3 Discussion
Astrocytes on TnC show characteristics of quiescence and this has been shown to be
inhibitory to myelination, in vitro. No differences were found in monolayer composition
between those quiescent (TnC-astrocytes) and activated astrocytes (PLL-astrocytes). The
reduced level of axonal ensheathment by oligodendrocytes on quiescent astrocytes is
reversible upon the addition of activated-astrocytes conditioned media or by the cytokine
CNTF.
Holley et al. (2005) achieved quiescence not only by plating astrocytes on a TnC substrate
but also by serum deprivation. It has also been demonstrated that Bone Morphogenetic
GH
0
20
40
60
80
100
Unt
reat
ed
+CN
TF
+ T
nC C
M
Unt
reat
ed
+CN
TF
+ PL
L C
M
Ne
uri
te D
ens
ity
 (%
)
Cultures on PLL-astrocytes Cultures on TnC-astrocytes
Pre 
CNT
F
PLL
-ast
rocy
te C
M
Pre 
CNT
F
PLL
-ast
rocy
te C
M
Cu
ltu
res
 on
 PL
L-a
stro
cyt
es
Untreated + TnC CM pre-CNTF CM
Untreated + PLL CM + pre-CNTF CMC
ult
ure
s o
n T
nC
-as
tro
cyt
es
A B C
D E F
25µm
SMI31 PLP
*5
0
1
2
3
4
My
eli
nat
ion
(sta
nd
ard
ise
d)
Unt
reat
ed
+CN
TF
+ T
nC C
M
Pre 
CNT
F
PLL
-ast
rocy
te C
M
Cultures on PLL-astrocytes Cultures on TnC-astrocytes
Unt
reat
ed
+CN
TF
+ PL
L C
M
*
ns *
Pre 
CNT
F
PLL
-ast
rocy
te C
M
Figure 6.6 Please see overleaf for figure legend.
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Figure 6.6 Myelinating Cultures Conditioned with Astrocytes Pre-
treated with CNTF Increased Myelination and this effect was
Dominant to the Reduction in Myelination by Quiescent Astrocytes.
E15.5 mixed spinal cord cultures were plated onto a confluent monolayer
of astrocytes on PLL (A-C) or TnC (D- F). Myelinating cultures were left
untreated (A, D), or treated with CNTF (not shown). Myelinating cultures
plated on PLL-astrocytes were conditioned by coverslips of TnC-
astrocytes, whilst myelinating cultures plated on TnC-astrocytes were
conditioned by coverslips of PLL-astrocytes (B, E respectively).
Myelinating cultures on PLL and TnC were conditioned with PLL-
astrocytes pre-treated with CNTF for 24-48 hours. (C, F). PLL cultures
were unaffected by TnC CM (B, G). Myelination was increased on TnC
cultures conditioned with PLL CM (E, G). CNTF-treated CM increased
myelination on both PLL and TnC cultures (C, F respectively, and G).
Neurite density was unaffected in any of the conditions (H). Scale bar 100
µm. CM conditioned media. Experiments were performed in triplicate.
Error bars indicate standard error of the mean.
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Protein-like factors (BMPs) in serum can induce astrocyte differentiation (Obayashi et al.,
2009). It has long been proposed the astrocytes in cultures display an ‘activated’ phenotype
and resemble the activated astrocyte, especially since most astrocyte preparations are
exposed to serum whereas astrocytes in the normal brain are not (Espinosa de los Monteros
et al., 1993; Loo et al., 1995). As astrocytes in these experiments, including TnC-
astrocytes, are grown in serum the extent to which our TnC-astrocytes can be termed
‘quiescent’ is yet to be fully established. In this study, it is reported that TnC-astrocytes
can not support myelination to the same extent to those grown on PLL. We and others
hypothesise that activated astrocytes (PLL-astrocytes) have a secretory profile which is
favourable to myelination, whereas quiescent astrocytes do not. For instance, in response
to electrical stimulation, LIF, a member of the IL-6 family, was secreted by astrocytes in
response to ATP being liberated from firing axons (Ishibashi et al., 2006). The authors also
demonstrate that the exogenous addition of LIF onto co-cultures comprising of DRG
neurons and OPCs, lead to a concentration dependent increase in the number of myelinated
fibres. Thus, LIF-secretion by electrically stimulated astrocytes results in enhanced
oligodendrocyte differentiation. However, it can also be speculated that activated
astrocytes may suppress an inhibitory factor for myelination and quiescent ones do not. For
instance, TNFα, member of the tumour necrosis family, is secreted at low levels by
astrocytes in culture but strongly amplified when induced by pro-inflammatory agents,
such as Interferon-γ (IFN-γ) and Interleukin-1β (IL-1β) (Chung and Benveniste, 1990).
TNFα has been reported to induce both myelin and oligodendrocyte damage in vitro
(Selmaj and Raine, 1988; Cammer and Zhang, 1999; Deng et al., 2010) and its expression
in MS plaques from patients is positively correlated with the extent of demyelination
(Bitsch et al., 2000). Thus, it is not known whether activated astrocytes secrete factors that
promote myelination or factors which inhibit other molecules from hindering myelination.
Taken together these data suggest that quiescent astrocytes do not support myelination.
Although they have the opposite expression profile to reactive astrocytes, reported in the
glial scar, both types display properties which are inhibitory to myelination.
Due to the inhibitory nature of TnC on OPC differentiation, it is reasonable to question if
the reduction in myelination on TnC-astrocytes is simply due to expression of TnC from
the substrate or by upregulation on the astrocyte surface. To address the above questions,
the levels of TnC on PLL-astrocytes and TnC-astrocytes was compared. TnC-astrocytes
expressed comparable levels of TnC compared to PLL-astrocytes (Fig 6.5). This therefore
suggests that the TnC substrate does not lead to the re-expression of TnC on the astrocytes.
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Although the astrocyte monolayer is fully confluent (as shown by F-actin, Fig 6.4), it can
not be assumed that the TnC substrate is not exposed to developing OPCs.
Neurite outgrowth on TnC-astrocytes was unaffected, as SMI31-positive neurites can be
seen covering the coverslip (Fig 4.5 A, D and Fig 4.1 C, D). TnC is multi-domain
molecule, comprising of a cysteine-rich amino terminal domain, 14.5 EGF-type repeats
(mouse), 8 fibronectin type III homologous repeats and fibrinogen β and γ homologous
domain at the carboxyl-terminal end (Husmann et al., 1992). Work by Lochter et al. (1991)
demonstrates that TnC can have dual effect on neurite outgrowth. The authors found
neurites extended processes 40% longer on TnC than on control substrate (poly-ornithine)
whereas the addition of soluble TnC largely inhibited neurite outgrowth. The domain
identified to be responsible for neurite outgrowth is flanked by the 10th and 11th fibronectin
type III homologous repeats. The domains between 3rd and 5th fibronectin type III
homologous repeats have been shown to positively influence migration of rat cerebellar
neurons (Husmann et al., 1992). Andrews et al. (2009) have shown that α9β1 integrin,
which was previously shown to bind to the fibronectin type III domain (Yokosaki et al.,
1998), expressed in neurons can overcome the inhibitory function of TnC both in vitro and
in the injured CNS. The study demonstrates that cell types with the ‘appropriate’ receptor
repertoire are able to overcome the inhibitory nature of TnC. Therefore, it is critical to
identify the inhibitory domains to specific injuries or the pro-regenerative cell receptors
which may overcome it, in order to develop antibody targeted therapy and/or transgenic
cell transplantation to prevail over the glial scar.
It was shown in previous chapters (Chapters 4 and 5) that CNTF is most likely to act on the
astrocyte by increasing its state of activation. There is a great deal of research undertaken
regarding the activation of astrocytes, which was previously discussed (Section 1.4.2). It
was found that cultures on TnC-astrocytes can be ‘rescued’ to increase the number of
myelinated neurites by the addition of CNTF. In addition, the characteristics of TnC
astrocytes shown here bear a resemblance to those described as quiescent in the literature.
Thus, it is hypothesised that CNTF addition to cultures on quiescent TnC astrocytes
reverses their state to one which is more activated. Astrocyte re-activation has been
previously described in Holley et al. (2005) where the quiescence of TnC-astrocytes in
serum-free media was partially reversed by addition of serum. This was shown to increase
both nestin and basic fibroblast growth factor expression, suggesting the phenotype had
reverted back to an activated one. In another study, lipopolysaccharide-induced activation
of astrocytes reduces the expression of iNOS, TNFα and IL-1β by the addition of sodium
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benzoate, a sodium salt of benzoic acid (Bramachari et al., 2009) and lovastatin, a drug
used as a hypolipidemic agent (Pehan et al., 1997). Furthermore, morphological change of
astrocytes from stellate to flat is a characteristic of astrogliosis and can be induced by
thrombins, which are serine proteases (Pindon et al., 1998). The authors show that this
morphologically-induced change by thrombin can be blocked by a serine/threonine-kinase
inhibitor, H7. The phenotype of astrocytes, defined  their expression of ‘reactive’ markers
and their morphology, can therefore be reversed via numerous ways. This is of significant
value as understanding the possible reversal of astrocytes within the glial scar may lead to
a combinational treatment for CNS conditions which involve reactive gliosis.
The activated astrocyte (PLL-astrocytes) can support myelination and can be cytokine-
induced to a higher level of activation which can further support myelination. Quiescent
astrocytes (TnC-astrocytes) do not support myelination but this can be overcome by
activated astrocyte conditioned media or the addition of CNTF. Tenascin-C is upregulated
in astrocytes after injury (McKeon et al., 1991; Laywell et al., 1992) and is also identified
as a component of the glial scar (Gutowski et al., 1999) suggesting an inhibitory role for
growth and repair. Thus, an astrocyte in a reactive state, like in an MS glial scar and one
which is in a quiescent state, like those on TnC, both do not support myelination to the
same extent as an activated astrocyte (see Figure 1.8). These data demonstrate the dual role
of astrocytes and the remarkable effect this has on the myelinating capability of the
oligodendrocytes. The identification of these pro-myelinating factors is crucial in
establishing the secretory profile of an activated astrocyte and in the understanding of
myelination biology. In MS, these factors can be manipulated to ameliorate the
environment in which remyelination can resume successfully.
Chapter 7
Identification of Molecules Secreted by
Activated and Quiescent Astrocytes
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7.1.1 Introduction
The function of astrocytes, especially in disease, is highly dependent on their environment.
The molecular changes that occur during the changes in their environment are key in
understanding astrocyte biology and whether or not they maintain the support they provide
to surrounding cells. The term phenotype is used to represent the characteristic of the
astrocytes in terms of morphological and physiological properties. In this study, two
astrocyte phenotypes have been identified; astrocytes plated on PLL (PLL-astrocytes)
which support myelination are classified as ‘activated’ whereas those on TnC (TnC-
astrocytes) which do not support myelination to the same to the same extent, and have been
termed in the literature as ‘quiescent’. A highly activated astrocyte by cytokine activation
(addition of CNTF) is more supportive for myelination,. Thus, the reactive status of
astrocytes determines their capability to support myelination. In order to further understand
the molecular changes between these astrocyte phenotypes, a more detailed investigation
into the genetic profiles is required.
A microarray uses a platform with tens of thousands of known genes and it a method to
measure gene expression profile changes in cells grown under different conditions. A
microarray study yields an enormous amount of data, which is then analysed and sorted by
fold change differences and statistical significance.
Although microarray gene expression profile studies provide a vast amount of information,
the validation of these genes in a feasible model is also necessary. Target genes can be
identified, but they are of little use if their functions are not confirmed using a reliable
biological system. Zhang et al. (2006) used a microarray analysis approach of cytokine
treated astrocyte and identified IL-11, a member of the IL-6 family of cytokines, to be
produced by astrocytes and important in oligodendrocyte protection and myelin formation.
In this study, the authors treated human fetal astrocytes with IL-1β or TGFβ1, cytokines
known to be upregulated in MS (Baranzini et al., 2000). They identified IL-11 to be highly
upregulated in cytokine treated astrocytes when compared to untreated astrocytes. IL-11
was then validated in a myelinating culture model using dorsal root ganglion (DRG)
neurons and purified oligodendrocytes. They found a concentration dependent increase in
Identification of Molecules by Activated and Quiescent
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the number of myelin segments per field of view with IL-11 treatment. Zhang and
colleagues illustrate the usefulness of gene identification studies by testing target genes on
a model system to show a functional effect.
The myelinating cultures used in our study provides an excellent platform for microarray
analysis. These cultures contain multiple cell types which develop from embryonic cells to
mature differentiated cells over 28 days. Validation of gene function by addition of
proteins or/and neutralising antibodies into the myelinating cultures at defined time points
allows specific questions regarding how differentiation can be affected. For instance,
adding a protein once myelination is complete would probe whether the exogenous
addition of this protein has the potential to demyelinate myelinated axons and addition
factors during myelin ensheathment may compromise the end stages of myelination.
7.1.2 Aims
The aim of this chapter is to identify novel genes which are associated with changes in the
supportive nature of astrocytes, correlating this with its reactivity status and validate these
genes using myelinating cultures.
7.2 Results
Many of the figures in this chapter are Venn diagrams which represent genes which are
shared between two conditions. Tables are also used to list all genes within a category.
7.2.1 Schematic of Experimental Design and Analysis of
Microarray
Neurosphere derived astrocytes were harvested and grown in DMEM-FBS on either PLL
or TnC coated coverslips (Fig 7.1). When confluent, the media was changed to
differentiation media, as used in the myelinating cultures, for 5 days. Some of the PLL-
astrocytes received 2 ng/ml of CNTF. RNA was extracted at 4 hours and 24 hours post-
treatment, but only at 4 hours for TnC-astrocytes. RNA was converted to cRNA and
(see Section 2.10.4 for more details). Significance was determined using the False
However, only genes with relevance to the work presented in this thesis (marked by 
asterisks adjacent to the results tables) will be discussed.
hybridized using an Illumina BeadArray Reader platform and analysed using Beadstudio
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Discovery Rates (FDR) multiple testing correction method (Benjamini and Hochberg,
1995), with a FDR cut-off of 5%. Venn diagrams were used to look for consistent
differences between time points and conditions.
7.2.2 Gene Expression Changes over Time in Untreated and CNTF
Treated PLL-Astrocytes
In order to assess differences over time with and without CNTF treatment, PLL-astrocytes
were left untreated (Fig 7.2 A) or treated with CNTF (Fig 7.2 B) and compared after 4
hours and 24 hours. Genes which were changed over time in both untreated and CNTF-
treated PLL-astrocytes (Fig 7.2 AB) were also included. The expression of 30 genes
changed over time in untreated PLL-astrocytes. It would be of interest to keep astrocytes
for a longer time and assess whether the age of astrocytes affects the support they provide
the process of myelination and whether there are genes associated with older/younger
these experiments were beyond the scope of this thesis.
astrocytes (Fig 7.2 B). This group represents the genes which may influence the increase in
myelination we have found with CNTF treatment in the myelinating cultures. Furthermore,
there were 47 genes which were upregulated in both PLL-astrocytes untreated and treated
with CNTF over time (Fig 7.2 AB). Group AB represents genes changes which are
changed over time in both PLL-astrocytes and PLL-astrocytes treated with CNTF.
Table 7.1, 7.2 and 7.3 represents gene groups shown in Figure 7.2. A disintegrin and
metalloproteinase with thrombospondin motifs 1 (ADAMTS1) was down regulated in both
PLL-astrocytes untreated and treated with CNTF over time (-1.6657 for untreated and -
1.5781 for CNTF treatment, Table 7.3, both FDR < 0.05). ADAMTS1 belongs to a group
of protease enzymes play a role in degradation of chondroitin sulphate proteoglycans.
Haddock et al. (2006) have shown that ADAMTS1 expression is reduced in MS tissue
compared with normal tissue using qRT-PCR. However, when investigating protein levels,
ADAMTS1 levels in MS tissue are similar to normal tissue. In fact, there is a slight
increase in chronically inactive lesions. These observations suggest that the presence of
ADAMTS1 is associated with extracellular matrix modulation in MS and may contribute
to the overall inhibitory environment around the cells involved in myelin formation.
astrocytes which do/do not support myelination. However, although extremely relevant,
There were 60 genes that changed over time from 4 hours to 24 hours in CNTF-treated
PLLTnC PLL
+ CNTF
Astrocytes added
to coverslip
When confluent,
serum deprivation
for 5 days
followed by
treatment
mRNA extracted at 4
hours and 24 hours
RNA cDNA
cRNA *
*
* **
*
**
*
* **
*
*
cRNA hybridised and
added onto Beadchip.
Gene expression changes
measured using Illumina
BeadArray
Data is analysed
using Illumina
Beadstudio
Figure 7.1 Schematic Diagram Representing the Experimental
Plan and Step Wise Process of a Microarray Study. Neurosphere-
derived astrocytes are plated on to PLL or TnC-coated coverslips.
Upon confluency, astrocytes were serum deprived so as to resemble
the culture conditions for a myelinating culture. After 5 days some
PLL-astrocytes were treated with 2 ng/ml CNTF. RNA was extracted
from TnC-astrocytes at 4 hours, PLL-astrocytes and PLL-astrocyte
treated with CNTF at 4 hours and 24 hours. RNA was then reverse
transcribed to cDNA and then using an In Vitro Transcription, cDNA
was converted to cRNA. Following several washing and blocking
steps, cDNA was hybridised to the Illumina Beadchip and changes in
gene expression were recorded using Illumina Beadarray Reader. The
recorded data was then analysed using Illumina Beadtudio where it
was sorted by fold changes and significance using a False Detection
Rate of cut off of 5%.
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A
PLL-astrocytes at 24 hours
vs.
PLL-astrocytes at 4 hours
(77)
30
(A)
B
PLL-astrocytes + CNTF at 24 hours
vs.
PLL-astrocytes + CNTF at 4 hours
(107)
47
(AB)
60
(B)
Figure 7.2 Venn diagram Representing Transcript Distribution over time in
PLL-astrocytes with and without CNTF Treatment. Section A represents the
number of genes with changed expression between untreated PLL-astrocytes
after 4 hours and 24 hours. Section B represents the number of genes with
changed expression between PLL-astrocytes treated with CNTF (2 ng/ml) after
24 hours and 4 hours. Section AB represents the number of genes changed
between untreated and CNTF-treated PLL-astrocytes over time. Numbers
represent the number of genes having significantly different expression between
conditions (FDR > 0.05, n=3).
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PROBE_ID ILMN_GENE FDR FC
ILMN_1371619 KBTBD9_PREDICTED 0.0114 -1.9734
ILMN_1367475 ALDH1A1 0.0340 -1.7993
ILMN_1365068 S100A3 0.0365 -1.7578
ILMN_1530390 TMEM140 0.0340 -1.7456
ILMN_1367962 LOC310395 0.0340 -1.7425
ILMN_1349829 MAFK 0.0430 -1.7166
ILMN_1366331 HABP4_PREDICTED 0.0447 -1.7061
ILMN_1361905 RGD1309930 0.0469 -1.6657
ILMN_1374837 RGD1308967_PREDICTED 0.0398 -1.6558
ILMN_1350901 KCND3 0.0340 -1.6293
ILMN_1358334 LOC501407 0.0340 -1.6291
ILMN_1359646 SOX11 0.0447 -1.5592
ILMN_1349555 COQ10B 0.0469 -1.5507
ILMN_1357848 SLC35D1_PREDICTED 0.0470 1.4978
ILMN_1368643 THRSP 0.0399 1.5201
ILMN_1371109 RGD1561135_PREDICTED 0.0397 1.5338
ILMN_1650251 RGD1309427_PREDICTED 0.0396 1.5347
ILMN_1351683 RILP_PREDICTED 0.0362 1.5512
ILMN_1369914 RASD1 0.0353 1.5561
ILMN_1358490 CDC2 0.0364 1.5606
ILMN_1360216 ID3 0.0399 1.5655
ILMN_2039396 NQO1 0.0470 1.5890
ILMN_1348939 CD93 0.0469 1.5898
ILMN_1350709 NDOR1_PREDICTED 0.0398 1.6155
ILMN_1354279 MMP11 0.0399 1.6167
ILMN_1354198 UAP1L1_PREDICTED 0.0340 1.6184
ILMN_1360039 PAFAH1B3 0.0251 1.6198
ILMN_1355084 RGD1562952_PREDICTED 0.0190 1.6365
ILMN_1368826 RTP4_PREDICTED 0.0353 1.6382
ILMN_1368089 RRM2 0.0190 1.6748
CON24 - CON4
A.only
Table 7.1 Genes identified by Microarray Expression
Profiling between PLL-Astrocytes at 4 and 24 hours (Section
A of Figure 7.2). The table shows the 30 probes significantly
different (FDR < 0.05) in PLL-astrocytes untreated after 4 hours
and 24 hours. These correspond in Figure 7.2 Section A of the
Venn diagram. Shown here are false discovery rates (FDR) and
fold changes (FC).
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PROBE_ID ILMN_GENE FDR FC
ILMN_1376630 MAP6 0.0113 -2.0664
ILMN_1367985 NRP1 0.0082 -2.0364
ILMN_1373357 SPHK1 0.0169 -1.9606
ILMN_1363074 AREG 0.0099 -1.9275
ILMN_1373253 PNLIP 0.0077 -1.8890
ILMN_1370665 ZFAND2A 0.0298 -1.8107
ILMN_1364335 CXCL10 0.0164 -1.8091
ILMN_1368793 CDR2 0.0303 -1.7976
ILMN_1365343 BAIAP2 0.0186 -1.7908
ILMN_1351883 CHRM3 0.0186 -1.7519
ILMN_1358241 ADAMTS9_PREDICTED 0.0196 -1.7492
ILMN_1367508 EEF1A2 0.0241 -1.7426
ILMN_1349804 ATP2B1 0.0297 -1.7245
ILMN_1364257 KCNK3 0.0253 -1.7231
ILMN_1353549 RRAS2 0.0446 -1.6957
ILMN_1375224 PRICKLE1 0.0420 -1.6951
ILMN_1349890 SLC30A1 0.0490 -1.6782
ILMN_1360331 HIST1H2BN_PREDICTED 0.0340 -1.6749
ILMN_1364908 TMEPAI_PREDICTED 0.0282 -1.6571
ILMN_1354679 ADAMTS7_PREDICTED 0.0455 -1.6477
ILMN_1350369 FLRT3_PREDICTED 0.0303 -1.6360
ILMN_1359095 MAT2A 0.0225 -1.6351
ILMN_1369446 OLR757 0.0420 -1.6081
ILMN_1376823 LOX 0.0449 -1.6047
ILMN_1651066 RGD1310975_PREDICTED 0.0292 -1.5906
ILMN_1362230 NGFB_MAPPED 0.0443 -1.5902
ILMN_1357070 RNPC1_PREDICTED 0.0295 -1.5881
ILMN_1366621 RGD1306235_PREDICTED 0.0417 -1.5821
ILMN_1367486 DUSP1 0.0303 -1.5790
ILMN_1349946 EIF1B_PREDICTED 0.0420 -1.5788
ILMN_1354409 NGEF_PREDICTED 0.0422 -1.5744
ILMN_1376851 RND3 0.0443 -1.5623
ILMN_1354516 KCNS3 0.0443 -1.5610
ILMN_1350042 THBS4 0.0343 -1.5470
ILMN_1361968 RGD1560523_PREDICTED 0.0476 -1.5468
ILMN_1352105 CRY1 0.0482 -1.5453
ILMN_1371209 SECTM1 0.0360 -1.5440
ILMN_1360404 STC1 0.0493 -1.5423
ILMN_1356203 ADM 0.0443 -1.5415
ILMN_1649910 CXCR4 0.0417 -1.5243
ILMN_1650382 RGD1560542_PREDICTED 0.0443 -1.5029
ILMN_1363836 EPHB6 0.0482 1.4512
ILMN_1357297 STAT6_PREDICTED 0.0451 1.4564
ILMN_1365818 LOC503241 0.0432 1.4628
ILMN_1366631 MVP 0.0429 1.4659
B.only
CNTF24 - CNTF4
Table 7.2 Please see overleaf for continuation of table and  figure legend.
*
*
*
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FDR FC
ILMN_1368121 OGFRL1 0.0444 1.4681
ILMN_1362982 C1GALT1 0.0432 1.4697
ILMN_1351782 RGD1305779_PREDICTED 0.0417 1.4774
ILMN_1350274 EFNA4_PREDICTED 0.0443 1.5013
ILMN_1355240 PNOC 0.0335 1.5054
ILMN_1357041 PCP4 0.0298 1.5198
ILMN_1370145 MTERFD3 0.0251 1.5390
ILMN_1376411 PPP1R3C 0.0417 1.5428
ILMN_1376818 TUBB3 0.0443 1.5494
ILMN_1376479 GSTP1 0.0169 1.5665
ILMN_1356454 FGFRL1 0.0340 1.5963
ILMN_1375078 RGD1561154_PREDICTED 0.0082 1.6565
ILMN_1358030 CLDN10_PREDICTED 0.0090 1.6929
ILMN_1360780 UGT1A6 0.0170 1.6931
ILMN_1368809 BTG2 0.0169 1.6936
CNTF24 - CNTF4
B.only
Table 7.2 Genes Identified by Microarray
Expression Profiling between PLL-Astrocytes
Treated with CNTF at 4 and 24 hours (Section B of
Figure 7.2). The table shows the 60 probes
significantly different (FDR < 0.05) in PLL-astrocytes
treated with CNTF after 4 hours and 24 hours. These
correspond in Figure 7.2 Section B of the Venn
diagram. Shown here are false discovery rates (FDR)
and fold changes (FC).
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PROBE_ID ILMN_GENE FDR FC FDR FC
ILMN_1650285 HMOX1 0.0000 -3.4716 0.0009 -4.2928
ILMN_1367740 MT1A 0.0000 -2.9376 0.0009 -2.9539
ILMN_2040557 SERPINE1 0.0055 -2.2778 0.0041 -2.8045
ILMN_1355237 CXCL1 0.0053 -2.2499 0.0009 -2.7131
ILMN_1371618 PHLDA1 0.0081 -2.1644 0.0036 -2.5620
ILMN_1364192 RGD1560523_PREDICTED 0.0072 -2.1526 0.0036 -2.5534
ILMN_1364747 JUB 0.0072 -2.0911 0.0041 -2.4653
ILMN_1372919 CYR61 0.0081 -2.0687 0.0041 -2.4503
ILMN_1350180 EMP1 0.0083 -2.0520 0.0041 -2.4424
ILMN_1376417 SERPINE1 0.0084 -2.0306 0.0041 -2.2579
ILMN_1365610 RGD1565319_PREDICTED 0.0083 -2.0218 0.0074 -2.1306
ILMN_1364149 RGD1560587_PREDICTED 0.0101 -1.9952 0.0041 -2.1240
ILMN_1372925 LOC498208 0.0104 -1.9902 0.0077 -2.0965
ILMN_1359516 GCLC 0.0084 -1.9775 0.0077 -2.0901
ILMN_1364863 HIST1H2AO_PREDICTED 0.0114 -1.9730 0.0077 -2.0508
ILMN_1357783 HBEGF 0.0084 -1.9416 0.0073 -2.0427
ILMN_1351237 TXNRD1 0.0149 -1.9098 0.0123 -2.0417
ILMN_1364005 RND1 0.0163 -1.8933 0.0082 -2.0243
ILMN_1375922 NR4A3 0.0114 -1.8929 0.0098 -1.9909
ILMN_1353747 FST 0.0114 -1.8913 0.0169 -1.9192
ILMN_1373609 TNFRSF12A 0.0114 -1.8794 0.0154 -1.8585
ILMN_1364113 CTGF 0.0141 -1.8304 0.0275 -1.8495
ILMN_1361302 KLF5 0.0281 -1.7926 0.0152 -1.8395
ILMN_1351674 GDF15 0.0340 -1.7895 0.0100 -1.8377
ILMN_1354748 OSGIN1 0.0341 -1.7894 0.0100 -1.7897
ILMN_1354070 ISG12(B) 0.0359 -1.7759 0.0335 -1.7768
ILMN_1370948 CREG_PREDICTED 0.0359 -1.7752 0.0164 -1.7622
ILMN_1356516 RGD1563344_PREDICTED 0.0362 -1.7718 0.0404 -1.7309
ILMN_1363449 OCIL 0.0353 -1.7312 0.0186 -1.7091
ILMN_1362353 LOC683385 0.0413 -1.7226 0.0169 -1.6901
ILMN_1371943 RUNX1 0.0447 -1.7095 0.0171 -1.6839
ILMN_1369511 BCAR3_PREDICTED 0.0362 -1.6979 0.0340 -1.6746
ILMN_1353590 GADD45B 0.0398 -1.6970 0.0304 -1.6298
ILMN_1363245 CSF1 0.0353 -1.6849 0.0320 -1.6208
ILMN_1650105 UGT8 0.0469 -1.6704 0.0360 -1.5987
ILMN_1367103 ADAMTS1 0.0321 -1.6657 0.0420 -1.5781
ILMN_1352067 CITED2 0.0398 -1.6172 0.0491 -1.5659
ILMN_1371786 CPEB4_PREDICTED 0.0353 -1.6151 0.0449 -1.5519
ILMN_1371772 PVR 0.0398 -1.5793 0.0447 -1.5011
ILMN_1354540 PDCD4 0.0447 1.6022 0.0404 1.4837
ILMN_1358464 PDE9A 0.0203 1.6407 0.0292 1.5364
ILMN_1374191 SCD1 0.0081 1.7531 0.0443 1.5481
ILMN_1366138 LOC306428 0.0083 1.8256 0.0169 1.5705
ILMN_1366294 GSTP2 0.0082 1.8464 0.0169 1.5812
ILMN_1370454 AOX1 0.0014 2.0586 0.0090 1.6352
ILMN_1350091 G0S2 0.0012 2.0619 0.0100 1.6660
ILMN_1359696 TXNIP 0.0015 2.0803 0.0077 1.8669
CNTF24 - CNTF4
AB.
CON24 - CON4
Table 7.3 Genes identified by Microarray Expression Profiling between
PLL-Astrocytes Untreated and Treated with CNTF after 4 and 24 hours
(Section AB of Figure 7.2). The table shows the 47 probes significantly
different (FDR < 0.05) in PLL-astrocytes untreated and treated with CNTF
after 4 hours and 24 hours. These correspond in Figure 6.2 Section AB of the
Venn diagram. Shown here are false discovery rates (FDR) and fold changes
(FC).
*
*
*
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Furthermore, Cross et al. (2006) show that there is an increase in ADAMST1 following
focal cerebral ischaemia, suggesting that extracellular matrix breakdown is observed
following injury. Data presented here suggests that this gene is downregulated over time in
astrocytes which are supportive for myelination which is consistent with data in the
literature, and supports the view that ADAMST1 expression contributes to an environment
which is non-supportive for myelination.
7.2.3 Very few genes are changed in Untreated PLL-astrocytes
compared to those Treated with CNTF
In order to investigate the genes which are responsible for the increase in myelination and
how these differ from the untreated cultures, PLL-astrocytes treated with CNTF at 4 hours
were compared to those untreated at 4 hours (Fig 7.3 A). Surprisingly, no genes were
identified in this category. When PLL-astrocytes treated for 24 hours with CNTF were
compared to those untreated at 24 hours, only 2 genes were identified (Fig 7.3 B).
Consequently, no genes were upregulated in both categories (Fig 7.3 AB). This result was
unexpected and may be due to the fact that both astrocytes support myelination and
therefore genes which are attributable to this are common to both conditions. Other
possible reasons for this observation are further investigated in the discussion.
The two genes which were down-regulated in PLL-astrocyte treated with CNTF for 24
hours compared to untreated PLL-astrocytes for 24 hours are represented in Table 7.4.
Growth differentiation factor 15 (GFD15) was downregulated by -1.7955 folds (FDR <
0.0455). GDF15 is a protein belonging to the transforming growth factor β superfamily. It
is expressed in the CNS including the choroid plexus as well as various brain regions e.g.
such as the cortex, and striatum. GDF15 is also expressed in cultured astrocytes,
oligodendrocytes and dorsal root ganglia cells (Böttner et al., 1999; Strelau et al., 2000).
Cluster of Differentiation 93 (CD93) was also down regulated in CNTF-treated astrocytes
at 24 hours by -1.7056 (FDR > 0.0277). CD93 is a transmembrane receptor which is
expressed by monocytes and macrophages and has been shown to play a role in the
regulation of phagocytosis and cell adhesion (Nepomuceno et al., 1999; Ikewaki et al.,
2000). The expression of CD93 is not associated with astrocytes, but instead other cells
types including myeloid cells, microglia and enthothelial cells (Jeon et al., 2010). This
suggests that the downregulation of CD93 in CNTF-treated astrocytes may be due to a
contaminating cell type.
0
(A)
0
(AB)
2
(B)
A
PLL-astrocytes + CNTF  4 hours
vs.
PLL-astrocytes at 4 hours
(0)
B
PLL-astrocytes + CNTF at 24 hours
vs.
PLL-astrocytes at 24 hours
(2)
Figure 7.3 Venn diagram Representing Transcript Distribution between
PLL-astrocytes Untreated and Treated with CNTF after 4 hours and 24
hours. Section A represents the number of genes with changed expression in
untreated PLL-astrocytes when compared to CNTF-treated astrocytes after 4
hours. Section B represents the number of genes with changed expression
between CNTF-treated astrocytes and untreated astrocytes at 24 hours. Section
AB represents the number of genes which are changed in both astrocyte
conditions at 4 and 24 hours. Numbers represents the number of genes having
significantly different expression between conditions (FDR > 0.05, n=3).
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PROBE_ID ILMN_GENE FDR FC
PROBE_ID ILMN_GENE FDR FC
ILMN_1351674 GDF15 0.0455 -1.7955
ILMN_1348939 CD93 0.0227 -1.7056
CNTF4 - CON4
CNTF24 - CON24
B.only
A. Only
Table 7.4 Genes identified by Microarray Expression
Profiling between PLL-Astrocytes Untreated and Treated
with CNTF after 24 hours (Figure 7.3). The table shows the
2 probes significantly different (FDR < 0.05) in PLL-
astrocytes untreated and treated with CNTF after 24 hours.
Note that there were no probes identified when comparing the
same conditions after 4 hours. These correspond to Figure 7.3.
Shown here are false discovery rates (FDR) and fold changes
(FC).
**
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7.2.4 Numerous Genes are identified when TnC-astrocytes were
compared to untreated and CNTF-Treated PLL-Astrocytes at 4
hours and 24 hours
TnC-astrocytes were compared to both PLL-astrocytes untreated and treated with CNTF at
4 hours. Ten and 30 genes were changed in PLL-astrocytes untreated and PLL-astrocytes
treated with CNTF when compared to TnC-astrocytes (Fig 7.4 A and B, respectively).
Interestingly, when comparing TnC-astrocytes to both CNTF-treated and untreated
astrocytes, 22 genes were changed (Fig 7.4 AB).
Table 7.5 represents all the genes within the categories A and B, whereas Table 7.6
represents AB from Figure 7.4. These includes pleiotrophin, Transgelin, Tenascin-R, and
Insulin-like growth factor binding protein.
Pleiotrophin (PTN), also known as heparin-binding growth-associated molecule (HB-
GAM), is a protein that has a diverse array of functions including neurite outgrowth and
oligodendrocyte differentiation (Deuel et al., 2002). The expression of PTN is
downregulated in TnC-astrocytes compared with untreated PLL-astrocytes by -2.0740
(Table 7.5, A only, FDR < 0.0269).
Trangelin, a gene associated with changes in cell shape (Shapland et al., 1988), where it
binds to actin changing its loose distribution to one which is more aggregated and tousled.
Transgelin is upregulated in TnC-astrocytes by 1.8136 (Table 7.5, FDR < 0.473), which is
interesting as morphological changes are associated with different astrocyte phenotypes.
Expression of tenascin-R (TNR) is down regulated -1.8005 (FDR < 0.0099) in TnC-
astrocytes when compared to untreated astrocytes at 4 hours (Table 7.5, A only). TNR is an
extracellular glycoprotein which is part of the Tenascin family and its expression is
associated with enhanced oligodendroglial differentiation and adhesion (Pesheva et al.,
1997). It has been shown that TNR enhanced cell adhesion and expression of myelin
proteins when pre-myelinating oligodendrocytes were plated on a TNR substrate.
The expression of Insulin-like growth factor binding protein (IGFBP2, Table 7.6, AB) was
found to be downregulated in TnC-astrocytes when compared to untreated PLL-astrocytes
by -2.1250 (FDR < 0.0442) and in CNTF treated PLL-astrocytes by -2.5403 (FDR <
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0.0190). IGFBP2 is a polypeptide known to be secreted by astrocytes and involved in
tightly regulating the actions of Insulin Growth Factors (IGFs) which in turn control the
survival and differentiation of oligodendrocytes (Liu et al., 1994; Chesik et al., 2008). The
downregulation of IGFBP2 may contribute to an astrocyte phenotype which is
unsupportive to myelination. Interestingly, the comparison of TnC-astrocytes to both PLL-
astrocytes untreated and PLL-astrocytes treated with CNTF after 24 hours also shows a
downregulation of IGF gene expression (Table 7.9 AB, fold change of -1.6064 and -
1.5895, respectively) further supporting a role for IGF and IGFBP in the support of
myelination.
The comparison of TnC-astrocytes at 4 hours and PLL-astrocytes untreated and treated
with CNTF at 24 hours exemplifies the spectrum of astrocyte support for myelination.
These comparisons look into genes which are changed at either end of the spectrum; TnC-
astrocyte, being the least supportive, and PLL-astrocyte treated with CNTF, being the most
supportive. Figure 7.5 represents genes which were changed between TnC-astrocytes and
PLL-astrocytes untreated (Fig 7.5 A), PLL-astrocytes treated with CNTF (Fig. 7.5 B) and
the genes which were changed in both PLL-astrocytes untreated and treated with CNTF
(Fig 7.5 AB).
Of the genes which were changed in both PLL-astrocyte conditions (untreated and treated
with CNTF after 24 hours) compared to TnC-astrocytes after 4 hours is connective tissue
growth factor (CTGF, Table 7.9 AB, fold change of 4.3210 when compared with untreated
PLL-astrocytes and 4.1239 for PLL-astrocytes treated with CNTF, both FDR < 0.05).
Thus, the expression of CTGF was high in TnC-astrocytes when compared to the other
conditions. CTGF is an astrocyte-derived extracellular matrix molecule associated with
astrocytosis (Kondo et al., 1999; Conrad et al., 2005).
Expression of the extracellular matrix glycoprotein Thrombospondin-4 (THBS4), was
upregulated in TnC-astrocytes by 3.2528 compared to PLL-astrocytes and 3.3336
compared to PLL-astrocytes treated with CNTF (Table 7.9 AB, both FDR < 0.05). The
function of THBS4 in the CNS is not known and its expression in the normal CNS is
relatively low (Lawler et al., 1993). However, astrocyte-derived THSB1, a member of the
same family as THSB4, has been reported to be involved in the regulation of
oligodendrocyte precursor migration (Scott-Drew and ffrench-Constant, 1997).  This
suggests that THSB4 may also have an effect on myelination.
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The expression of C-X-C motif chemokine 10 (CXCL10), also known as IFN-gamma-
inducible protein-10 (IP-10),  was found to be upregulated in TnC-astrocytes by 3.3695
compared to PLL-astrocytes and by 3.6146 when compared to PLL-astrocytes treated with
CNTF (Table 7.9 AB, both FDR < 0.05). CXCL10 binds to the receptor CXCR3, and is
implicated in the recruitment of leukocytes into the CNS. The inhibition of CXCL10 using
neutralising antibodies is associated with reduced EAE progression (Fife et al., 2001).
Moreover, it is also downregulated in PLL-astrocytes treated with CNTF over time (Table
7.2).
Interestingly, the expression of CTGF, THBS4 and CXCL10 is also increased in TnC-
molecules upregulated in TnC-astrocytes demonstrate the array of factors which may
contribute to an astrocyte phenotype which is non-supportive for myelination. These
observations reveal a startling resemblance between quiescent astrocytes (TnC-astrocytes)
and reactive astrocytes found within the glial scar, as is has been suggested that the
presence of reactive astrocytes may contribute to the remyelination failure (Fawcett and
Asher, 1999).
7.2.5 Validation of CXCL10 by qRT-PCR in TnC-Astrocytes
The microarray analysis identified numerous potential genes which are altered in the
various astrocyte phenotypes, some of which may either be supportive or non-supportive to
oligodendrocyte growth, differentiation and myelination. In order to verify these candidate
genes, qRT-PCR was performed on the original RNA samples used for the microarray.
cDNA was synthesised from RNA samples and qRT-PCR was performed using GAPDH
as an internal control.
The results for the qRT-PCR can be seen in Fig 7.6. The two polarized forms of astrocyte
phenotypes were compared (TnC-astrocytes and PLL-astrocytes + CNTF). The expression
of CXCL10 was significantly increased (p < 0.05). CTGF was also confirmed to be
expressed in higher levels on TnC-astrocytes, although this was not found to be statistically
significant. GDF15 and IGF2 were also investigated and found not to be significantly
different but their expression followed the same direction as the expression seen in the
microarray analysis. Expression of THBS4, however, was upregulated in the microarray in
TnC-astrocytes but this was found to be unchanged when expression levels were compared
to PLL-astrocyte treated with CNTF after qRT-PCR. The lack of significance within the
rRT-PCR data samples will be discussed later.
astrocytes at 4 hours when compared to PLL-astrocytes at 4 hours. (Table 7.6). The
10
(A)
22
(AB)
30
(B)
A
TnC-astrocytes 4 hours
vs.
PLL-astrocytes at 4 hours
(32)
B
TnC-astrocytes at 4 hours
vs.
PLL-astrocytes + CNTF at 4 hours
(52)
Figure 7.4 Venn diagram Representing Transcript Distribution between
TnC-astrocytes compared to PLL-astrocytes untreated and treated with
CNTF after 4 hours. Section A represents the number of genes with
changed expression in TnC-astrocytes after 4 hours compared to PLL-
astrocytes after 4 hours. Section B represents the number of genes with
changed expression in TnC-astrocytes when compared to PLL-astrocyte +
CNTF also at 4 hours. Section AB represents the number of genes with
changed expression in TnC-astrocytes when comparing PLL-astrocytes
untreated and treated with CNTF. Numbers represents the number of genes
having significantly different expression between conditions (FDR > 0.05,
n=3).
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PROBE_ID ILMN_GENE FDR FC
ILMN_1365825 PTN 0.0269 -2.0740
ILMN_1367475 ALDH1A1 0.0157 -1.8723
ILMN_1353848 TNR 0.0099 -1.8005
ILMN_1354799 KCNN2 0.0258 -1.6854
ILMN_1366046 LOC298120 0.0428 -1.6485
ILMN_1530180 ASRGL1 0.0445 -1.6260
ILMN_1363608 CYP1A1 0.0473 1.6327
ILMN_1357368 LOC497841 0.0428 1.7687
ILMN_1376842 TAGLN 0.0473 1.8136
ILMN_1361708 FBLN5 0.0269 1.9776
PROBE_ID ILMN_GENE FDR FC
ILMN_1353118 CALN1_PREDICTED 0.0358 -2.1498
ILMN_1372909 LSAMP 0.0358 -2.1325
ILMN_1367450 DBX2 0.0365 -2.0063
ILMN_1349449 HTRA1 0.0487 -1.9084
ILMN_1353247 ELOVL2_PREDICTED 0.0365 -1.5716
ILMN_1358241 ADAMTS9_PREDICTED 0.0432 -1.5340
ILMN_1366515 TJP2 0.0408 -1.4863
ILMN_1367519 IDI1 0.0358 -1.4833
ILMN_2040770 RGD1560826_PREDICTED 0.0358 -1.4809
ILMN_1361968 RGD1560523_PREDICTED 0.0408 -1.4613
ILMN_1351240 HSPA5 0.0487 1.4996
ILMN_1367697 GALP 0.0388 1.5376
ILMN_1374720 ITGB4 0.0365 1.5542
ILMN_1376615 EFEMP1 0.0358 1.5734
ILMN_1530551 RN.23597 0.0405 1.5824
ILMN_1363601 RGD1560020_PREDICTED 0.0253 1.6136
ILMN_1352410 PENK1 0.0365 1.6380
ILMN_1368826 RTP4_PREDICTED 0.0190 1.6520
ILMN_1351851 LOC499513 0.0432 1.6789
ILMN_1356945 DYNLRB2_PREDICTED 0.0190 1.6975
ILMN_1352469 IRF7 0.0408 1.6996
ILMN_1373796 RGD1561932_PREDICTED 0.0378 1.7258
ILMN_1349672 RGD1310052_PREDICTED 0.0358 1.7574
ILMN_1352762 IFITM3 0.0487 1.7846
ILMN_1376635 CYP1B1 0.0379 1.8704
ILMN_1365965 PCDH8 0.0418 1.9188
ILMN_1363449 OCIL 0.0190 1.9311
ILMN_1359696 TXNIP 0.0186 1.9699
ILMN_2040297 NDRG1 0.0190 1.9860
ILMN_1353876 SULT1A1 0.0225 2.1284
A . only
TNC4 - CON4
TNC4 - CNTF4
B.only
Table 7.5 Genes identified by Microarray Expression Profiling between
TnC-Astrocytes and PLL-Astrocytes untreated (A) and treated with CNTF
(B) after 4 hours (Figure 7.4, A and B). Results of the microarray experiment
for the 10 probes significantly different (FDR < 0.05) in comparing TnC-
astrocytes compared with PLL-astrocytes at 4 hours (A only). The table also
shows the 30 probes different in TnC-astrocytes compared to PLL-astrocytes
treated with CNTF at 4 hours (B only). These correspond to Section A and B in
Figure 7.4. Shown here are false discovery rates (FDR) and fold changes (FC).
*
*
*
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Table 7.6 Genes identified by Microarray Expression Profiling between TnC-
Astrocytes and both PLL-Astrocytes untreated and treated with CNTF at 4
hours (Figure 7.4, Section AB). The table shows the 22 probes significantly
different (FDR < 0.05) in TnC-astrocytes compared to both PLL-astrocytes treated
and untreated with CNTF at 4 hours (Fig 7.4, AB). These correspond to Section
AB in Figure 7.4. Shown here are false discovery rates (FDR) and fold changes
(FC).
*
*
*
*
PROBE_ID ILMN_GENE FDR FC FDR FC
ILMN_1352040 SLC22A3 0.0090 -2.2266 0.0171 -2.7262
ILMN_1360048 IGFBP2 0.0442 -2.1250 0.0190 -2.5403
ILMN_1352018RGS16 0.0445 -2.0783 0.0171 -2.3598
ILMN_1369130 PCDH17 PREDICTED 0.0457 -2.0653 0.0340 -2.1265
ILMN_1371157 LOC360435 0.0057 -2.0234 0.0492 -1.7746
ILMN_1367577 SLC4A4 0.0445 -1.6211 0.0405 -1.4621
ILMN_1363947HMGCS2 0.0457 1.6399 0.0358 1.5742
ILMN_1351562CASP12 0.0445 1.8401 0.0171 1.7511
ILMN_1356949COL6A1 PREDICTED 0.0457 1.9627 0.0309 1.7974
ILMN_1350896GSTM2 0.0269 1.9684 0.0271 1.8117
ILMN_1349973CHRDL1 0.0269 1.9759 0.0171 1.8120
ILMN_1365298MFAP5_PREDICTED 0.0258 2.0044 0.0190 1.9362
ILMN_1352014OGN_PREDICTED 0.0375 2.0476 0.0358 1.9857
ILMN_1354048NUPR1 0.0087 2.0630 0.0131 1.9893
ILMN_1364335CXCL10 0.0090 2.1209 0.0171 2.0031
ILMN_1361636MLF1_PREDICTED 0.0036 2.3218 0.0171 2.0492
ILMN_1364113CTGF 0.0122 2.3439 0.0171 2.1884
ILMN_1348956 FN1 0.0099 2.4481 0.0171 2.1933
ILMN_1350042 THBS4 0.0086 2.4851 0.0084 2.2384
ILMN_1375112OMD 0.0060 2.7953 0.0036 2.4431
ILMN_1361640 LTBP2 0.0036 2.8963 0.0032 2.7241
ILMN_1373199KRT19 0.0009 5.3350 0.0009 3.7854
TNC4 – CON4 TNC4 - CNTF4
AB.
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A
TnC-astrocytes at 4 hours
vs.
PLL-astrocytes at 24 hours
(120)
B
TnC-astrocytes at 4 hours
vs.
PLL-astrocytes + CNTF at 24 hours
(109)
Figure 7.5 Venn diagram Representing Transcript Distribution between
TnC-astrocytes at 4 hours compared to PLL-astrocytes untreated and
treated with CNTF at 24 hours. Section A represents the number of genes
with changed expression in TnC-astrocytes at 4 hours compared to PLL-
astrocytes at 24 hours. Section B represents the number of genes with changed
expression  in TnC-astrocytes compared to PLL-astrocyte treated with CNTF
also at 24 hours. Section AB represents the number of genes with changed
expression in TnC-astrocytes when compared to PLL-astrocytes untreated and
treated with CNTF. Numbers represents the number of genes significantly
different between conditions (FDR > 0.05, n=3).
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PROBE_ID ILMN_GENE FDR FC
ILMN_1366294 GSTP2 0.0132 -2.3734
ILMN_1365825 PTN 0.0242 -2.2467
ILMN_1352040 SLC22A3 0.0277 -2.1563
ILMN_1370454 AOX1 0.0342 -2.0466
ILMN_1353118 CALN1_PREDICTED 0.0375 -2.0177
ILMN_1350723 RAB3B 0.0375 -1.9685
ILMN_1376725 CSPG5 0.0405 -1.9173
ILMN_1369295 BHLHB5_PREDICTED 0.0411 -1.9008
ILMN_1365134 DBC1 0.0411 -1.8882
ILMN_1371675 RGS8 0.0417 -1.8676
ILMN_2039308 NPPB 0.0454 -1.8437
ILMN_1359461 LIX1_PREDICTED 0.0466 -1.7691
ILMN_1371639 GUCY1B3 0.0262 -1.7136
ILMN_1373210 ENTPD5 0.0282 -1.6270
ILMN_1650251 RGD1309427_PREDICTED 0.0284 -1.6115
ILMN_1363531 LOC498427 0.0325 -1.5676
ILMN_1362982 C1GALT1 0.0342 -1.5552
ILMN_1364149 RGD1560587_PREDICTED 0.0466 1.6869
ILMN_1357783 HBEGF 0.0454 1.6938
ILMN_1364257 KCNK3 0.0411 1.7335
ILMN_1366621 RGD1306235_PREDICTED 0.0411 1.7355
ILMN_1361672 TM4SF1_PREDICTED 0.0492 1.7504
ILMN_1361214 NCOR2_PREDICTED 0.0407 1.7671
ILMN_1366331 HABP4_PREDICTED 0.0446 1.7758
ILMN_1373796 RGD1561932_PREDICTED 0.0284 1.8660
ILMN_1650120 CLDN11 0.0284 1.8758
ILMN_1365343 BAIAP2 0.0284 1.8835
ILMN_1371299 RGD1308329_PREDICTED 0.0409 1.8882
ILMN_1372919 CYR61 0.0277 1.9157
ILMN_1351851 LOC499513 0.0466 1.9488
ILMN_1362278 SLC5A3 0.0345 1.9545
ILMN_1357413 LOC360443 0.0256 1.9818
ILMN_1372782 SERPINA3N 0.0422 2.0018
ILMN_1367643 OLFML3_PREDICTED 0.0405 2.0319
ILMN_1350480 S100A6 0.0311 2.0608
ILMN_1360121 FLNC_PREDICTED 0.0375 2.0720
ILMN_1359282 GPRC5A 0.0298 2.0729
ILMN_1354048 NUPR1 0.0208 2.2669
ILMN_1357368 LOC497841 0.0198 2.3348
ILMN_1348956 FN1 0.0089 2.4422
TNC4 - CON24
A. only
Table 7.7 Genes identified by Microarray Expression Profiling between
TnC-Astrocytes at 4 hours and PLL-Astrocytes at 24 hours (Figure 7.5,
Section A). The table shows the 40 probes significantly different (FDR < 0.05)
in TnC-astrocytes at 4 hours compared to PLL-astrocytes at 24 hours. These
correspond to Section A in Figure 7.5. Shown here are false discovery rates
(FDR) and fold changes (FC).
*
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PROBE_ID ILMN_GENE FDR FC
ILMN_1356454 FGFRL1 0.0236 -1.8987
ILMN_1530180 ASRGL1 0.0489 -1.8403
ILMN_1376479 GSTP1 0.0269 -1.8221
ILMN_1356032 MMD2 0.0349 -1.8155
ILMN_1371346 LOC685529 0.0359 -1.8072
ILMN_1371895 RGD1561849_PREDICTED 0.0317 -1.8014
ILMN_1353247 ELOVL2_PREDICTED 0.0389 -1.7356
ILMN_1366515 TJP2 0.0334 -1.6876
ILMN_1365159 RGD1564459_PREDICTED 0.0397 -1.5523
ILMN_1352067 CITED2 0.0401 1.7388
ILMN_1650537 GPC4 0.0434 1.7722
ILMN_1362820 SSG1 0.0418 1.7742
ILMN_1364414 VGF 0.0406 1.7916
ILMN_1356140 LOC501170 0.0312 1.8253
ILMN_1352762 IFITM3 0.0312 1.8268
ILMN_1351367 RNF7_PREDICTED 0.0358 1.8308
ILMN_1349809 METTL7A 0.0312 1.8394
ILMN_1355920 MX2 0.0359 1.8402
ILMN_1353833 ACOT1 0.0330 1.8872
ILMN_1353540 CYP4B1 0.0269 1.9237
ILMN_1360556 RGD1559432_PREDICTED 0.0286 1.9289
ILMN_1351562 CASP12 0.0408 1.9394
ILMN_1367697 GALP 0.0406 1.9410
ILMN_1371943 RUNX1 0.0361 1.9673
ILMN_1370948 CREG_PREDICTED 0.0240 1.9729
ILMN_1352477 LRRK1_PREDICTED 0.0334 1.9988
ILMN_1355237 CXCL1 0.0266 2.1258
ILMN_1351674 GDF15 0.0062 2.8475
B only
TNC4 - CNTF24
Table 7.8 Genes identified by Microarray Expression Profiling
between TnC-Astrocytes after 4 hours and PLL-Astrocytes
Treated with CNTF after 24 hours (Figure 7.5, Section B). The
table shows the 29 probes significantly different (FDR < 0.05) in
TnC-astrocytes at 4 hours compared to PLL-astrocytes treated with
CNTF at 24 hours. These correspond to Section B in Figure 7.5.
Shown here are false discovery rates (FDR) and fold changes (FC).
*
ILMN_1360425 ANK2 0.0282 -1.9326
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PROBE_ID ILMN_GENE FDR FC FDR FC
ILMN_1367450 DBX2 0.0034 -3.0915 0.0031 -2.9256
ILMN_1369130 PCDH17_PREDICTED 0.0136 -2.6927 0.0050 -2.6069
ILMN_1354799 KCNN2 0.0102 -2.5139 0.0153 -2.4251
ILMN_1366607 TRH 0.0242 -2.2849 0.0133 -2.2205
ILMN_1371157 LOC360435 0.0220 -2.2561 0.0137 -2.2122
ILMN_1372909 LSAMP 0.0256 -2.1968 0.0152 -2.1154
ILMN_1368199 SEZ6 0.0194 -2.1573 0.0047 -2.0644
ILMN_1350091 G0S2 0.0284 -2.1356 0.0149 -1.9979
ILMN_1352018 RGS16 0.0284 -2.1129 0.0074 -1.9873
ILMN_1370876 ANK2 0.0305 -2.0611 0.0269 -1.9786
ILMN_1358464 PDE9A 0.0411 -1.9831 0.0149 -1.9084
ILMN_1366138 LOC306428 0.0436 -1.9739 0.0312 -1.9084
ILMN_1374191 SCD1 0.0375 -1.9708 0.0282 -1.8997
ILMN_1351871 PTPRR 0.0375 -1.9487 0.0449 -1.8548
ILMN_1364348 CAR2 0.0281 -1.8993 0.0347 -1.8169
ILMN_1359367 RGD1310117_PREDICTED 0.0284 -1.8217 0.0389 -1.7892
ILMN_1367246 CAMK2B 0.0492 -1.7899 0.0418 -1.7712
ILMN_1530410 TM7SF2 0.0496 -1.7894 0.0171 -1.6912
ILMN_1360838 DMPK_PREDICTED 0.0284 -1.7850 0.0492 -1.6825
ILMN_1370437 GPNMB 0.0396 -1.7478 0.0240 -1.6403
ILMN_1358030 CLDN10_PREDICTED 0.0277 -1.6430 0.0269 -1.6183
ILMN_1359301 IGF2 0.0288 -1.6064 0.0312 -1.5895
ILMN_1376258 DDIT4L 0.0321 -1.5725 0.0359 -1.5610
ILMN_1353848 TNR 0.0469 -1.4937 0.0416 -1.5488
ILMN_1371618 PHLDA1 0.0417 1.7761 0.0416 1.7273
ILMN_1353747 FST 0.0360 1.7845 0.0416 1.7308
ILMN_1371491 METRNL 0.0344 1.7881 0.0359 1.7586
ILMN_1354516 KCNS3 0.0342 1.8002 0.0416 1.7811
ILMN_1369511 BCAR3_PREDICTED 0.0289 1.8535 0.0337 1.7885
ILMN_1373820 GLDN 0.0288 1.8642 0.0406 1.7944
ILMN_1364744 LOC294942 0.0466 1.8754 0.0336 1.8679
ILMN_1364984 AZIN1 0.0321 1.8822 0.0279 1.8762
ILMN_1361708 FBLN5 0.0430 1.9033 0.0320 1.8892
ILMN_1376851 RND3 0.0411 1.9286 0.0279 1.8902
ILMN_1359095 MAT2A 0.0259 1.9608 0.0317 1.8954
ILMN_1350369 FLRT3_PREDICTED 0.0388 1.9738 0.0312 1.9014
ILMN_1356313 KCNK1 0.0423 1.9930 0.0312 1.9031
ILMN_1360331 HIST1H2BN_PREDICTED 0.0286 2.0000 0.0312 1.9095
ILMN_1650285 HMOX1 0.0242 2.0112 0.0312 1.9110
ILMN_1361968 RGD1560523_PREDICTED 0.0242 2.0147 0.0442 1.9131
ILMN_1364192 RGD1560523_PREDICTED 0.0282 2.0234 0.0358 1.9708
ILMN_1370795 IFITM1_PREDICTED 0.0411 2.0275 0.0275 1.9842
ILMN_1367752 PRSS23 0.0242 2.0282 0.0239 1.9906
ILMN_1376823 LOX 0.0311 2.0325 0.0277 2.0156
TNC4 - CNTF24
AB.
TNC4 - CON24
Table 7.9 Please see overleaf for continuation of table and figure legend
*
*
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Table 7.9 Genes identified by Microarray Expression Profiling between TnC-
Astrocytes after 4 hours and PLL-Astrocytes Untreated and Treated with
CNTF after 24 hours (Figure 7.5, Section AB). The table shows the 80 probes
significantly different (FDR < 0.05) in TnC-astrocytes after 4 hours compared to
both PLL-astrocytes untreated and treated with CNTF after 24 hours. These
correspond to Section AB in Figure 7.5. Shown here are false discovery rates (FDR)
and fold changes (FC).
*
**
*
PROBE_ID ILMN_GENE FDR FC FDR FC
ILMN_1373357 SPHK1 0.0277 2.0470 0.0227 2.0172
ILMN_1364863 HIST1H2AO_PREDICTED 0.0327 2.0503 0.0269 2.0180
ILMN_2040297 NDRG1 0.0305 2.0663 0.0237 2.0367
ILMN_1376842 TAGLN 0.0289 2.0878 0.0317 2.0419
ILMN_1650153 THBS2 0.0284 2.1029 0.0236 2.0424
ILMN_1354409 NGEF_PREDICTED 0.0254 2.1058 0.0227 2.0539
ILMN_1370339 RARRES2 0.0325 2.1191 0.0312 2.0630
ILMN_1349829 MAFK 0.0284 2.1285 0.0310 2.0860
ILMN_1359626 LOC311772 0.0277 2.1642 0.0176 2.0942
ILMN_1363431 LTBP1 0.0298 2.2010 0.0279 2.1034
ILMN_1361905 RGD1309930 0.0271 2.2192 0.0279 2.1236
ILMN_1372925 LOC498208 0.0262 2.2327 0.0155 2.1410
ILMN_1365610 RGD1565319_PREDICTED 0.0183 2.2628 0.0149 2.1542
ILMN_1353876 SULT1A1 0.0281 2.2887 0.0236 2.2123
ILMN_1352014 OGN_PREDICTED 0.0256 2.3879 0.0149 2.2149
ILMN_1364747 JUB 0.0242 2.4005 0.0116 2.2253
ILMN_1349973 CHRDL1 0.0220 2.4798 0.0149 2.2272
ILMN_1361636 MLF1_PREDICTED 0.0119 2.5049 0.0227 2.2382
ILMN_1350896 GSTM2 0.0158 2.5249 0.0227 2.2398
ILMN_1373609 TNFRSF12A 0.0135 2.6316 0.0062 2.3543
ILMN_1376635 CYP1B1 0.0184 2.6348 0.0074 2.3992
ILMN_1376417 SERPINE1 0.0108 2.7266 0.0051 2.4563
ILMN_1356949 COL6A1_PREDICTED 0.0083 2.8252 0.0062 2.4676
ILMN_1365298 MFAP5_PREDICTED 0.0089 2.9099 0.0137 2.4993
ILMN_1371619 KBTBD9_PREDICTED 0.0089 2.9264 0.0051 2.9561
ILMN_1354712 COL1A2 0.0084 3.1408 0.0050 2.9580
ILMN_1375112 OMD 0.0069 3.1696 0.0058 3.0105
ILMN_1363449 OCIL 0.0080 3.2439 0.0050 3.2762
ILMN_1350042 THBS4 0.0069 3.2528 0.0047 3.3336
ILMN_1364335 CXCL10 0.0058 3.3695 0.0041 3.6146
ILMN_1373199 KRT19 0.0058 3.4419 0.0036 3.6239
ILMN_1361640 LTBP2 0.0058 3.5159 0.0031 3.7369
ILMN_1367740 MT1A 0.0020 3.8202 0.0031 3.7382
ILMN_2040557 SERPINE1 0.0020 3.9793 0.0033 3.7769
ILMN_1350180 EMP1 0.0020 4.2599 0.0031 3.8603
ILMN_1364113 CTGF 0.0018 4.3210 0.0027 4.1239
AB continued.
TNC-CON24 TNC-CNTF24
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Figure 7.6 Validation of CXCL10 in TnC-Astrocytes. Relative
quantification (RQ) for CXCL10, CTGF and THBS4 mRNA.
Neurosphere derived astrocytes were plated on PLL (PLL-
astrocytes) until confluency and treated with CNTF (2 ng/ml) for
24 hours were compared with astrocytes plated on TnC (TnC-
astrocytes) after 4 hours. CXCL10 mRNA was significantly
increased in TnC-astrocytes when compared to PLL-astrocytes
treated with CNTF (p < 0.05, n=3).
PLL-As + CNTF at 24h
TnC-As at 4 h
0
5
10
15
20
25
30
35
CXCL10 CTGF THBS4 GDF15 IGF2
RQ
*
166
167
7.2.6 CXCL10 Antibodies Increase Myelination in TnC-Astrocytes
Cultures
To determine if CXCL10 can actually reduce myelination on TnC-astrocytes, the
neutralising antibody to CXCL10 was added to myelinating cultures plated on PLL-
astrocytes (Fig 7.7 B, D, F, G) and TnC-astrocytes (Fig 7.7 A, C, E, G) at concentrations
from 0.2-20 µg/ml, added on day 12. As shown previously, cultures on TnC-astrocytes
have reduced levels of myelination compared to cultures on PLL-astrocytes (Fig 6.1, p <
0.05). The addition of neutralising antibodies, at all concentrations, resulted in an increase
in the percentage of myelinated fibres (Fig 7.7 C, E, G and Fig 7.8 A), although this was
not significant (p > 0.05). Conversely, the addition of CXCL10 neutralising antibodies
resulted in a slight reduction in myelinated fibres (Fig 7.7 D, F, H and Fig 7.8 A), although
this was not statistically significant. The neurite density for all conditions was similar (Fig
7.8 B). These observations suggest that the inhibition of CXCL10, which is highly
expressed in TnC astrocytes, results in an increase in myelination.
Since antibodies to cytokines can be notoriously difficult to modulate function in culture, a
more reliable method to examine the effects CXCL10 would be to use recombinant
protein. CXCL10 was added to myelinating cultures plated in PLL-astrocytes from day 12
onwards and also on myelinating cultures at day 28 where it was added for a further 5 days
(Fig 7.9).  The addition of CXCL10 on day 12 resulted in a decrease in myelination which
was found to be statistically different to untreated cultures on PLL-astrocytes (Fig 7.9 A,
B, D, p < 0.05). The addition of CXCL10 on day 28 lead to a slight reduction in
myelination, but this was not significant (Fig 7.9 C, D). Therefore, this data supports the
trend seen for the addition of neutralising antibodies on myelination in cultures on TnC-
astrocytes, and shows a significant effect of CXCL10 protein to decrease myelination on
PLL-astrocytes.
To assess if CXCL10 can reduce myelination in cultures plated on TnC–astrocytes,
myelinating cultures plated on TnC-astrocytes were treated with CXCL10 from day 12
onwards (Fig 7.10). The addition of CXCL10 did not result in a further decrease in
myelination (Fig 7.10 A-C). No change in neurite density was observed (Fig 7.10 D).
6.2.7 CNTF may Regulate the Expression of CXCL10
As shown previously, the addition of CNTF to myelinating cultures plated on TnC-
astrocytes lead to an increase in myelination when compared to untreated myelinating
control cultures (Fig 6.6). The next logical step was to investigate whether CNTF is able to
modulate the expression of CXCL10. It was hypothesised that the addition of CNTF to
cultures on TnC-astrocytes would downregulate the expression of CXLC10 and thus lead
to an increase in myelination. To test this hypothesis, myelinating cultures plated on PLL-
astrocytes and TnC-astrocytes, where some were left untreated and others treated with
CNTF (2 ng/ml). After 24 hours of treatment, cultures were lysed, RNA was extracted,
cDNA was synthesised and qRT-PCR was performed. Myelinating cultures on TnC-
astrocytes show a reduction in CXCL10 expression after CNTF treatment, although this
was not statistically significant (Fig 6.11, p > 0.05). Interestingly, untreated myelinating
cultures plated on PLL-astrocytes and TnC-astrocytes had similar levels of CXCL10
expression, which was surprising, as it was presumed that myelinating cultures plated on
TnC-astrocytes were expected to have a higher expression of CXCL10. There are two
possible explanations for this. Firstly, CXCL10 was not upregulated in the TnC-astrocytes
in this particular experiment or alternatively, other cells in myelinating cultures on PLL-
astrocytes might also express CXCL10, for example, microglia, which mask the expression
of CXCL10 in astrocytes.
7.3 Discussion
The identification of genes which contribute to a particular astrocyte phenotype is central
to understanding astrocyte behavior in health and in disease. As astrocytes make up the
largest population of cells in the CNS, they are heavily involved in much of its function.
For example, astrocytes are involved in the regulation of minute changes in the pH of the
tissue environment as well as taking on extreme morphological and metabolic changes in
disease states. In this study, microarray analysis identified an increase in mRNA
expression of CXCL10 in TnC-astrocytes. The role of CXCL10 in myelination was
validated using myelinating cultures. The addition of neutralising antibodies to CXCL10 to
myelinating cultures plated on TnC-astrocytes resulted in a trend in increase in myelination
whereas the addition of CXCL10 to myelinating cultures on PLL-astrocytes resulted in a
decrease in myelination. These observations demonstrate the efficiency of microarray data
collection, their validation in a working culture system as well as the importance of gene
selection for future therapeutics in MS.
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Figure 7.7 CXCL10 Neutralising Antibodies increase Myelination in
TnC-Astrocytes. Myelinating cultures were plated onto TnC-astrocytes
(A, C, E, G) or PLL-astrocytes (B, D, F, H). Cultures were either left
untreated (A-B) or treated with neutralising antibodies to CXCL10 at 0.2
µg/ml (C-D), 2 µg/ml (E-F) and 20 µg/ml (G-H). Myelination and neurite
density was calculated by immunofluorescence using SMI31 antibody (red)
for neurites and anti-PLP (green) for mature myelin using Image J and
Adobe Photoshop. Treatment with neutralising antibodies to CXCL10
resulted in an increase in myelination in TnC-astrocytes compared to
control cultures. Treatment with antibodies resulted in a slight decrease in
myelination in PLL-astrocytes. Scale bar 100 µm. Experiments were
performed in triplicates.
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Figure 7.8 CXCL10 Neutralising Antibodies increase Myelination in
TnC-Astrocytes with no effect on Neurite Density. Myelinating
cultures were plated onto PLL-astrocytes or TnC-astrocytes. Bar chart
represents quantification from Figure 6.7. Cultures were either left
untreated or treated with neutralising antibodies to CXCL10 at 0.2-20
µg/ml Myelination and neurite density was calculated by
immunofluorescence using SMI31 antibody (red) for neurites and anti-
PLP (green) for mature myelin using Image J and Abobe Photoshop.
Treatment with neutralising antibodies to CXCL10 resulted in an
increase in myelination in cultures on TnC-astrocytes compared to
Treatment with antibodies resulted in a slight decrease in myelination in
PLL-astrocytes, which was not significant (A). The neurite density was
unaffected by treatment across all conditions (B). Experiments were
performed in triplicates. Error bars indicate standard error of the mean.
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cultures on PLL-astrocytes, although this was not significant (A).
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Figure 7.9 The Addition of CXCL10 to Myelinating Cultures on PLL-
Astrocytes Resulted in a decrease in Myelination. Myelinating cultures
were plated onto PLL-astrocytes. Cultures were either left untreated (A) or
treated with CXCL10 on day 12 (B) or 28 (C). Myelination and neurite
density was calculated by immunofluorescence using SMI31 antibody (red)
for neurites and anti-PLP (green) for mature myelin using Image J and
Adobe Photoshop. Treatment with CXCL10 on day 12 resulted in a
significant decrease in myelination (D, p < 0.05). The addition of CXCL10
on day 28 had no affect on myelination (D). The neurite density was
unaffected by treatment across all conditions. Scale bar 100 µm.
Experiments were carried out in triplicates. Error bars indicate standard error
of the mean.
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Figure 7.10 The Addition of CXCL10 to Myelinating Cultures on
TnC-Astrocytes does not affect Myelination. Myelinating cultures
were plated onto TnC-astrocytes. Cultures were either left untreated (A)
or treated with CXCL10 on day 12 onwards (B). Myelination and
neurite density was calculated by immunofluorescence using SMI31
antibody (red) for neurites and anti-PLP (green) for mature myelin
using Image J and Adobe Photoshop. Myelination was quantified and it
can be seen that treatment with CXCL10 did not affect myelination
levels compared to untreated cultures on TnC-astrocytes (C). The
neurite density was calculated and found to be unaffected by treatment
(D). Experiments were performed in triplicates. Scale bar 100 µm. Error
bars indicate the standard error of the mean.
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Figure 7.11 CXCL10 is slightly reduced in Myelinating
Cultures plated on TnC-Astrocytes Treated with CNTF as
Measured by qRT-PCR. Myelinating cultures were plated on
PLL-astrocytes and TnC-astrocytes; on day 12 some cultures were
left untreated and others treated with CNTF (2 ng/ml). After 24
hours, the cultures were lysed, RNA was extracted and cDNA
synthesised. qRT-PCR was performed using primers for CXCL10
and GAPDH (house keeping gene). Bar chart represents the
relative quantification (RQ) results for CXCL10 mRNA after
CNTF treatment in myelinating cultures plated on PLL-astrocytes
and TnC-astrocytes. Myelinating cultures on TnC-astrocytes had a
slight reduction in CXCL10 expression after CNTF treatment,
although not significant. CNTF treatment of myelinating cultures
plated on PLL astrocytes had no effect on CXCL10 expression.
Experiments were performed in triplicate. Error bars indicate the
standard error of the mean.
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The expression of genes which change when comparison is made between TnC-astrocytes
at 4 hours and PLL-astrocyte untreated or treated with CNTF at 24 hours correlate with the
phenotype of the astrocyte (TnC-astrocyte being least supportive and PLL-astrocyte treated
with CNTF being the most supportive). In hindsight, a more appropriate comparison
should have been with the gene expression changes in TnC-astrocytes after 24 hours. The
original decision not to include this time frame was made because astrocytes plated on TnC
do not receive any particular treatment, and timing starts with media change at 4 hours as
carried out for untreated PLL-astrocytes. Thus, one time point was chosen. However,
analysis of mRNA expression in TnC-astrocytes after 24 hours is still expected to obtain
changes in the expression of other genes of interest. Nonetheless, the comparison between
TnC-astrocytes at 4 hours and those on PLL-astrocytes at 24 hours in culture did yield
many key genes which can be further investigated in myelinating cultures.
The Illlumina BeadArray Reader and Beadstudio programs used in the microarray have
rigorous methods of analysis using the FDR as well as fold changes. The experimental
astrocyte samples were derived from different groups of pups, each from a different
outbred female, and therefore have a wide range of genetic variability which is translated
into noise in the resulting data sets. The analytical methods performed using Illumina
Beadstudio filtered out the noise in the data and thus presenting a sound and statistically
significant product. The same RNA samples used for the microarray were used for the
qRT-PCR analysis. No noise filtering took place when quantifying the qRT-PCT data
which may explain the lack of significance for genes which were identified as significant
in the microarray.
Many reports have demonstrated the pro-regenerative properties of cytokine-activated
astrocytes although the exact factor(s) secreted and targets are still unknown (Ridet et al.,
1997; Liberto et al., 2004; Williams et al, 2007). Using the microarray gene expression
profiling of the various treated astrocyte monolayers, only the change in expression of 2
genes were observed when comparison was made between untreated PLL-astrocytes and
those treated with CNTF. This may be because analysis was carried out on pure astrocyte
monolayers lacking myelinating cultures plated on their surface. Without the mixed cell
population from the myelinating cultures we may be eliminating any cross talk between the
various cell types (oligodendrocyte, microglia, stem cells etc.). For example, CNTF
treatment may promote the secretion of an astrocyte factor which in turn affects
oligodendrocyte lineage cells to secrete a factor that either directly or indirectly (via the
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astrocyte) influences myelination. It is also possible that CNTF could not activate
astrocytes due to the lack of one of the components of its receptor. CNTF effects are
mediated by a tripartite receptor complex consisting of the CNTF receptor α, LIFRβ
receptor and gp130 (Lee et al., 1997; Sleeman et al., 2000; Fig 5.1). Signal transduction by
CNTF requires the binding of CNTF to CNTFR α, permitting the recruitment of gp130 and
LIFRβ which leads to heterodimerization of the receptor subunits and tyrosine
phosphorylation. As it has been shown that neurons shed the CNTFR α subunit (Sleeman
et al., 2000), it is possible to speculate that the lack genes obtained from the microarray
study may be due to the absence of one of its receptor component and thus their inability to
form the tripartite complex required for signalling.
The downregulation of GDF15 in PLL-astrocytes treated with CNTF for 24 hours
compared to control PLL-astrocytes as well as its upregulation in TnC-astrocytes is
interesting as GDF15 has previously been associated with neuroprotection and injury
states. For instance, Strelau et al. (2000) show the neuroprotective actions of GDF15 in the
6-hydroxydopamine (6-OHDA) model of Parkinson’s disease. 6-OHDA was injected into
the rat brain and resulted in loss of dopaminergic nigrostriatal neurons. Intravenous
administration of GDF15 into the medial forebrain bundle prior to the 6-OHDA injection
resulted in a significant increase of neuronal survival. The authors argue that the
neuroprotective effect observed is not due to astrocytes as no change in their proliferation
or maturation after GDF15 treatment was observed. However, it is not necessary for
astroglial numbers to change in order for them to respond to a particular treatment as
astrocytes more distal to a lesion, although termed activated, do not show a proliferative
profile (Sonfroniew and Vinters, 2010). In our study, TnC-astrocytes which do not support
myelination show an increase in GDF15 whilst PLL-astrocytes treated with CNTF which
do support myelination show a decrease in GFD15. As CNTF leads to an increase in
myelination when added to the myelinating cultures, it was surprising that the expression
of GDF15 expression in these astrocyte cultures is in contrast to that reported in the
literature. It is a possibility that GDF15 has multiple roles, including novel roles not yet
identified, and that GDF15 may act differently in vivo and in vitro. GDF15’s role remains
unresolved and will need further investigation.
The changes in TnC-astrocytes compared to untreated and CNTF-treated PLL-astrocytes at
4 and 24 hours will now be discussed. This comparison represents the ‘extremes’ in
astrocyte support for myelination. TnC-astrocytes are the least supportive, whereas PLL-
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astrocytes at a later time-point are most supportive, especially with CNTF treatment. A
number of relevant genes were identified with a change in expression after treatment,
including PTN, Transgelin, TNR, IGFBP2, IGF1, CXCL10, CTGF and THSB4. The
relevance of each will be discussed in turn.
PTN was downregulated in TnC-astrocytes. PTN is associated with the syndycan family,
which is a subtype of heparan sulfate proteoglycans (HSPGs) which can bind to PTN.
Syndycan expression is associated with reactive astrocytes, therefore suggesting that PTN
may be associated with the glial scar and may have possible roles post injury (Iseki et al.,
2002). In a model of spinal cord injury, an increase in the expression of PTN correlated
with reactive astrocytes as well as oligodendrocytes and neurons, suggesting a wider role
after injury (Wang et al., 2004). The authors attribute the expression of PTN as supportive,
although they show no evidence of this in their work. The presence of PTN could equally
hinder regeneration attempts. The downregulation of PTN in TnC-astrocytes is not yet
fully understood as the role of PTN in injury is not fully known. If PTN is indeed
supportive to regeneration, then its downregulation in TnC-astrocytes could contribute to
the non-supportive phenotype of astrocytes and hence the reduction in myelination
observed when myelinating cultures are plated on TnC-astrocytes.
Astrocyte size and shape have widely been associated with their reactivity status. Olk et
al., (2010) show that the knock down of the connexin Cx43 (using RNAi) resulted in a
decrease in astrocyte size, which was associated with an increase in Transgelin. Similarly,
TnC-astrocytes used in this study are smaller (Fig 6.3) and upregulated Transgelin.
Although Transgelin may not have an active and direct role to play in lack of support for
myelination, its increased expression in TnC-astrocytes contributes to the overall astrocyte
phenotype and thereby contributing indirectly to an environment which does not support
myelination.
TNR is expressed in oligodendrocytes (Pesheva et al., 1997; Zhao et al., 2009) and its
presence is either due to contaminating oligodendrocytes progenitors or its presence in
astrocytes. If the latter is true this will be a novel finding. It is likely to be the former and
indeed Czopka et al. (2009) have shown that pre-oligodendrocytes from TNR null mice
grow normally but have reduced MBP expression on a control substrate (P-Orn) and can be
rescued if plated on the TNR substrate. Therefore the expression of TNR on
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oligodendrocytes is required for the differentiation of oligodendrocyte precursors. Since
TnC-astrocytes in our study have a reduced TNR expression compared to PLL-astrocytes,
it suggests that although the progenitors are present, they do no differentiate. However, it
must be noted that this observation implies that progenitors are also present on PLL-
astrocytes which are not inhibited from differentiating. This observation also suggests that
progenitor cells on top of the astrocyte monolayer contribute to the myelinating
oligodendrocyte population in the myelinating cultures.
Liu et al. (1994) have shown that the expression of IGFBP2 and IGF1 in astrocytes in EAE
animals correlated with the expression of IGF1 receptor in oligodendrocytes. These data
suggest that the presence of IGFBP2 on astrocytes contributes to the remyelination
process. Furthermore, Yao et al. (1995) used a cryogenic model of spinal cord injury to
induce neuronal loss and demyelination and found that IGFBP2-expressing astrocytes were
in proximity to regenerating neurons and remyelination. TnC-astrocytes downregulate the
expression of this molecule further supporting the fact that these molecules contribute to a
phenotype of astrocytes which is not supportive for myelination.
The increased expression of CTGF in TnC-astrocytes unquestionably requires further
investigation. There is a strong association of the overexpression of CTGF with astrocytes
which form the glial scar (Kondo et al., 1999; Hertel et al., 2000; Conrad et al., 2005). In
addition, Stritt et al. (2009) demonstrated that the adenovirus-mediated expression of
CTGF in mice resulted in reduced number of mature oligodendrocytes in vivo. They
further investigate the mechanism of this reduction in an in vitro set up. Oligodendrocytes
normally increase in number in the presence of IGF whereas the addition of IGF with
CTGF inhibited this increase in oligodendrocytes. These observations, along with the
downregulation of IGF in TnC-astrocytes (Table 6.9 AB) strongly suggest an imperative
role for CTGF in astrocyte/oligodendrocyte interaction as well as the regulation of
myelination.
Reactive astrocytes have also been shown to secrete CXCL10 (Ransohoff et al., 1993).
This is a small molecule belonging to the CXC chemokine family and shares its CXCR3
receptor with CXCL9 and CXCL11. Interestingly, CXCL10 has been shown to be
expressed by reactive astrocytes surrounding active MS lesions (Omari et al., 2005; Carter
et al., 2007). Since oligodendrocytes express the CXCR3 receptor they may be the target
for CXCLl0. Furthermore, CXCL10 mRNA was shown to be significantly increased
during peak disease and reduced during the recovery phases in animal models of MS
including MOG-induced EAE (Godiska et al., 1995; Glabinski, et al., 1997; Fife et al.,
2001). It has been shown, that CXCL10-/- and CXCR3-/- mice provoked more severe
clinical and histological symptoms and earlier onset in MS disease models compared to
wild type controls (Klein et al., 2004; Liu et al., 2006; Muller et al., 2007). However, in a
viral model of MS, neutralising antibodies to CXCL10 lead to a reduction in disease
progression and suppressed ongoing demyelination (Liu et al., 2001). This conflicting
evidence for the effects of CXCL10 suggests possible multiple functions on CNS
pathologies. In the data presented here, the addition of CXCL10 to cultures on PLL-
astrocytes resulted in a decrease in myelination and the addition of neutralising antibodies
to cultures on TnC-astrocytes shows a trend where there is an increase in myelination. The
validation of this gene in the myelinating culture system demonstrates an obvious
inhibitory role played by astrocyte-derived CXCL10.
These findings are the first show that polarization of astrocyte phenotypes can affect
myelination; quiescent (TnC-astrocytes) do not support myelination whereas activated
(PLL-astrocytes treated with CNTF) do to a high degree. Untreated PLL-astrocytes also
support myelination, suggesting that when astrocytes are plated in vitro they become
activated (as discussed in Section 1.4.6). The quiescent phenotype, which was defined as a
phenotype resembling that of a resting astrocyte in the normal brain (Holley et al., 2005),
does not appear to be a passive phenotype as it prevents myelination by the secretion of
CXCL10, a factor reported to be expressed by reactive astrocytes (Ransohoff et al., 1993;
Tani et al., 1996). These data suggest that astrocytes are, to some extent, activated in vitro
and can promote myelination. This degree of activation can be further induced by
cytokines, such as CNTF. Furthermore, CNTF can also reverse the quiescent phenotype to
a more activated one, possibly by downregulating expression of CXCL10. While CXCL10
evidently plays a role in myelination it should be noted that other possible candidates were
identified in the microarray analysis and it is possible they all contribute to the effects
observed. The identification of other molecules that are associated with the varied
astrocyte phenotypes will shed light on the complex and multifaceted environment of
astrocytosis and may lead to therapeutic avenues for the treatment of MS.
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Chapter 8
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General Discussion
8.1 Cross-talk Between Astrocytes and Neurons
In this thesis I have demonstrated the important role for astrocytes in regulating aspects of
myelination. From the literature and what has been described in this thesis, it is apparent
that astrocytes can exist in different ‘states’. These ‘states’ determine their functional
outcome and for this reason this topic needs further investigation. In this thesis, two
astrocyte phenotypes were described, namely, the ‘activated’ astrocyte and the ‘quiescent’
astrocyte. Activated astrocytes used as a monolayer for myelinating cultures supported
myelination whereas quiescent astrocytes did not. CXCL10 was identified as an quiescent
astrocyte-derived molecule which inhibited myelination and its neutralisation resulted in an
increase in myelination. CNTF was used to activate astrocytes and its addition to
myelinating cultures resulted in an increase in myelination. However, comparing
microarray data from untreated and CNTF treated astrocytes did not identify any genes
which could be attributable to the increase in myelination. A likely explanation for this
observation is the required cross-talk between astrocytes and other cell types. Indeed,
cross-talk between astrocytes and neurons has previously been described by Wang et al.
(2009) regarding neuropathic pain. The authors show data demonstrating that astrocytic
activation enhances neuronal activation, and therefore strengthening the idea of cross-talk
between cells in order to achieve their function. As previously discussed in Chapter 5,
CNTF requires the α subunit of its receptor complex in order to activate signaling
pathways, which may be shed from neurites (Kahn et al., 1997). Furthermore, astrocytes
may require signals from other cells types in order to secrete promyelinating factors. In
order to investigate this hypothesis, a microarray study needs to be conducted on whole
myelinating cultures, rather than astrocyte monolayers alone. A comparison between
myelinating cultures left untreated and treated with CNTF on activated and quiescent
astrocytes will undoubtedly identify more genes associated with the phenotypic state of the
astrocytes. However, as the myelinating cultures comprise many different cell types, and
genes which will be identified may not necessary be astrocyte-specific ones. To resolve
this, genes identified should be tested in the myelinating cultures and their effects on
astrocytes in particular can be verified via Western blotting, immunohistochemistry or
qRT-PCR.
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8.2 Mechanisms of Action
In terms of modes of action, the role of CXCL10 was not fully investigated. It is
hypothesised that CXCL10 secretion from astrocytes acts directly on the oligodendrocyte
precursor cells (OPCs). There are several experiments that should next be carried out in
order to verify this hypothesis. For instance, CXCL10 can be directly added to purified
OPCs and cell death, proliferation and ability to differentiate into mature myelin forming
oligodendrocytes can be investigated. Furthermore, the descending pathways which lead to
these effects would also need to be investigated. For instance, could CXCL10 be affecting
oligodendrocyte differentiation via the upregulation of Hes5, which ultimately leads to
blockage of oligodendrocyte maturation (John et al., 2002)? Alternatively, CXCL10 could
be inducing apoptotic and/or necrotic cell death via the activation of Caspase 3 (Casaccia-
Bonnefil, 2000).
Upstream signaling pathways of CXCL10 also need to be investigated to understand the
triggers which lead to its expression. NF-κB is a protein complex and its descending
canonical pathway can act as a ‘master switch’ for many inflammatory mechanisms
(Schmid et al., 2006). Indeed, the activation of NF-κB has been demonstrated using
inflammatory cytokines such as IL-1β, IFN-γ and TNF-γ and interestingly, resulted in the
upregulation of CXCL10 message and protein in endothelial cells (Yeruva et al., 2008;
Lombardi et al., 2001). Whether this is the same case in astrocytes, remains to be
elucidated. Interestingly, the deactivation of astroglial-NF-κB in transgenic mice resulted
in improved functional recovery, increased white matter preservation, reduced expression
of chondroitin sulfate proteoglycans and reduced expression of inflammatory cytokines
including CXCL10, 8 weeks after spinal cord injury (Brambilla et al., 2005). Although the
exact mechanisms are not clear, it is apparent that CXCL10 regulates the inflammatory
response of astrocytes, which in turn affects oligodendrocyte maturation and/or survival
(Fig 8.1). It would be extremely interesting to investigate whether NF-κB is responsible for
the effects observed in quiescent astrocytes.
8.3 Astrocyte Phenotype and Control of Myelination
The definitions of astrocytes as reactive, activated and quiescent are still quite nebulous.
Quiescent astrocytes have been described as ‘passive’ and this may be the incorrect
definition of these cells. In fact they actively regulate the process of myelination. It is
hypothesised that quiescent astrocytes express CXCL10 in order to ‘control’ myelination.
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Indeed, myelination occurs in early life and usually ends in adolescence (Buffo et al.,
2010) and CXCL10 is not expressed in normal adult tissue (John et al., 2002). Therefore, it
could be hypothesised that astrocytes secrete CXCL10 in late adolescence in order to stop
myelination and once it is stopped, the expression of CXCL10 would no longer be
required. It would be interesting to find out whether tissue from the developing rodent
corresponds to this hypothesis. Undoubtedly, other astrocyte-specific molecules may also
regulate myelination during development. To what extent the expression of these
molecules can be ‘re-activated’ or ‘de-activated’ to induce myelination during disease is
yet to be investigated.
8.4 Astrocyte Heterogeneity
A complexity in understanding astrocyte behavior in disease is their heterogeneity which
depends on their morphology and location (Zhang and Barres, 2010). Astrocytes in
different locations of the brain may respond differently to particular injuries and
consequently treatments. Yeh et al. (2009) used a microarray gene analysis study to
investigate and compare the heterogeneity of astrocytes from the neocortex, cerebellum,
brainstem and optic nerve. They found that the astrocytes fell into individual groups with
both similarities and distinctions in gene profiles suggesting that astrocytes many have
overlapping and distinct functions depending on their location. Interestingly, Hochstim et
al. (2008) have confirmed the presence of three positionally distinct astrocytes subtypes.
By using loss and gain of function experiments, the authors were able to demonstrate the
three subtypes based on their expression of Reelin and Slit1, which are guidance
molecules. The data from these studies propose that not only do astrocytes from
anatomically distinct regions vary in heterogeneity, but also that there are subtypes within
these regions. It would be interesting to develop these studies further and investigate how
these astrocyte subtypes react to inflammatory agents and/or physical injury as well as how
their support and/or communication with other cells, like neurons and oligodendrocytes, is
altered. It seems that astrocyte heterogeneity is much more complex than originally
anticipated. This could therefore explain the variety in astrocytic response depending on
treatment agent, type of injury and location in the CNS. To what extent these
heterogeneous astrocyte subtypes correspond to the continuum of astrocytes reactivity is
undeniably a very important question and in need of further investigation.
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8.5 Astrocytes Phenotypes In Vivo
The identification of astrocyte phenotypes in vivo is fundamental in understanding
astrocyte biology; where the identification of particular molecules is associated with
specific astrocyte phenotype. It is likely that future therapies will identify specific astrocyte
phenotypes and target secretory or expressional molecules to reverse or change from one
phenotype to another in vivo. A method to directly target a specific gene, or a number of
genes, is the use of conditional knockout animals. However, knockout animals may
consequently be affected by the lack of particular proteins developmentally and may not
answer the specific questions about disease states in the adult. Therefore, RNA interference
(RNAi) may be used to target specific genes in the adult without developmental
interference. RNAi is also known as post transcriptional gene silencing in plants and
quelling in fungi (Zeringue and Constantine-Paton, 2004), is where double stranded RNA
is delivered to the cell leading the degradation of transcripts with complementary
sequences. This approach will aid in understanding the cellular and molecular basis of
particular proteins and how these in turn affect the animal in vivo. Once more is understood
about particular sets of genes attributable to a particular phenotype, these can then be
targeted and switched on or off in order to reverse the phenotype. For instance, CXCL10
can be switched off in astrocytes within the glial scar whilst CNTF can be switched on in
astrocytes distal to the scar. Although these changes may not ‘cure’ MS, they may create a
more favorable environment in which re-myelination can take place and therefore
providing some functional recovery. The treatment for MS is largely symptomatic and
usually to control the inflammation. These drugs can inhibit, to some extent, the
inflammatory component of MS but they do not suppress the progressive clinical
disability. Furthermore, immunosuppressive agents can usually also disturb
immunoregulatory mechanisms and cause adverse effects (Condarri et al., 2010). Mangas
et al. (2010) argue that MS should not be viewed only as an inflammatory disease and
other aspects of MS should be incorporated into drug manufacturing including oxidative
stress, demyelination and neuronal death. It has also been argued that therapies should
focus on strategies which promote remyelination via promoting the division, recruitment,
and differentiation of OPCs (Casaccia-Bonnefil, 2000). Thus, MS will greatly benefit if
researchers and drug manufacturers were to be more innovative and resourceful using a
combinatorial approach to treat MS.
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8.6 Cytokines and Models of Multiple Sclerosis
It is extremely difficult to investigate the role of cytokines in MS due to its multifaceted
nature. The use of preclinical models of MS requires much more investigation before their
translation into human work. Firstly, the induction of MS in these models is artificial and
although similar characteristics are observed, they are not a true representation of the
disease. As a result, the treatments used for these models do not translate well into human
research. Secondly, data using cytokines in MS models are often oversimplified (Codarri et
al., 2010). The models do not translate well in human trials because cytokine-related
effects are likely to be indirect and involving many cells. Therefore, until the etiology of
MS is resolved, it will remain difficult to interpret the data obtained from animal models of
MS and their potential use of cytokines in treatment.
Takuya et al. (2000) discuss several methods whereby cytokines could be incorporated into
future experimentation and disease conditions. Firstly, the discussed the potential of
neutralising IL-6 using a cocktail of neutralising antibodies or using a constructed fusion
protein of mutated IL-6 and its soluble subunit (sIL-6R) which are covalently bound and
act as effective antagonists without inducing dimerization (Renne et al., 1998; Beck et al.,
1994; Wendling et al., 1996). Secondly, some cytokines have both anti-inflammatory and
pro-inflammatory effects and addressing the balance in these may provide therapeutic
advantages when combined with other treatments. Finally, the ‘receptor conversion model’
is whereby a cytokine is coupled with its soluble receptor linked by a flexible peptide chain
(Fischer et al., 1996) could be used. These joint molecules have been shown to illicit
actions on cells non responsive to the particular cytokine thereby increasing the receptor
repertoire. Furthermore, they have also been found to activate slightly differing descending
pathways. These attributes could be balanced in order to provide therapeutic strategies for
many cytokine-related diseases. Thus, when the activity of cytokines is finely tuned, it is
likely that they will greatly contribute to the therapeutic outcome of many inflammatory
diseases.
8.7 Future Experiments
The results from this thesis shed some light on the existence of astrocyte-specific
molecules which influence myelination. However, there are a vast number of questions left
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unanswered. Firstly, the effects of CNTF on astrocytes are not fully understood in the
myelinating culture context. Although CNTF’s action on neurite diameter, microglial
numbers and oligodendrocyte proliferation and maturation have been ruled out, the direct
action on astrocytes has not been fully established. For instance, the levels of GFAP, nestin
and other astrocyte molecules which have been attributed to astrocyte reactivity could have
been measured within the myelinating cultures with and without CNTF treatment.
Secondly, a microarray experiment comparing CNTF treated cultures to untreated could
also reveal how CNTF is activating astrocytes and the resulting effects this has on other
cells types. The microarray experiments will reveal the importance of cross-talk between
astrocytes and other cell types in the myelinating cultures. Thirdly, the use of astrocyte-
specific gp130-/-  mice will establish whether CNTF is acting via the astrocyte monolayer.
However, the results of this experiment must be interpreted with care as gp130 is a shared
receptor component of other members of the IL-6 family, in which CNTF belongs.
Therefore, the effects observed might be a wider effect of IL-6 family members rather than
CNTF specific effects. Finally, it was discussed that CNTF requires the α subunit to
mediate its effects. The soluble α subunit can be purchased and added alongside CNTF in
order to activate astrocyte monolayers to test whether this hypothesis is true.
A microarray to comparing quiescent and activated astrocytes in culture should also be
investigated with and without CNTF. This will explore whether CNTF can modulate the
astrocytic phenotype from quiescent to a more activated one and therefore relating this to
the astrocytes’ ability to support myelination.
It was found that the astrocyte-derived CXCL10 lead to the reduction of myelination. In
terms of mechanisms of action, the ability of CXCL10 to inhibit myelination has not been
fully assessed. It is known, however, that CXCL10 does not induce demyelination as its
addition to mature myelinating cultures does not lead to a reduction in myelination. What
requires further investigation is how CXCL10 affects OPCs, i.e. inhibiting proliferation
and/or differentiation or their ability to extend processes and ensheath axons. These
experiments are straight forward and will answer many questions about CXCL10 biology.
Although the myelinating cultures provide a functional model for myelination, they can
also be used to investigate descending pathways. The cultures can be lysed and particular
downstream pathways could be investigated.
In terms of in vivo experimentation, animals with experimental autoimmune
encephalomyelitis (EAE) or spinal cord injuries could be used to further investigate
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astrocyte-related molecules. For instance, astrocyte-specific RNAi could target glial
scaring by downregulating the expression of chondroitin sulphate proteoglycans and
particular cytokines and chemokines, such as CXCL10. This method should be used a
combinatorial approach with other astrocyte-related molecules and systemic drugs which
ameliorate the inhibitory environment. Immunohistochemical studies would reveal the
extent of scarring after treatment compared to control animals. Furthermore, behavioural
analysis could be used to assess functional recovery after treatment therefore providing a
true indication of how efficacious the treatment is.
8.8 Conclusions of Thesis
Many laboratories are now recognising astrocytes as more than an obstacle to regeneration.
It is believed that astrocytes may hold therapeutic potential if they were triggered via the
correct methods (Buffo et al., 2010; Hamby and Sofroniew, 2010). As astrocytes make up a
large majority of the cells in the CNS, as well as contributing to numerous functions, it is
not surprising that they respond dynamically to injury. Although reactive gliosis is a
characteristic feature of MS, it is also manifested in numerous neurodegenerative diseases,
including Alzheimer’s disease, and Huntington disease (Norton et al., 1992; Mucke and
Eddelston, 1993). Therefore, any efforts to further our understanding of astrocytes and how
they respond to disease and injury will benefit a wide range of patients with varying
diseases. The future of astrocyte biology holds promising potential therapies. Astrocyte
biology and relating phenotype is an emerging field in neuroscience and is finally
beginning to get the attention it deserves.
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Myelin Macro
//set the thresholds here
thresh_red = 33;
thresh_green = 85;
thresh_blue = 128;
//get the name of the open image, and the folder it came from
iTitle=getTitle;
imageDirectory = getDirectory("image");
print (imageDirectory);
print ("Image name,Red Black,Red White,Green Black,Green White,Blue
Black,Blue White")
//build a list of all images in the folder
fList=getFileList(imageDirectory);
selectWindow(iTitle);
run("Close");
//start the loop to open files
for (i=0; i<fList.length; i++){
//check that file is a valid image
if (endsWith(fList[i],"tif")) {
//if it is valid, open it
open(imageDirectory + fList[i]);
//build names of color component images
iTitle=getTitle;
iTitleRed=iTitle + " (red)";
iTitleGreen=iTitle + " (green)";
iTitleBlue=iTitle + " (blue)";
//split image into colour components
run("RGB Split");
//get red and blue areas and threshold
string="image1=["+iTitleGreen + "] operation=AND image2=[" +
iTitleBlue+"] create";
run("Image Calculator...", string);
iTitleAND = getTitle;
setThreshold(thresh_blue, 255);
run("Threshold", "thresholded remaining black");
run("Invert");
//measure areas
getStatistics(area, mean, min, max, std, histogram);
n_blue_black=histogram[0];
n_blue_white=histogram[255];
//close windows
selectWindow(iTitleAND);
run("Close");
selectWindow(iTitleBlue);
run("Close");
//get red threshold
selectWindow(iTitleRed);
setThreshold(thresh_red, 255);
run("Threshold", "thresholded remaining black");
run("Invert");
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//measure areas
getStatistics(area, mean, min, max, std, histogram);
n_red_black=histogram[0];
n_red_white=histogram[255];
selectWindow(iTitleRed);
run("Close");
//get green threshold
selectWindow(iTitleGreen);
setThreshold(thresh_green, 255);
run("Threshold", "thresholded remaining black");
run("Invert");
//measure areas
getStatistics(area, mean, min, max, std, histogram);
n_green_black=histogram[0];
n_green_white=histogram[255];
selectWindow(iTitleGreen);
run("Close");
//display results
print
(iTitle+","+n_red_black+","+n_red_white+","+n_green_black+","+n_green_whi
te+","+n_blue_black+","+n_blue_white);
}
}
